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Abstract: 
 
Background:	  	  Untreated	  persistent	  pain	  causes	  much	  hardship	  for	  elderly	  nursing	  
home	  residents.	  	  Analgesic	  prescribing	  can	  be	  critical	  to	  alleviate	  this	  pain,	  but	  
inappropriate	  opioid	  prescribing	  can	  create	  serious	  health	  risks	  for	  residents.	  	  
	  
Objectives:	  This	  dissertation	  examined	  the	  lack	  of	  analgesic	  prescribing	  for	  elderly	  
nursing	  home	  residents	  in	  persistent	  pain,	  as	  well	  as	  opioid	  prescribing	  deviating	  
from	  Food	  and	  Drug	  Administration	  (FDA)	  conditions,	  and	  identified	  those	  factors	  
associated	  with	  no	  analgesic	  prescribing	  and	  inappropriate	  opioid	  prescribing.	  
	  
Methods:	  	  Our	  study	  population	  is	  from	  a	  cross-­‐section	  of	  all	  long-­‐stay	  U.S.	  nursing	  
home	  residents	  ≥65	  years	  in	  2008	  with	  a	  Minimum	  Data	  Set	  assessment	  and	  
Medicare	  Part	  D	  enrollment.	  	  Using	  these	  records,	  we	  quantified	  no	  analgesic	  
prescribing	  for	  residents	  with	  persistent	  pain	  (aim	  one);	  inappropriate	  transdermal	  
fentanyl	  initiation,	  i.e.,	  without	  prior	  opioid	  use	  (“opioid-­‐naïve”)	  or	  no	  persistent	  
pain	  (aim	  two);	  and	  inappropriate	  oxycodone	  extended-­‐release	  (ER)	  co-­‐prescribing,	  
i.e.,	  with	  any	  central	  nervous	  system	  (CNS)	  depressant	  (aim	  three).	  	  We	  estimated	  
associations	  of	  patient	  and	  facility	  attributes	  with	  these	  outcomes	  using	  multilevel	  
mixed	  effects	  logistic	  regression	  analyses.	  	  	  
	  
Results:	  We	  found	  16.7%	  of	  residents	  with	  persistent	  pain	  did	  not	  receive	  a	  
prescription	  analgesic	  (aim	  one);	  36.3%	  of	  residents	  initiating	  transdermal	  fentanyl	  
were	  opioid-­‐naïve	  and	  91.8%	  did	  not	  have	  persistent	  pain	  (aim	  two);	  and	  26.6%	  of	  
	   iii 
residents	  were	  co-­‐prescribed	  a	  CNS	  depressant	  with	  oxycodone	  ER	  (aim	  three).	  	  
Residents	  who	  were	  older	  or	  more	  cognitively	  impaired	  were	  less	  likely	  to	  receive	  a	  
prescription	  analgesic	  (aim	  one);	  more	  likely	  to	  be	  opioid-­‐naïve	  when	  initiating	  
transdermal	  fentanyl	  (aim	  two);	  and	  less	  likely	  to	  be	  co-­‐prescribed	  two	  or	  more	  CNS	  
depressants	  with	  oxycodone	  ER	  (aim	  three).	  	  
	  
Conclusion:	  	  Pain	  remains	  incompletely	  treated	  in	  U.S.	  nursing	  homes,	  especially	  
among	  certain	  subpopulations,	  such	  as	  residents	  with	  greater	  cognitive	  impairment	  
and	  older	  age.	  	  There	  are	  also	  substantial	  deviations	  in	  nursing	  homes	  from	  FDA	  
conditions	  for	  safe	  use	  of	  long-­‐acting	  opioids.	  	  FDA	  should	  take	  action	  to	  
communicate	  these	  risks	  to	  nursing	  homes	  and	  ensure	  proper	  use,	  including	  
through	  the	  long-­‐acting	  opioid	  Risk	  Evaluation	  and	  Mitigation	  Strategy	  (REMS).	  	  
Nursing	  homes	  should	  take	  steps	  to	  ensure	  appropriate	  long-­‐acting	  opioid	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Nursing home residents and their care 
 
Nursing home care is critical for the health of millions in the United States.  In 
2009 over 2.8 million Americans 65 years and older resided in a nursing home at some 
point during the year.1 Over 1 million of these residents were 85 years and older.  More 
elderly will reside in nursing homes as the American population grows.  Nursing homes 
provide multiple services for residents, including housing, nutrition, and social services, 
as well as medical care and assistance with daily tasks.  In 2012 there were nearly 16,000 
nursing homes in the United States that were certified for Medicare and Medicaid 
reimbursement.2  
Most elderly nursing home residents experience significant diseases and 
debilitating conditions related to older age.  Four out of five nursing home residents need 
assistance with at least one basic “activity of daily living” (ADL) and three out of five 
need assistance with at least four ADLs.2 Three out of five nursing home residents also 
have a moderate or severe cognitive deficit.2 These figures demonstrate this population’s 
vulnerability. 
A groundbreaking report in 2001 from the Institute of Medicine (IOM) brought to 
light numerous problems in the care for nursing home residents.3 The IOM report 
identified critical care deficiencies in nursing homes, such as the high prevalence of 
pressure sores, malnutrition, and pain in residents, as well as the improper treatment of 
residents, including the use of physical and chemical restraints.3 The IOM report 
acknowledged the limitations of nursing home resident and staff resources, as well as the 
important role of Medicare and Medicaid payment structures, for aspects of care.  Despite 
these limitations, the report emphasized nursing homes should take immediate steps to 
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rectify these care problems, particularly resulting from neglect.  The report then provided 
recommendations for improving resident access to needed services, strengthening 
external oversight of nursing homes, developing the work force, increasing organizational 
capacity, and addressing reimbursement issues.  
 
Persistent non-cancer pain in nursing home residents 
The IOM identified the management of resident pain as a public health priority in 
nursing homes.3 Before the 2001 IOM report was issued, studies estimated that between 
45 to 80 percent of residents lived with some degree of pain that impaired their 
functioning and quality of life.4-6 This common pain experience is caused by the higher 
prevalence of age-related conditions in the elderly, such as arthritis, musculoskeletal 
disorders and peripheral vascular diseases.7,8 Pain in older individuals can cause 
functional impairment, falls, slow rehabilitation, and greater health-care use and costs.8-10 
In particular, pain in nursing home residents can diminish their physical and cognitive 
functioning and decrease their quality of life.5,11-13 Many nursing home residents are 
particularly vulnerable to pain’s ill effects because of their greater frailty and diminished 
resilience.7  
In the last decade, studies have continued to find that a large proportion of 
residents experience significant pain.7 The Institute of Medicine examined in 2011 the 
problem of pain in America and emphasized the vulnerability of nursing home residents 
to substantial pain and its debilitating effects.14 Many studies have assessed pain in large 
nursing home sample populations using federal survey data.15-18 In these studies the 
prevalence of pain, measured over a prior one-week period, have ranged from 4% for 
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daily pain that was excruciating at times;15 17% for daily pain that was moderate or 
severe;16 and 22-23% for any pain.17,18 Another study using federal survey data found that 
annual prevalence of moderate-to-severe pain, occurring within the past week, in 
residents decreased from 29% in 2006 to 22% in 2009.19 Studies in smaller U.S. nursing 
home sample populations that relied on resident interviews and medical record reviews 
have identified greater percentages of residents in pain: 42% for more severe pain20 and 
51% for any pain.13  
Persistent pain is longer in duration, typically defined as any pain occurring for at 
least a three-month period.21 Cancer is one cause of persistent pain, but many nursing 
residents without cancer also experience lasting pain from diseases and health 
conditions.8 One study estimated that nearly half of all nursing home residents experience 
some degree of persistent non-cancer pain (i.e., any degree of pain over a three-month 
period).21 Studies have estimated that between 5-49 percent of nursing home residents 
experience persistent, non-cancer pain, depending on the duration and intensity 
threshold.12,21,22 This persistent pain can range in intensity from mild to severe and is 
associated with more adverse health outcomes in residents.21   
 
Treatment options for pain in nursing homes 
Analgesics are an important part of the nursing home’s armamentarium for 
treating resident pain, including acetaminophen, nonsteroidal anti-inflammatory drugs 
(NSAIDs), and prescription opioids.  Studies have found that acetaminophen and 
NSAIDs can be effective for certain types of persistent pain in the elderly, such as low 
back pain and osteoarthritis.5,8,23 However, there are safety concerns with these drugs in 
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the elderly, including hepatic toxicity from long-term acetaminophen use at high doses 
and serious and life-threatening gastrointestinal and cardiovascular adverse events from 
NSAIDs, including newer COX-2 inhibitors (like Celebrex®).5,8,23 
Under this framework for balancing risk and benefits, opioids are another 
important treatment option for persistent non-cancer pain in the elderly.  Prescription 
opioids have been used for decades to treat short, acute pain, as well as cancer pain.2 
Some studies suggest that prescription opioids can be appropriate for certain types of 
non-cancer persistent pain under a cautious approach that includes careful selection, 
titration, and monitoring.8,23,24 Many of these drugs can be administered in different 
dosage forms, such as through oral, sublingual, and intravenous routes.  There are two 
classes of opioids for temporal effects, either as immediate release for up to 4 hours 
duration or extended release for up to 24 hours duration.25,26 
Despite this range of analgesic options, studies in nursing home populations have 
found that between 25 to 40 percent of nursing home residents with non-cancer pain do 
not receive any analgesics.7,21,27,28 Due to this glaring gap, the IOM has encouraged 
greater use of analgesics, including opioids, for nursing home residents suffering from 
pain.14 The IOM also stressed the need to update these findings on analgesic use, 
especially studies assessing the safety and effectiveness of opioids for persistent pain.  
 
Appropriate selection and use of prescription opioids in nursing home residents   
In order for prescription opioids to successfully alleviate persistent non-cancer 
pain for nursing home residents, the drugs must be used carefully under the proper 
conditions.  The reliance on pharmaceutical therapies can be effective for many 
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conditions and types of pain if nursing home practitioners carefully select, administer and 
monitor the prescription drug use.8,24,29 However, inappropriate drug prescribing can 
threaten patient safety because of adverse effects.  The elderly are particularly vulnerable 
because of their pharmacokinetic and pharmacodynamic differences from the general 
population and diminished resilience.8,24,29 In addition, the co-prescribing of drugs can 
harm patients from interactive effects.30 Because nursing home residents take numerous 
pharmaceuticals (at least 8 on average), the risks for drug interaction are much higher.31 
The administration of numerous drugs to an individual (“polypharmacy”) has been 
identified as a serious risk factor for adverse events in nursing homes.31,32 
These risks can be heightened in the nursing home setting, where inappropriate 
prescribing is an important concern.  One study estimated that over 50 percent of elderly 
nursing home residents receive at least one potentially inappropriate prescription each 
year.33 Nursing home residents are particularly vulnerable to the harms from 
inappropriate opioid prescribing because they use more medications and have more co-
morbid conditions.32,34,35 One study in the elderly found that 26% of patients with 
osteoarthritis were inappropriately prescribed an opioid because of potentially dangerous 
interactions with other drugs taken by the patients.30 The co-prescribing of other CNS 
drugs, such as atypical antipsychotics and antidepressants, with opioids increases the 
risks for psychoactive adverse events, including delusions and sedation.36 These findings 
demonstrate how opioid prescribing decisions must account for multiple patient factors, 
including co-prescribing for other conditions.  
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Practice guidelines for persistent non-cancer pain care and pharmaceutical use 
Public health and health care organizations have attempted to respond to this 
acute need for improved pain management in the United States, including in nursing 
homes.  These organizations play an important role in the treatment of persistent non-
cancer pain, including the use of prescription drug therapies, through policy and practice 
recommendations.  These recommendations attempt to help practitioners make more 
informed decisions about analgesic prescribing for patients.  Simply increasing the 
frequency of analgesic prescribing in the nursing home population will not, by itself, 
ensure better pain management.  Instead, the goal is to ensure that more patients, such as 
nursing home residents, have their pain managed safely and effectively. 
The World Health Organization (WHO) provided the foundation for these pain 
management recommendations in addressing pharmaceutical therapies for cancer pain.  
The WHO established a three-step “ladder” approach for persistent pain management in 
cancer patients that has also been applied to non-cancer patients.37 Under this approach, 
non-opioids should be administered first for the patient’s pain.  If these are insufficient, 
then opioids for mild-to-moderate pain (such as codeine) can be administered next in 
conjunction with the non-opioid.  Finally, opioids for moderate-to-severe pain (such as 
morphine) can be administered as a final step in conjunction with the non-opioid.  For 
each of these steps, an adjuvant drug may also be administered.     
Many organizations have recommended practices for pain management and 
analgesic use based on their own review of the evidence,38 including the American Pain 
Society (APS) and American Academy of Pain Medicine (AAPM),39 as well as the 
American Society of International Pain Physicians (ASIPP).40 The American Geriatric 
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Society (AGS) recently issued practice guidelines for the use of analgesics, including 
opioids, in elderly adults with persistent pain.8 The AGS reviewed three categories of 
analgesics – acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and 
opioids.  Following the WHO guidelines for cancer pain use, the AGS recommended that 
these analgesics be carefully selected for the individual patient, initiated at low doses and 
slowly titrated upwards if necessary, and include regular monitoring and frequent dosage 
reassessment.8 The AGS emphasized potential adverse effects from opioids, such as from 
the failure to follow labeling instructions for contraindications and proper dosing.8   
The American Medical Directors Association (AMDA) has published a practice 
guideline for pain management in nursing homes and addressed the role of prescription 
drugs, including opioids.24 The AMDA guidelines emphasize that nursing homes should 
follow the stepped approach in the WHO guidelines for analgesic use.24 The guidelines 
also recommend that nursing homes carefully titrate the analgesic dose and monitor the 
drug’s safety and effectiveness in each resident over time.24 For monitoring, the guideline 
stresses the need for an ongoing assessment of each nursing home resident’s ability to 
perform ADLs and their cognition.24  
 
Role of federal agencies for nursing home and pharmaceutical oversight 
Two federal agencies also play an important role in these efforts to improve 
nursing home care for residents and their analgesic use: the U.S. Centers for Medicare 
and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA).  CMS 
has regulatory authority over nursing home, while FDA has regulatory authority over 
prescription drugs.  After passage of the Omnibus Budget Reconciliation Act of 1987 
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(OBRA), which provided greater federal authority over nursing homes receiving 
Medicaid and Medicare reimbursements, CMS issued nursing home regulations in the 
1990’s to ensure better care for residents, as well as guidelines for pain management 
(F309) and prescription drug use (F329).3,41 
The CMS pain management guideline emphasizes that prescription opioid drugs 
should be selected and dosed in accordance with current standards of practice.41 The 
guideline states that careful titration and monitoring for the drug’s safety and 
effectiveness is necessary.41 The prescription drug guideline warns against a drug’s use in 
excessive dose or duration and with inadequate monitoring for effectiveness and safety.41 
CMS works with states to inspect nursing home facilities to assess compliance with these 
guidelines.41  
FDA also plays an important role in ensuring appropriate pharmaceutical use by 
regulating the approval, manufacturing, and marketing of prescription drugs, including 
analgesics.  FDA must evaluate each prescription drug’s safety and efficacy before the 
agency can approve that drug for a specific use.  FDA also must approve the drug’s 
labeling, specifying the indications for which the drug is effective, as well as the safe 
conditions for use.42 The labeling includes any warnings and cautions about possible side 
effects, including safety risks to specific types of patients and potential dangerous 
interactions with other drugs.42   
Importantly, FDA generally does not regulate prescribing decisions by medical 
practitioners, including within nursing homes.  Because FDA does not regulate the 
practice of medicine, health care practitioners can use an approved drug for an individual 
patient in a different way from the indications and conditions in the drug labeling.43 This 
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“off-label use” should be based on the practitioner’s professional judgment, which can be 
based on more recent medical and scientific knowledge, such as described in practice 
guidelines.43 Despite this discretion given to medical professionals by FDA, nursing 
home practitioners must carefully consider FDA’s critical judgment how the drug may be 
safely used, as reflected in the approved labeling conditions.  Although FDA does not 
regulate analgesic prescribing decisions for nursing home residents, CMS guidelines 
recommend that nursing homes follow FDA labeling conditions for drug prescribing.41 
FDA has other regulatory tools after a drug’s approval to help ensure safe use.  
FDA can strengthen warnings on the drug’s labeling (e.g., a “Black Box” warning) to 
identify more clearly for health care practitioners the most important risks.44 FDA can 
also inform patients and health care providers about potential risks from adverse events 
through safety communications on its website and outreach to stakeholder groups.44,45 In 
addition, FDA can implement a Risk Evaluation and Mitigation Strategy (REMS) that 
includes special conditions for prescription drug use.  Questions have been raised, 
though, if these additional steps have minimized the targeted drug risks.44,46   
 
FDA steps for prescription opioids 
FDA’s role in ensuring prescription drug safety has been particularly visible in the 
agency’s regulation of opioids.  Deaths and serious injury resulting from opioid overdose 
have been a significant public health concern in recent years.47 Despite recent attention 
on prescription opioid misuse in the general population, addiction is not a significant 
concern for elderly nursing home residents.4 However, a significant portion of adverse 
events have occurred in patients taking the opioid drug as prescribed.39,40    
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Extended-release (ER) prescription opioids in particular have faced heightened 
scrutiny about safety risks.45 FDA approved ER formulations for opioids that provide a 
longer drug release in the patient’s body.26 Oxycodone hydrochloride (“oxycodone”) ER 
and transdermal fentanyl (“fentanyl”) ER, available since the 1990’s, are widely used 
opioids in nursing homes.21,48 Although effective in treating more serious pain over a 
longer duration, these drugs can increase a patient’s risk for adverse effects, such as 
overdose and severe respiratory depression, particularly upon first being administered 
and for the elderly.49-52 The FDA-approved labeling warns of this risk and emphasizes 
that these drugs are only for use in patients with moderate-to-severe, continuous pain.49,50  
Each prescription opioid has additional cautions and warnings, depending on the 
safety evidence for that drug.  For example, the fentanyl ER labeling warns that opioid-
naïve patients (who have not first tried another short-acting opioid drug) should not be 
prescribed the drug because of the risks for respiratory depression and overdose.  The 
oxycodone ER labeling cautions against use of the drug in combination with other central 
nervous system (CNS) depressants, which creates serious risks in patients for fatal 
respiratory depression, profound sedation, or coma.50,51 The labeling in both drugs also 
warns that the elderly are even more susceptible to these side effects.50,53   
Health care practitioners must carefully select an opioid for an individual’s 
persistent pain based on these different safety concerns and warnings.  However, it is not 
clear if these warnings have ensured safer use, particularly in nursing homes.  In fact, one 
study found that ER opioids were commonly prescribed in opioid-naïve nursing home 
residents in Rhode Island during 2004-2005 despite the FDA labeling statements.  Since 
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this time, FDA has taken additional regulatory steps beyond the labeling to ensure safer 
ER opioid use. 
First, FDA issued multiple communications in successive years to physicians and 
the public about transdermal fentanyl risks, including that opioid-naïve patients should 
not be initiated on the drug.54 Second, FDA implemented a Risk Evaluation and 
Mitigation Strategy (REMS) in 2012 for ER opioids such as transdermal fentanyl and 
oxycodone that provides additional precautionary steps for their prescribing, such as 
healthcare provider training about the risks and appropriate use.55 FDA, though, did not 
target these steps at the use of prescription opioids in nursing home residents, and it is not 
clear if they are reducing inappropriate prescribing in nursing homes. 
 
Disparities within nursing homes 
Much attention has been focused in recent years on disparities in health care in the 
United States.  Studies have found that certain subpopulations, particularly with lower 
socioeconomic standing (SES) and minority groups, suffer disproportionately worse 
health outcomes than others, such as chronic diseases and life expectancy.56 These 
divisions exist between and within nursing homes themselves, depending on the facility 
and resident characteristics.3 These disparities are even more troubling considering that 
nursing home residents are a more vulnerable population compared to otherwise similar 
individuals (i.e., community-living seniors) in the U.S. population.3  
The outcomes affected by nursing home disparities include the adequacy of care 
for residents, such as pain management and appropriate analgesic prescribing.  The IOM 
expressed significant concerns in its 2001 and 2010 reports that pain treatment lags 
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further behind for certain individuals and at specific facilities.3,14 Prior studies have 
identified disparities in pain management for nursing home residents who are non-white57 
or cognitively impaired.58 Other studies have found that non-white, older, and cognitively 
impaired residents are less likely to receive analgesics for non-cancer pain12,27 and cancer 
pain.59 In addition, certain facility characteristics, such as for-profit status, have been 
associated with worse health outcomes for residents.60 Thus, efforts to improve 
prescribing practices for resident pain must also focus on even more vulnerable 
subpopulations within nursing homes, rather than simply using a general approach across 




The analytic framework for this research, assessing nursing home analgesic prescribing 
for persistent pain, can be organized in the following steps: 
1. Nursing homes must first identify a resident’s persistent pain. 
2. Once identified, nursing homes can provide an analgesic as part of a therapeutic 
approach.  These analgesic options are acetaminophen, NSAIDs, and short-acting 
(i.e., immediate release) opioids, depending on the frequency, duration, and type 
of pain.  Practice guidelines, CMS requirements, and FDA regulatory steps (such 
as drug labeling) are critical external factors that inform and shape this decision. 
3. If these different options for analgesic therapy do not adequately treat the 
resident’s persistent pain, then nursing homes can consider a prescription long-
acting (i.e., extended release) opioid as a possible option.  Transdermal fentanyl 
ER is the example in our model.  Practice guidelines and federal regulation also 
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inform and shape this prescribing decision.  FDA-approved drug labeling and 
communications emphasize that the drug should only be initiated in patients who  
 have moderate-to-severe, persistent pain and  
 are opioid tolerant (i.e., have already taken an opioid and are thus not 
opioid naïve)   
4. For these long-acting opioid prescribing decisions, nursing homes must also 
consider the other drugs that residents take for possible interaction effects.  Again, 
practice guidelines and federal regulation can shape these decisions.  Oxycodone 
ER is the example in our model.  Considerations for drug interactions are relevant 
as the opioid therapy is  
 initiated (i.e., accounting for other currently prescribed drugs) and then 
 maintained in the future (accounting for future decisions about other 
drugs)  
5. Along this treatment continuum, disparities in pain management and appropriate 
prescribing can influence nursing home decisions about residents’ therapies in 
steps 2, 3, and 4. 
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Dissertation goals and specific aims 
Overall Goal of the Dissertation 
The dissertation’s overall goal is to assess the appropriateness of analgesic 
prescribing in elderly nursing home residents.  The dissertation examines the prescribing 
of any analgesics for residents with persistent pain, as well as the prescribing of certain 
ER opioids for residents regardless of pain experience.  
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Conceptual Framework 
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 Assess the prevalence of analgesic prescribing (e.g., acetaminophen, NSAID, and 
opioid drugs) for elderly residents with persistent pain and identify any 
associations between no prescribing and individual and facility characteristics; 
 Assess the prevalence of transdermal fentanyl ER prescribing in elderly residents 
who are opioid-naïve (i.e., non-compliant with FDA labeling) and identify any 
associations between no prescribing and individual and facility characteristics; 
and 
 Assess the prevalence of concomitant prescribing of CNS depressants and other 
CNS agents with oxycodone ER (i.e., non-compliant with FDA labeling) in 
elderly residents and identify any associations between concomitant prescribing 
and individual and facility characteristics. 
 
Specific Aim 1:  To assess prescription analgesic utilization and the characteristics of 
prescription analgesic use for persistent non-cancer pain in elderly nursing home 
residents in the United States. 
 Hypothesis 1:  We hypothesize that resident characteristics (poorer cognitive 
functioning, older age, lower socioeconomic status, and non-white race) and facility 
characteristics (smaller staff-to-resident ratio, fewer private pay residents, and for-profit 
status) will be associated with lower incident use of analgesics, including opioids, for 
persistent non-cancer pain. 
 
Specific Aim 2:  To assess the prevalence of non-adherence in nursing home residents to 
conditions established by the U.S. Food and Drug Administration for transdermal 
	   17 
fentanyl initiation, and to identify patient and facility characteristics associated with non-
adherence. 
Hypothesis 2:  We hypothesize that adherence to these conditions for transdermal 
fentanyl initiation will be lower for residents who have poorer cognitive functioning, 
older age, lower socioeconomic status, or are not white and in nursing home facilities 
that have smaller staff-to-resident ratio, fewer private pay residents, and are for-profit. 
 
Specific Aim 3:  To assess the prevalence in nursing home residents of central nervous 
system (CNS) drug co-prescribing with extended-release oxycodone and adherence to 
conditions established by the U.S. Food and Drug Administration for extended-release 
oxycodone use, and to identify patient and facility characteristics associated with non-
adherence. 
Hypothesis 3:  We hypothesize that adherence to these conditions for extended-release 
oxycodone use will be lower for residents who have poorer cognitive functioning, older 
age, lower socioeconomic status, or are not white and in nursing home facilities that 
have smaller staff-to-resident ratio, fewer private pay residents, and are for-profit. 
 
Organization of this Dissertation   
Chapter 1 (this chapter) provides the pertinent background for the research and 
reviews the relevant literature.  Chapter 2 assesses the prevalence of analgesic prescribing 
for elderly nursing home residents with persistent non-cancer pain and analyzes whether 
certain individual or facility characteristics are associated with no analgesic prescribing 
for this pain.  Chapter 3 assesses the prevalence of transdermal fentanyl ER prescribing in 
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elderly nursing home residents who are opioid-naïve and analyzes whether the individual 
or facility characteristics (from the prior model) are associated with opioid-naïve 
prescribing, in contrast to FDA warnings.  Chapter 4 assesses the prevalence of 
concomitant prescribing of CNS depressants and other CNS agents with oxycodone ER 
and analyzes whether the individual or facility characteristics (from the prior models) are 
associated with opioid-naïve prescribing, in contrast to FDA warnings.  Each chapter is a 
separate, unique manuscript and includes individual appendices.  Chapter 5 presents a 
summary of the findings and the conclusion. 
 
Data Sources 
This dissertation relied on data for all U.S. nursing home residents during 2007-
2008 from the Minimum Data Set (MDS); the Online Survey, Certification and Reporting 
(OSCAR) database; and Medicare Part D.   
The MDS is a standardized survey instrument measuring each nursing home 
resident on fifteen domains, including any degree of pain, cognitive and physical 
functioning, psychosocial well-being, activities and diseases.61 The MDS assessor, a 
trained nursing home staff person, relies on personal observation, interviews with 
residents, resident medical records, discussions with resident family, and consultation 
with clinicians and other staff to complete the MDS questions and record all information 
on the MDS forms.61,62 The information gathered for the MDS is then used by the nursing 
home to develop individual care plans for each resident.3,62 The nursing home assesses 
each resident every three months for certain MDS measures (including cognitive and 
physical functioning, mood, and pain) and annually for all MDS measures and when any 
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significant change in resident status occurs.61 A revised version of the MDS (MDS 2.0) 
was used during our 2007-08 study period.  The MDS 2.0 measures in this dissertation 
have been found generally reliable and valid for the domains when used by trained 
staff.63 For example, MDS 2.0 items have been incorporated into other valid and reliable 
instruments (e.g., MDS ADL Scale, MDS Cognitive Performance Scale) to measure 
resident characteristics, such as physical and cognitive functioning.63-65  
The dissertation also relied on OSCAR data for measurement of facility factors, 
such as the facility’s staff-to-resident ratio, percentage of private pay residents, for-profit 
status, and compliance with federal law.  The federal government compiles annually in 
OSCAR this information about each nursing home facility.66 Finally, the dissertation 
relied on Medicare Part D claims to determine analgesic and other prescribing for 
residents in our population.  This data includes the drug, dose, dosage form, and length of 
prescription (e.g., 30 days).67 
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CHAPTER 2: FREQUENCY AND PREDICTORS OF 
ANALGESIC PRESCRIBING IN U.S. NURSING HOME 
RESIDENTS WITH PERSISTENT PAIN 
  




Objective:  To quantify prescription analgesic use among elderly nursing home residents 
with persistent non-cancer pain and to identify individual and facility traits associated 
with the absence of such treatment.   
 
Design:  Cross-sectional study. 
 
Setting:  Linked Minimum Data Set (MDS) assessments; Online Survey, Certification 
and Reporting (OSCAR) records; and Medicare Part D claims. 
 
Participants:  From a cross-section of all long-stay U.S. nursing home residents in 2008 
with an MDS assessment and Medicare Part D enrollment, we identified individuals ≥65 
years old with persistent non-cancer pain, but without Alzheimer’s, severe cognitive 
impairment or receipt of hospice care. 
 
Measurements:  Residents with moderate-to-severe, daily pain on consecutive 
assessments at least 90 days apart comprised our cohort with persistent pain.  We 
identified Part D dispensing for an opioid or non-steroidal anti-inflammatory (NSAID) 
within 30 days of persistent pain onset.  Resident and facility characteristics were 
obtained from MDS and OSCAR records.  We estimated associations of patient and 
facility attributes and pain treatment from multilevel mixed effects logistic regression 
analyses. 
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Results:  Among 18,526 residents with persistent pain, 3,094 (16.7%) did not receive 
prescription pain medicine; 12,815 (69.2%) received a prescription opioid; 485 (2.6%) 
received a prescription NSAID; and 2,132 (11.5%) received a prescription opioid and 
NSAID.  In the regression analysis with adjustments, residents who were older 
(compared to ages 65-74, ages 75-84 odds ratio (OR)=1.30 , 95% CI=1.16-1.47;  ages 85-
94 OR=1.63 , 95% CI=1.44-1.85;  ages ≥95 OR= 2.06, 95% CI=1.70-2.49); Black 
(compared to White residents, OR=1.20, 95% CI= 1.03-1.39); and more cognitively 
impaired (compared to no cognitive impairment, borderline intact OR=1.11, 95% 
CI=0.97-1.27; mild impairment OR=1.31 , 95% CI=1.15-1.49; moderate impairment 
OR=1.62, 95% CI=1.42-1.83; moderate-to-severe cognitive impairment, OR=2.12, 95% 
CI = 1.71-2.62) were less likely to receive a prescription pain medicine.  
 
Conclusion:  Pain remains incompletely treated in U.S. nursing homes, especially among 
certain subpopulations of residents such as those with cognitive impairment.  Changes in 
pain management practice and policies may be necessary to target these more vulnerable 
residents.  
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INTRODUCTION 
 
Nursing home care is critical for the health of millions in the United States.  
Nearly 3 million Americans aged 65 years and older resided in a nursing home at some 
point in 2009, and over 1 million of these residents were 85 years and older.1 More 
elderly will reside in nursing homes as the American population grows.  In 2009 there 
were nearly 16,000 nursing homes in the United States that were certified for Medicare 
and/or Medicaid reimbursement.1   
Most elderly nursing home residents experience significant diseases and 
debilitating conditions related to older age, including persistent pain.  Such pain usually 
occurs for at least three months and can vary in intensity.2 Prior studies have found that 
between 45 to 80 percent of residents experience some degree of pain that impairs 
functioning and quality of life,3 and that 5 to 49 percent of residents have persistent non-
cancer pain, depending on the duration and intensity threshold.2,4,5 This common pain 
experience is caused by the higher prevalence of age-related conditions in the elderly, 
such as arthritis, musculoskeletal disorders, and peripheral vascular diseases.6 Pain in 
older individuals can adversely affect their physical functioning, mental health, and social 
engagement, as well as create greater health-care use and costs.7-9 These damaging effects 
have also been found in elderly nursing home residents and can severely limit their 
quality of life.6,10,11 Many nursing home residents are particularly vulnerable to pain’s ill 
effects because of their greater frailty and diminished resilience.6  
A recent report by the Institute of Medicine (IOM) stressed the importance of 
improved pain management in nursing homes.12 Analgesics are an important part of the 
nursing home’s armamentarium for treating resident pain, including acetaminophen, 
nonsteroidal anti-inflammatory drugs (NSAIDs), and prescription opioids.  However, 
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studies have found that between 25 to 40 percent of nursing home residents with non-
cancer pain did not receive any analgesics.2,6,11 Due to this glaring gap, the IOM and 
professional societies have encouraged greater use of prescription analgesics for nursing 
home residents suffering from persistent pain.7,12 The IOM emphasized the need to update 
these study findings on analgesic use.12  
Even if analgesic prescribing has increased in this population with persistent pain 
over recent years, there remains concern that treatment may lag behind for more 
vulnerable subpopulations within nursing homes and at specific types of facilities.  Prior 
studies have identified disparities in pain management for nursing home residents who 
are non-white13 or cognitive impaired.14 Other studies have found that non-white, older, 
and cognitively impaired residents are less likely to receive analgesics for non-cancer 
pain5,11 and cancer pain.15 In addition, certain facility characteristics, such as for-profit 
status, have been associated with worse health outcomes for residents.16  
In response to the IOM’s call for updated research on these questions, we assessed 
data on nursing home residents, facilities, and medication prescribing in 2007-2008 from 
the national Minimum Data Set (MDS), the Online Survey, Certification, and Reporting 
(OSCAR) database, and Medicare Part D to evaluate the extent of analgesic prescribing 
for elderly nursing home residents with persistent non-cancer pain, defined as moderate-
to-severe pain lasting at least 3 months.  We also assessed if certain individual and 
facility-level factors were associated with no analgesic use for these residents with 
persistent non-cancer pain. 
  





 Our source population was the approximately 2.99 million individuals aged 65 
and older who resided in nursing homes in the United States at any time between 
December 1, 2007, through November 30, 2008, and had an MDS record.  
Inclusion Criteria.  We limited our analysis to the 53% of elderly residents with at 
least two MDS assessments over a 90-day period or longer (Figure 2.1).  We then 
included in our study those individuals from the source population who had persistent 
non-cancer pain, defined as moderate-to-severe pain lasting 3 months or longer.2 Each 
nursing home resident is assessed in the MDS at least every 3 months for the frequency 
and intensity of any pain over the previous 7 days.17 This measurement has been found 
valid for measuring pain frequency and intensity in a scored scale.18 For our study, a 
nursing home resident was considered in persistent pain if the individual had two 
consecutive MDS reports, at least 90 days apart but no more than 180 days apart, with 
moderate or severe pain daily during the prior 7-day period.  We used this pain intensity 
definition (moderate-to-severe) to match the guideline recommendations for analgesic 
use.  We defined “persistent pain onset” as the date of the second MDS pain assessment 
satisfying the persistent pain definition, yielding a population of 59,114 individuals (3.8% 
of eligible source population).    
Exclusion Criteria.  We excluded those individuals who had cancer, were 
terminally ill, or had Alzheimer’s disease or most severe cognitive impairment, defined 
as an MDS Cognitive Performance Scale (CPS) score of 5 or 6 (Figure 2.1).  We 
excluded the most cognitively impaired because of the difficulty in assessing accurately 
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their pain levels.14 We also excluded those individuals who had not resided in the nursing 
home for at least 90 continuous days at persistent pain onset.  After these exclusions, 
22,943 individuals remained in our study population.  We then excluded 2,776 residents 
(12.1%) who did not have any Part D prescription drug records during the time period.  
Next, we excluded 1,018 individuals (5.0%) who resided in hospital-based facilities.  
Finally, data were missing for at least one covariate for 623 of the 19,149 participants 
(3.3% of the sample).  We dropped these subjects from the analysis.  Our study 
population then consisted of 18,526 individuals (Figure 2.1). 
Measures 
We analyzed data about each nursing home resident from the MDS, a 
standardized survey instrument that measures each resident on fifteen domains, including 
pain status, cognitive and physical functioning, psychosocial well-being, activities and 
diseases.17 All U.S. nursing homes (certified for Medicare and/or Medicaid) are required 
by federal law to use the MDS survey instrument to assess periodically each nursing 
home resident.19 The MDS assessor, a trained nursing home staff person, relies on 
personal observation, interviews with residents, resident medical records, discussions 
with resident family, and consultation with clinicians and other staff to complete the 
MDS questions and record all information on the MDS forms.17,20 The information 
gathered for the MDS is then used by the nursing home to develop individual care plans 
for each resident.19,20 The nursing home assesses each resident every three months for 
many MDS measures (e.g., cognitive and physical functioning, mood, and pain) and 
annually for all MDS measures and when any significant change in resident status 
occurs.17  
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Our study relied on the MDS 2.0 version, which was used during our 2007-08 
study period.  The MDS 2.0 measures in our study have been found generally reliable and 
valid for the domains when used by trained staff.21 For example, MDS 2.0 items have 
been incorporated into valid and reliable instruments (e.g., MDS ADL Scale, MDS 
Cognitive Performance Scale) to measure resident characteristics, such as physical and 
cognitive functioning.21-23  
We also relied on OSCAR data for measurement of facility factors, such as the 
facility’s staff-to-resident ratio, percentage of private pay residents, for-profit status, and 
compliance with federal law.  The federal government compiles annually in OSCAR this 
information about each nursing home facility.24 Finally, we analyzed each resident’s drug 
prescribing using Medicare Part D records. This data includes the drug, dose, dosage 
form, and duration (e.g., 30 days).25   
Analgesic Prescribing.  Our primary outcome was whether each resident with 
persistent non-cancer pain failed to receive a prescription for an opioid or non-steroidal 
anti-inflammatory drug (NSAID).  Our definition of an opioid prescription included mu 
agonist opioids (codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, 
meperedine, methadone, morphine, oxycodone, oxymorphone, and propoxyphene) and 
dual mechanism opioids (tramadol), as well as prescription drugs with these opioid active 
ingredients in combination with other analgesic ingredients, such as hydrocodone or 
oxycodone with acetaminophen (Figure 2.2).  Our definition of NSAIDs included newer 
Cox-II inhibitors, such as Celebrex (Figure 2.2).  We did not include over-the-counter 
(OTC) acetaminophen or NSAIDs in the analgesic definition, because Part D does not 
cover OTC drugs25 and our study focuses on the most substantial (moderate-to-severe) 
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persistent pain. We characterized those residents with an analgesic prescription dated 
within 30 days before or after persistent pain onset under our definition as having an 
analgesic prescription.  We also assessed other alternative pain treatments recorded in the 
Part D or MDS records within this 30-day window, such as different prescription drugs 
(i.e., muscle relaxants, steroids, and gabapentin) and physical therapy. 
Covariates. We evaluated whether certain individual and facility factors were 
associated with not having an analgesic prescription.  For individual factors, we 
hypothesized that older age, poorer cognitive functioning, lower socioeconomic status 
(SES), and non-white race/ethnicity would be associated with less analgesic prescribing.  
We measured cognitive functioning in the MDS measurement (at persistent pain onset) 
based on the CPS score from 0 (intact) to 4 (moderate-to-severe impairment).  We 
measured SES based on highest completed education level and whether the resident paid 
for nursing home non-medical services out-of-pocket (“self-pay”).  For facility factors, 
we hypothesized that smaller staff-to-resident ratio, fewer private pay residents, and for-
profit status would be associated with less analgesic prescribing.  We obtained these 
facility measurements from the most recent OSCAR survey before persistent pain onset.   
We also identified potential confounders that could be associated with these 
individual and facility factors and analgesic prescribing: gender, physical impairment, 
mood, family support, and facility compliance with federal law.  We measured physical 
impairment in the most recent MDS (at or before persistent pain onset) by the degree of 
assistance needed for activities of daily living (ADLs) under the Morris Additive Scale 
from 0 (no help required) to 28 (most help needed); mood at the time of persistent pain 
onset by the MDS Mood Scale score from 0 (no mood symptoms) to 8 (most mood 
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symptoms); family support based on whether a family member or significant other 
participated in the most recent MDS care plan meeting (at or before persistent pain 
onset); and compliance with federal law based on whether there were any significant 
outstanding legal violations of federal nursing home requirements, as recorded in the 
most recent OSCAR survey before persistent pain onset.   
Statistical Analysis 
We first assessed the proportion of residents in our study population with non-
cancer pain who received a prescription analgesic.  To test our hypothesis that certain 
individual and facility factors were associated with no analgesic prescribing for residents 
in persistent non-cancer pain, we fit a series of logistic regression models with no 
analgesic prescribing (versus analgesic prescribing) as the outcome.   
The first models were univariate logistic regressions with one of the following 
predictors per model: age (categorized as <65 years, ≥65 to 74 years, ≥75 to 84 years, 
≥85 years); race/ethnicity (White, Black, Hispanic, Asian, and other); cognitive 
functioning (categorized from 0-4 on the CPS Scale); self-pay status (yes versus no); 
education level (categorized as less than high school graduate, high school graduate, or 
college graduate/graduate school); facility staff hours per resident (categorized as <2.5 
hours, ≥2.5 to 3.0 hours, ≥3.0 to 3.5-hours, ≥3.5 to 4 hours, ≥4.0 to 4.5 hours, ≥4.5 
hours); facility proportion of self-pay residents (categorized as <10%, ≥ 10% to 30%, ≥ 
30% to 50%, ≥ 50%); and facility for-profit status (yes versus no).  We also conducted 
the univariate logistic regression for each confounder in our model: gender; degree of 
ADL assistance (categorized as 0, 1-7, 8-14, 15-21, 22-28 from the Morris Additive 
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Scale), MDS Mood Scale (categorized as 0, 1-2, 3-4, 5-6, 7-8); family support (yes 
versus no); and facility compliance with federal law (yes versus no).   
The next model included all of these variables in a multilevel logistic regression.  
Because residents are clustered within nursing homes and nursing homes are clustered 
within states, we included random effects (i.e., intercepts) in all models for these two 
levels to ensure more accurate standard errors.  We also conducted sensitivity analyses 
using more stringent definitions of persistent pain (i.e., at least 3 consecutive MDS 
assessments with serious pain at least 90-180 days apart; at least 2 consecutive MDS 
assessments with serious pain at least 90-120 days apart).  In addition, because different 
diseases and health conditions can cause persistent pain, we conducted subgroup analysis 
in those residents with arthritis, diabetes, back pain, and osteoporosis, as recorded in the 




 Of the nearly 3 million elderly nursing home residents in our source population, 
nearly 60% had at least one MDS assessment with some degree of pain, including 22% 
with at least one episode of moderate or severe pain experienced on a daily basis for the 
prior 7 days (Figure 2.3).  Only 3.8% of eligible residents had persistent pain under our 
definition (i.e., at least 2 consecutive MDS assessments at least 90, but no more than 180, 
days apart with moderate or severe pain on a daily basis).  
Overall, 16.7% of participants with persistent non-cancer pain did not receive an 
analgesic prescription, while 53.0% received only an opioid/acetaminophen combination 
drug, 16.2% received only an opioid, 8.9% received both an opioid/acetaminophen 
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combination drug and a prescription NSAID, 2.7% received both an opioid and a 
prescription NSAID, and 2.5% received only a prescription NSAID (Table 2.1).   
Differences in Characteristics by Prescribing Status 
Participants who did or did not receive a prescription analgesic differed by 
gender, age, race, cognitive impairment, self-pay status, facility hours per resident, 
facility proportion of self-pay residents, facility for-profit status, physical impairment, 
mood, and family support (all p <=0.001) (Table 2.2).  There was no significant 
difference by resident education level (p=0.152) or facility compliance with federal law 
(p=0.817) (Table 2.2).  Of those residents not receiving any prescription analgesic, only a 
small percentage received other drugs prescribed for pain (muscle relaxant=3.9%, 
steroid=5.7%, gabapentin=10.5%) and only 8.6% received at least one day of physical 
therapy (Table 3).  Participants who did not have a prescription analgesic also had lower 
percentages for receipt of other prescribed drugs compared to those who had a prescribed 
analgesic (Table 2.3).  
Multivariate Associations 
Not receiving a prescription analgesic was associated with many individual 
resident factors (Table 2.4).  In the multivariable logistic model, after accounting for 
mood, physical impairment, family support, and facility compliance with federal law, 
residents had a greater odds for no analgesic prescribing if they were male (compared to 
female, OR=1.38, 95% CI 1.24-1.53) older (compared to ages 65-74, ages 75-84 
OR=1.30, 95% CI 1.16-1.47; ages 85-94 OR=1.63, 95% CI 1.44-1.85; ages ≥95 
OR=2.06, 95% CI 1.70-2.49); more cognitively impaired (compared to intact cognitive 
functioning, borderline intact OR=1.11, 95% CI 0.97-1.27; mild impairment OR=1.31, 
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95% CI 1.15-1.49; moderate impairment OR=1.61, 95% CI 1.42-1.83; moderate-severe 
impairment OR=2.12, 95% CI 1.71-2.62); Asian (compared to White, OR=1.97, 95% CI 
1.22-3.20) or Black (compared to White, OR=1.20, 95% CI 1.03-1.39); paid charges on 
their own (“self-pay” compared to non-self pay, OR=1.40, 95% CI 1.23-1.59); and had 
more education (compared to education less than high school graduate, high school 
graduate OR=1.10, 95% CI 1.01-1.21; college or graduate education OR=1.19, 95% CI 
1.00-1.40).   
The facility factors were not statistically significantly associated with no analgesic 
prescribing, except the facility’s proportion of self-pay residents in two categories had 
lower odds for no analgesic prescribing (compared to facilities with <10% self-pay 
residents, ≥10% to 30% OR=0.80, 95% CI 0.71-0.91; ≥30% to 50% OR=0.77, 95% CI 
0.66-0.91) and the facility’s average staff hours per resident in three categories 
(compared to facilities with < 2.5 average staff hours per resident, 2.5-3.0 hours 
OR=0.80, 95% CI 0.67-0.98; 3.0-3.5 hours OR=0.83, 95% CI 0.69-0.99; 3.5-4.0 hours 
OR=0.80, 95% CI 0.66-0.97). 
  In the sensitivity analyses, as well as subgroup analysis for residents with 
arthritis, the individual factors of increasing age, greater cognitive impairment, and self-
pay status were also statistically significantly associated with no analgesic prescribing 
(Appendices S2.A and S2.B).  In the model with the shortest time window (90-120 days 
rather than 90-180 days), the association between no analgesic prescribing and increasing 
cognitive impairment was even stronger (compared to intact functioning, moderate-
severe impairment OR=2.20, 95% CI=1.68-2.88).  For diabetic residents, Asian race 
(compared to White, Asian OR=2.52, 95% CI=1.33-4.79) and cognitive impairment 
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(compared to intact functioning, moderate-severe impairment OR=2.36, 95% CI=1.63-
3.40) were even more strongly associated with no analgesic prescribing.  
DISCUSSION 
 In our analysis of individual-level, nationally representative data capturing 
nursing home resident care, we found that nearly 17% of residents with persistent pain 
were prescribed no analgesics.  This figure is quite large, given that these residents had 
moderate-to-severe daily pain over at least a 3-month period.  We also found that more 
vulnerable residents within nursing homes, particularly the oldest-old and most 
cognitively impaired are less likely to receive prescription analgesics for this substantial, 
ongoing pain.  These findings from a national nursing home population in 2008, nearly a 
decade after the groundbreaking IOM report, reinforce the IOM concerns with pain 
neglect and care disparities in nursing homes.  
Persistent Pain and Analgesic Use 
Our findings that nearly 60% of eligible residents experienced some degree of 
pain, and that nearly 4% of residents had persistent pain, are consistent with prior studies 
assessing pain prevalence using the MDS.  These studies, depending on the specific pain 
definition, have identified pain prevalence in nursing home residents ranging between 4 
to 64%.6 Our 4% prevalence finding is lower than most studies because we used a higher 
pain intensity threshold (i.e. moderate-to-severe daily pain).  One recent study found that 
4.8% of nursing home residents had pain on a daily basis on two consecutive MDS 
assessments within 120 days.5   
We also found that 16.7% of the residents in our study population did not receive 
any prescription analgesics (i.e., opioid, NSAID, and/or acetaminophen).  This figure is 
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lower than the estimate of no analgesic use for pain in prior studies.  A study in nursing 
homes in 4 states from 1992-1995 found that approximately 25% of residents with any 
daily non-cancer pain (in one MDS assessment) did not receive any analgesics.11 Another 
study in nursing homes in 13 states from 1998-2000 found that approximately 25% of 
residents with any non-cancer pain (in two out of three quarterly MDS assessments) did 
not receive analgesics.2 Finally, a study in 185 nursing homes (predominantly in a for-
profit chain) from 2007-2009 found that approximately 23% of residents with any non-
cancer pain (in two consecutive MDS assessments) did not receive analgesics.26 A greater 
percentage of our study population may have received prescription analgesics (83.3% 
compared to 75-77% in the other three studies) because their pain levels were more 
intense with our focus on persistent pain (i.e., only including moderate or severe daily 
pain rather than any daily pain).  Because these residents experienced daily moderate-to-
severe pain over a longer duration (e.g., at least two consecutive MDS assessments at 
least 90 days apart), the lack of any analgesic prescribing for nearly 17% of these 
residents with persistent pain is concerning.  
Guidelines for Persistent Pain and Analgesic Use 
An important principle for our study is that these residents should have been 
provided a prescription analgesic at the time of persistent pain onset under our definition 
(i.e. their subsequent MDS assessment with daily moderate-to-severe pain).  Geriatric and 
nursing home practice guidelines support this principle by recommending the use of 
prescription analgesics, in addition to OTC drugs and non-pharmacological therapies, for 
persistent non-cancer pain.7,27,28 The American Geriatrics Society guideline recommends 
acetaminophen (typically found in over-the-counter medicines) as a first-line therapy for 
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pain, although cautions against maximum doses in the elderly because of potential 
hepatoxocity.7 In our study population, this first-line approach might have been 
appropriate at the initial onset of a resident’s pain (i.e., first MDS assessment with daily, 
moderate-to-severe pain).  By the time a resident experienced this intense pain 
continuously for at least 3 months under our persistent pain definition (i.e., subsequent 
MDS assessments with daily, moderate-to-severe pain), prescription analgesics would be 
appropriate under the guidelines.   
For persistent non-cancer pain that cannot be alleviated by acetaminophen, the 
guidelines recommend an NSAID or opioid prescription drug, but caution against long-
term use of NSAIDs because of the potential for gastrointestinal bleeding and 
cardiovascular risks and note the need for additional studies on long-term safety and 
effectiveness of opioid use for persistent non-cancer pain.7,27,28 A recent systematic 
review concluded that prescription opioids are “reasonable in the older patient with pain 
that has not responded to other treatments or when significant pain-related functional 
impairments are present despite treatment,” but cautioned that some studies have found 
opioids for persistent non-cancer pain to be associated with falls and hospitalizations in 
the elderly.29 One study in the nursing home setting, though, found that opioids were safe 
and effective for persistent non-cancer pain.30 Importantly, opioid addiction is not a 
significant risk in the nursing home population.7 For all of these reasons, the guidelines 
emphasize the need for careful dose selection, close monitoring of patients, and frequent 
reassessment of all analgesics for persistent pain.7,27,28  
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Alternative Therapies 
It is important to consider if these residents not receiving prescription analgesics 
might have received instead other forms of therapy for their pain.  Non-pharmacological 
therapies in nursing homes are also important for pain management.7,31-33 However, we 
found only 10% of residents in persistent pain without analgesic prescribing received any 
physical therapy, although 20% of our study population were excluded from this 
calculation because their physical therapy status was not recorded on the most recent 
MDS assessment (Table 2.3).  The percentages of these residents who received other 
drugs that might be prescribed for pain (e.g., muscle relaxant, oral steroid, gabapentin) 
were similarly low (Table 2.3).   
Factors Associated with No Analgesic Prescribing 
  Our study of nursing home residents with persistent pain identified important 
factors associated with no analgesic prescribing, including increasing age, greater 
cognitive impairment, being Black or Asian, paying for nursing home expenses on their 
own (“self-pay”), and being a high school or college graduate.  These effects remained 
even after adjustment for potential confounders: number of ADL’s requiring help, MDS 
mood score, presence of family support, and facility compliance with federal law.  We 
found this effect increased steadily with the increasing categories of age and cognitive 
impairment.  The strongest effect we identified, with an approximate doubling in the odds 
for no analgesic prescribing, was for those residents with oldest age (≥95 years) and 
moderate-severe cognitive impairment.   
These associations for increasing age, greater cognitive impairment, and non-
white race are consistent with our hypothesis that residents with these factors would be 
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less likely to receive analgesic prescriptions for persistent pain.  Prior studies have also 
found that increasing age, cognitive impairment, and non-white race are associated with 
no analgesic prescribing for those residents with non-cancer pain11,26 and cancer pain.15 
Our study expands these findings to a national nursing home population with persistent 
non-cancer pain.  These conclusions raise important concerns about disparities in 
treatment for more vulnerable subpopulations within nursing homes.       
Our finding that residents with greater socioeconomic status (i.e. resident self-pay 
and college/graduate school education) also have greater odds for not receiving 
prescription analgesics is the opposite conclusion from our hypothesis.  This result may 
indicate that residents who cannot pay for nursing home charges on their own, but instead 
receive formal assistance (such as through Medicaid), may receive better pain 
management care, but this possible explanation must be explored further.  In addition, a 
nursing home resident’s education level may be less helpful for actual care in the nursing 
home, after controlling for family support.   
For facility characteristics, the increasing proportion of self-pay residents (for the 
10-30% and 30-50% categories) was statistically significantly associated with lesser odds 
for no analgesic prescribing (i.e., equivalent to a greater odds for prescribing), which was 
consistent with our hypothesis for this factor.  This is consistent with a prior study’s 
conclusion that nursing home facilities with less than 10% private pay residents (and 
greater than 85% Medicaid residents) had poorer quality of care (measured by health 
deficiencies).34  
In addition, consistent with our hypothesis, there appears to be an association 
between increasing staff hours per resident and greater analgesic prescribing (i.e., odds 
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decrease for no analgesic prescribing), which peaks at the 3.5-4.0 staff hours per resident 
level.  A recent systematic review, though, cautioned against an overemphasis on staff 
numbers for the quality of care in nursing homes because of the importance of other 
staffing factors, such as staff turnover rates.35 Despite our hypothesis, we did not find any 
statistically significant association between for-profit status and analgesic prescribing.  
Interestingly, although treated as a confounder in our model, an increase in the 
number of mood indicators in a resident was statistically significantly associated with 
lower odds (nearly half for the category with most mood indicators) for no analgesic 
prescribing (i.e., equivalent to greater odds for analgesic prescribing).  This was 
consistent with the findings from another recent study26 and may indicate that residents 
with greater mood distress (e.g., verbal expression of distress, crying, tearfulness, 
repetitive health complaints) are more likely to receive staff attention for pain medicine 
prescribing.  This result may indicate that residents with less apparent distress are less 
likely to receive analgesic therapy, despite having persistent pain.  We also found that 
being male was associated with greater odds for no analgesic prescribing, which appears 
to be a new finding, although we did not include this relationship in our hypotheses. 
Implications 
 A critical question is how nursing homes can utilize our findings and consider 
modifying or adopting new practices and policies to help ensure that elderly residents 
with persistent non-cancer pain are receiving adequate treatment.  Many recent efforts 
have focused on improving the quality of pain care in nursing homes and emphasized the 
importance of multimodal approaches incorporating better pain assessment methods, 
improved communication between staff and clinicians, provision of pharmacological and 
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non-pharmacological treatments, and training and education for all of these steps.31,36,37 
For example, one initiative in 49 long-term care facilities increased the percentage of 
residents in pain receiving analgesics from 83 percent (similar to the percentage found in 
our study) to 90 percent.37 In addition, these efforts should ensure that more vulnerable 
subpopulations within nursing homes (e.g., more cognitively impaired, older, and non-
white residents), as well as residents who are male or have fewer mood symptoms, are 
not overlooked.   
Strengths and Limitations 
Our study has important strengths, particularly the generalizability of the results, 
because our study population is drawn from all nursing home residents in the United 
States.  In addition, our measures are based on comprehensive nursing home (MDS and 
OSCAR) and prescribing (Part D) data.  Importantly, we have addressed essential 
research needs identified by the IOM to estimate the extent of analgesic prescribing for 
nursing home residents in persistent pain and identify specific subpopulations that are 
less likely to receive analgesics. We were able to examine both individual and facility 
level factors, including SES, and control for potential confounders, including whether 
residents had family support and whether the facility was in compliance with federal law.  
Our study results confirm and expand upon prior research findings.  These results were 
similar in our sensitivity analysis using a stricter definition of persistent pain. 
The study also has important limitations.  Because the MDS 2.0 measures are 
used by the federal government to assess nursing home quality, it is possible that 
measures associated with poorer quality care (particularly pain) may be underreported.38 
This potential weakness might mean some residents with persistent pain were 
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inappropriately excluded from the study population.  In addition, the time lag between 
MDS measurements did not allow us to identify pain status on a more frequent basis 
within the 90-day period.  Nursing home MDS assessors may also fail to measure pain 
accurately.  To address any misclassification for persistent pain status (and study 
inclusion), we used alternative definitions in our sensitivity analysis and found similar 
results.  We also did not incorporate data about over-the-counter analgesic use.  Under 
current guidelines, though, over-the-counter analgesics would likely not be sufficient for 
those residents at the time of persistent pain onset (i.e., their subsequent consecutive 
MDS assessment with moderate-to-severe daily pain).7 Finally, we did not assess the 
dosing of prescription analgesics or other concomitant medication use to determine if the 
analgesic prescription was appropriate under the guidelines. 
CONCLUSION 
Our findings, from a study population drawn from all nursing home residents in the 
United States, indicate that a large proportion of nursing home residents with persistent 
pain are not receiving needed prescription analgesic therapy.  In addition, certain resident 
factors (i.e., being male, older, more cognitively impaired, Black or Asian, and higher 
SES) are associated with lower analgesic prescribing rates.  These results support the 
need for ongoing efforts by nursing homes to improve analgesic prescribing for residents 
in persistent pain, as well as additional steps to focus on these more neglected 
subpopulations. 
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Figures and Tables 
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Aged 65 and older 
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After Exclusions 
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Figure 2.2.  Prescription Analgesics Used in Nursing Homes in 2008.  
 
Opioids (Mu Agonist) NSAIDS (Non-Selective)* Acetaminophen 
   
Codeine Aspirin Acetaminophen 
Fentanyl Diclofenac Combinations with 
Hydrocodone Diflunisal Opioids, NSAIDs 
Hydromorphone Etodolac  
Levorphanol Fenoprofen  
Meperedine Flurbiprofen  
Methadone Ibuprofen  
Morphine Indomethacin  
Oxycodone Ketoprofen  
Oxymorphone Ketorolac  
Propoxyphene Meloxicam  
 Nabumetone  
Opioids (Dual Mechanism) Naproxen  
 Oxaprozin  
Tramadol Piroxicam  
 Sulindac  
 Tolmetin  
   
 NSAIDS (COX-2 Selective)*  
   
 Celexocib  
   
* NSAID=Non-Steroidal Anti-Inflammatory Drug 
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  Intermediate 
        581,857 
             20% 
Lowest 
  515,561 










-Severe or Moderate 
-Less Than Daily 
 
Lowest Pain  
-Mild Pain 
-Daily or Less Than Daily 
	  
	  
	  Number of Residents in Each Pain Category 
2,986,069 Total Residents 
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Table 2.1.  Analgesics Prescribed for Study Population with Persistent Pain 
(n=18,526) 
 
Analgesic Drug Number (Percentage)* 
Prescription Opioid Combinations 14,947  (80.7%) 
 Opioid Only 3,002 (16.2%) 
 Opioid and Acetaminophen 9,813 (53.0%) 
 Opioid and NSAID      49   (2.7%) 
 Opioid, Acetaminophen, and NSAID 1,639   (8.9%) 
Prescription NSAID Only     485     (2.6%) 
No Prescription Analgesic  3,094   (16.7%) 
* Percentages calculated for whole study population 
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Table 2.2.  Characteristics in Model of Nursing Home Residents in Persistent Pain 
in 2008 by Analgesic Prescribing (n=18,526)*  






Opioid or NSAID 
N (%)** 
Did Not Receive 
Prescription 




Total Population 15,432 (83.3%) 3,094 (16.7%)  
Characteristics    
Gender   <0.001 
Female 12,659 (82.0) 2,422 (78.3)  
Male 2,773 (18.0) 672 (21.7)  
Age <0.001 
65-74 3,787 (24.5) 564 (17.7)  
75-84 5,791 (37.5) 1,076 (34.8)  
85-94 5,057 (32.8) 1,219 (39.4)  
≥95  797 (5.2) 253 (8.2)  
Race <0.001 
White 13,415 (87.0) 2,599 (84.0)  
Black 1,367 (8.9) 337 (10.9)  
Hispanic 493 (3.2) 115 (3.7)  
Asian 76 (0.5) 31 (1.0)  
Other 81 (0.5) 12 (0.4)  
Cognitive Impairment by CPS Score <0.001 
Intact=0 4,317 (28.0) 652 (21.1)  
Borderline 
Intact=1 
3,141 (20.4) 523 (16.9)  
Mild 
Impairment=2 
3,427 (22.2) 731 (23.6)  
Moderate 
Impairment=3 
3,984 (25.8) 994 (32.1)  
Moderate-Severe 
Impairment=4 
563 (3.7) 194 (6.3)  
Resident Self-Pay <0.001 
No 13,720 (88.9) 2,586 (83.6)  
Yes 1,712 (11.1) 508 (16.4)  
Education Level 0.152 
<High 
School Graduate 
5,909 (38.3) 1,145 (37.0)  
High School  
Graduate 
8,586 (55.6) 1,737 (56.1)  
College Graduate 937 (6.1) 212 (6.9)  
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Staff Hours Per Resident 0.001 
<2.5 Hours 1,713 (7.6) 308 (10.0)  
2.5-3.0 Hours 2,597 (16.8) 523 (16.9)  
3.0-3.5 Hours 4,473 (29.0) 882 (28.5)  
3.5-4.0 Hours 3,772 (24.4) 712 (23.0)  
4.0-4.5 Hours 2,047 (13.3) 391 (12.6)  
>4.5 Hours 1,370 (8.9) 278 (9.0)  
Facility’s Proportion of Residents Self-Pay <0.001 
<10% 2,799 (18.1)  624 (20.2)  
10-30% 8,957 (58.0) 1,665 (53.8)  
30-50% 2,931 (19.0)  599 (19.4)  
>50% 745 (4.8) 206 (6.7)  
Facility For Profit <0.001 
No 4,310 (27.9) 976 (31.5)  
Yes 11,122 (72.1) 2,118 (68.5)  
ADL Help: Morris Additive Scale <0.001 
0 ADLs  1,291 (8.4) 206 (6.7)  
1-7 ADLs 2,972 (19.3) 521 (16.8)  
8-14 ADLs 3,482 (22.6) 690 (22.3)  
15-21 ADLs 5,396 (35.0) 1,129 (36.5)  
22-28 ADLs 2,291 (14.9) 548 (17.7)  
MDS Mood Scale <0.001 
0 7,568 (49.0) 1,669 (53.9)  
1-2 3,829 (24.8) 751 (24.3)  
3-4 2,847 (18.5) 473 (15.3)  
5-6 1,043 (6.8) 178 (5.8)  
7-8 145 (0.9) 23 (0.7)  
Family Support   <0.001 
No 8,652 (56.1) 1,603 (51.8)  
Yes 6,780 (43.9) 1,491 (48.2)  
Facility Compliant with Federal Law 0.817 
Yes 13,644 (88.4) 2,731 (88.3)  
No 1,788 (11.6) 363 (11.7)  
Notes: Due to rounding, percentages do not all sum to 100.  NSAID=Non-Steroidal Anti-
Inflammatory Drug.  ADL=Activities of Daily Living.  CPS=Cognitive Performance Scale. 
 
* Excludes 623 (3.3%) observations with missing values. 
** All percentages correspond to row totals. 
*** p value corresponds to the Χ2 statistic. 
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Table 2.3.  Additional Treatments or Medications for Nursing Home Residents in 
Persistent Pain in 2008 by Analgesic Prescribing (n=18,526)*  






Opioid or NSAID 
N (%)** 
Did Not Receive 
Prescription 




Total Population 15,432 (83.3%) 3,094 (16.7%)  
Treatments    
Muscle Relaxant <0.001 
No 14,034 (90.9) 2,972 (96.1)  
Yes 1,398 (9.1) 122 (3.9)  
Steroid <0.001 
No 13,856 (89.8) 2,917 (94.3)  
Yes 1,576 (10.2) 177 (5.7)  
Gabapentin <0.001 
No 12,222 (79.2) 2,770 (89.5)  
Yes 3,210 (20.8)  324 (10.5)  
Anti-Depressant <0.001 
No 4,806 (31.1) 1,591 (51.4)  
Yes 10,626 (68.9) 1,503 (48.6)  
Anti-Psychotic 0.065 
No 12,320 (79.8) 2,515 (81.3)  
Yes 3,112 (20.2) 579 (18.7)  
Mood Stabilizing/Anti-Convulsant <0.001 
No 11,222 (72.7) 2,607 (84.3)  
Yes 4,210 (27.3) 487 (15.7)  
Anti-Anxiety <0.001 
No 14,857 (96.3) 3,030 (97.9)  
Yes 575 (3.7) 64 (2.1)  
Physical Therapy (at least 1 day)**** 0.271 
No 11,318 (92.0) 2,338 (91.4)  
Yes 982 (8.0) 221 (8.6)  
Notes: Due to rounding, percentages do not all sum to 100.  NSAID=Non-Steroidal Anti-
Inflammatory Drug.  ADL=Activities of Daily Living.  CPS=Cognitive Performance Scale. 
 
* Excludes 623 (3.3%) observations with missing values. 
** All percentages correspond to row totals. 
*** p value corresponds to the Χ2 statistic. 
**** Excluded 3,667 (19.8%) additional observations without physical therapy recorded. 
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Table 2.4.  Odds Ratios for Not Receiving a Prescription Pain Medicine. 
 
 Univariate Models* (n=18,526) Multivariate Model** (n=18,526) 
 Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender       
Female (Ref)   (Ref)   
Male 1.30  1.17-1.44 <0.001 1.38 1.24-1.53 <0.001 
Age        
65-74 (Ref)   (Ref)   
75-84 1.29 1.16-1.46 <0.001 1.30 1.16-1.47 <0.001 
85-94 1.66 1.48-1.87 <0.001 1.63 1.44-1.85 <0.001 
≥95  2.18 1.82-2.61 <0.001 2.06 1.70-2.49 <0.001 
Race       
White (Ref)   (Ref)   
Black 1.25 1.09-1.45 0.002 1.20 1.03-1.39 0.017 
Hispanic 1.10 0.87-1.38 0.444 1.07 0.84-1.35 0.600 
Asian 2.18 1.35-3.53 0.002 1.97 1.22-3.20 0.006 
Other 0.85 0.44-1.63 0.623 0.94 0.48-1.82 0.854 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
1.09 0.96-1.25 0.181 1.11 0.97-1.27 0.120 
Mild 
Impairment=2 
1.37 1.21-1.55 <0.001 1.31 1.15-1.49 <0.001 
Moderate 
Impairment=3 




2.29 1.87-2.79 <0.001 2.12 1.71-2.62 <0.001 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
1.03 0.94-1.12 0.551 1.10 1.01-1.21 0.035 
College 
Graduate  
1.18 0.99-1.41 0.060 1.22 1.02-1.46 0.029 
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 Univariate Models (continued) Multivariate Model (continued) 
Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.82 0.68-0.99 0.040 0.80 0.67-0.98 0.027 
3.0-3.5 Hours 0.85 0.71-1.02 0.087 0.83 0.69-0.99 0.044 
3.5-4.0 Hours 0.85 0.70-1.02 0.084 0.80 0.66-0.97 0.021 
4.0-4.5 Hours 0.89 0.72-1.10 0.290 0.81 0.66-1.01 0.061 
>4.5 Hours 0.92 0.73-1.16 0.479 0.81 0.64-1.02 0.073 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 0.82 0.72-0.92 0.001 0.80 0.71-0.91 0.001 
30-50% 0.85 0.73-0.99 0.040 0.77 0.66-0.91 0.002 
>50% 1.16 0.93-1.45 0.179 0.91 0.72-1.16 0.454  
Facility For Profit 
No (Ref)      
Yes 0.87 0.78-0.97 0.009 0.91 0.81-1.01 0.078 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.09 0.91-1.31 0.357 1.00 0.83-1.20 0.980 
8-14 ADLs 1.27 1.06-1.52 0.009 1.11 0.92-1.33 0.285 
15-21 ADLs 1.36 1.14-1.62 0.001 1.15 0.96-1.37 0.130 
22-28 ADLs 1.56 1.30-1.89 <0.001 1.21 0.99-1.47 0.059  
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.85 0.77-0.95 0.003 0.82 0.74-0.91 <0.001 
3-4 0.72 0.64-0.81 <0.001 0.67 0.59-0.76 <0.001 
5-6 0.70 0.58-0.84 <0.001 0.61 0.51-0.74 <0.001 
7-8 0.65 0.40-1.04 0.069 0.52 0.32-0.83 0.007  
Family Support 
No (Ref)   (Ref)   
Yes 1.17 1.07-1.27 <0.001 1.09 1.00-1.19 0.042 
Facility Compliant with Federal Law 
Yes   (Ref)   (Ref)   
No  1.01 0.87-1.17 0.870 1.00 0.86-1.16 0.977 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Univariate Logistic Models.  This column presents the univariate logistic model results for each 
individual variable, unadjusted for the other variables. 
** Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive 
functioning; resident self-pay status; education; facility average staff hours per resident; facility 
percentage of residents who self-pay; facility for-profit status; resident number of activities of 
daily living (ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, 
resident family support; and facility compliance with federal law. 
 
All regressions used multi-level modeling at the state and facility levels. 
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Appendix S2.A.  Sensitivity Analyses: Vary Definition of “Persistent Pain” in 
Multivariate Models.*  Odds Ratios for Not Receiving a Prescription Pain Medicine. 
 
 Model 1: At least 3 consecutive 
visits at least 90-180 days apart 
(n=10,568) 
Model 2: At least 2 consecutive 




Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 1.43  1.24-1.65 <0.001 1.36 1.18-1.57 <0.001 
Age  
65-74 (Ref)   (Ref)   
75-84 1.44 1.23-1.70 <0.001 1.21 1.02-1.42 0.026 
85-94 1.80 1.52-2.13 <0.001 1.54 1.30-1.83 <0.001 
≥95  2.00 1.52-2.62 <0.001 2.08 1.63-2.68 <0.001 
Race 
White (Ref)   (Ref)   
Black 1.41 1.16-1.71 0.001 1.05 0.86-1.29 0.639 
Hispanic 1.05 0.75-1.48 0.777 1.15 0.85-1.56 0.350   
Asian 2.20 1.06-4.55 0.035 1.78 0.95-3.33 0.070 
Other 0.61 0.20-1.84 0.383 1.14 0.50-2.59 0.749 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
1.11 0.93-1.32 0.258 1.13 0.94-1.36 0.189 
Mild 
Impairment=2 
1.24 1.05-1.48 0.014 1.43 1.20-1.70 <0.001 
Moderate 
Impairment=3 




2.01 1.50-2.70 <0.001 2.24 1.69-2.98 <0.001 
Resident Self-Pay 
No (Ref)   (Ref)   
Yes 1.41 1.18-1.67 <0.001 1.40 1.18-1.70 <0.001 
Education Level       
<High School 
Graduate 
(Ref)   (Ref)   
High School 
Graduate 
1.05 0.92-1.18 0.477 1.22 1.08-1.38 0.002 
College Graduate  1.10 0.86-1.41 0.427 1.39 1.09-1.78 0.008 
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 Model 1 (continued) Model 2 (continued) 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.92 0.71-1.19 0.521 0.71 0.56-0.90 0.005 
3.0-3.5 Hours 0.82 0.64-1.06 0.127 0.80 0.64-1.01 0.056 
3.5-4.0 Hours 0.79 0.60-1.02 0.071 0.75 0.59-0.95 0.018 
4.0-4.5 Hours 0.82 0.62-1.10 0.190 0.78 0.59-1.02 0.069 
>4.5 Hours 0.85 0.61-1.16 0.300 0.73 0.54-0.98 0.035 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 0.75 0.64-0.89 0.001 0.84 0.71-0.98 0.032 
30-50% 0.74 0.60-0.92 0.006 0.80 0.64-0.98 0.034 
>50% 0.80 0.58-1.09 0.159 0.98 0.71-1.34 0.884 
Facility For Profit 
No (Ref)      
Yes 0.87 0.75-1.01 0.061 0.95 0.80-1.07 0.300 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.14 0.88-1.48 0.331 0.92 0.72-1.19 0.534 
8-14 ADLs 1.18 0.91-1.52 0.215 1.00 0.78-1.28 0.995 
15-21 ADLs 1.25 0.97-1.59 0.081 1.06 0.83-1.34 0.652 
22-28 ADLs 1.38 1.05-1.81 0.022 1.09 0.84-1.42 0.523 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.79 0.69-0.20 0.002 0.82 0.71-0.94 0.006 
3-4 0.63 0.54-0.75 <0.001 0.72 0.61-0.86 <0.001 
5-6 0.56 0.44-0.73 <0.001 0.68 0.53-0.87 0.003 
7-8 0.61 0.33-1.12 0.114 0.36 0.17-0.79 0.011 
Family Support 
No (Ref)   (Ref)   
Yes 1.10 0.98-1.24 0.101 1.11 0.99-1.25 0.076 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  0.96 0.79-1.16 0.657 1.10 0.91-1.33 0.332 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive functioning; 
resident self-pay status; education; facility average staff hours per resident; facility percentage of 
residents who self-pay; facility for-profit status; resident number of activities of daily living 
(ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, resident 
family support; and facility compliance with federal law. 
 
All regressions used multi-level modeling at the state and facility levels. 
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Appendix S2.B.  Subgroup Analysis by Disease or Condition: Four Multi-Level 
Models.*  Odds Ratios for Not Receiving a Prescription Pain Medicine. 
 
 Model 1: Arthritis (n=8,589) Model 2: Diabetes (n=6,403) 
 
Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 1.43  1.20-1.70 <0.001 1.39 1.17-1.66 <0.001 
Age  
65-74 (Ref)   (Ref)   
75-84 1.22 1.00-1.49 0.046 1.34 1.11-1.61 0.002 
85-94 1.59 1.30-1.94 <0.001 1.56 1.26-1.92 <0.001 
≥95  2.16 1.64-2.87 <0.001 1.46 0.91-2.32 0.114 
Race 
White (Ref)   (Ref)   
Black 1.49 1.20-1.86 <0.001 1.28 1.03-1.60 0.029 
Hispanic 1.00 0.66-1.51 0.998 1.20 0.85-1.70 0.296 
Asian 1.94 0.89-4.27 0.098 3.00 1.48-6.09 0.002 
Other 1.13 0.37-3.42 0.827 1.45 0.62-3.44 0.394 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
0.95 0.77-1.16 0.620 1.09 0.87-1.37 0.450 
Mild 
Impairment=2 
1.13 0.93-1.37 0.219 1.36 1.09-1.70 0.006 
Moderate 
Impairment=3 




1.70 1.20-2.39 0.003 2.40 1.64-3.51 <0.001 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
1.08 0.94-1.24 0.261 1.03 0.88-1.20 0.723 
College 
Graduate 
1.21 0.92-1.59 0.166 1.04 0.74-1.45 0.836 
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 Model 1: Arthritis (continued) Model 2: Diabetes (continued) 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.89 0.67-1.19 0.427 0.69 0.50-0.95 0.024 
3.0-3.5 Hours 1.03 0.78-1.35 0.832 0.88 0.65-1.18 0.390 
3.5-4.0 Hours 0.95 0.71-1.26 0.704 0.92 0.67-1.27 0.626 
4.0-4.5 Hours 0.99 0.73-1.36 0.966 0.83 0.58-1.18 0.300 
>4.5 Hours 1.02 0.73-1.43 0.909 0.85 0.58-1.25 0.419 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 0.81 0.67-0.97 0.019 0.86 0.70-1.05 0.130 
30-50% 0.77 0.61-0.97 0.024 0.80 0.61-1.04 0.097 
>50% 0.90 0.64-1.26 0.530 1.05 0.69-1.61 0.808 
Facility For Profit 
No (Ref)      
Yes 0.82 0.70-0.96 0.012 0.86 0.72-1.04 0.114 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.04 0.78-1.40 0.663 0.96 0.68-1.34 0.775 
8-14 ADLs 1.12 0.84-1.49 0.446 1.15 0.83-1.60 0.394 
15-21 ADLs 1.18 0.90-1.56 0.102 1.08 0.79-1.47 0.650 
22-28 ADLs 1.29 0.95-1.76 0.058 1.14 0.81-1.61 0.459 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.85 0.73-1.00 0.051 0.78 0.65-0.94 0.010 
3-4 0.66 0.55-0.80 <0.001 0.66 0.53-0.82 <0.001 
5-6 0.63 0.49-0.83 0.001 0.51 0.36-0.73 <0.001  
7-8 0.57 0.30-1.07 0.079 0.66 0.29-1.52 0.333  
Family Support 
No (Ref)   (Ref)   
Yes 0.98 0.86-1.12 0.810 1.09 0.93-1.27 0.276 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  0.89 0.72-1.10 0.279 1.12 0.88-1.41 0.357 
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 Model 3: Back Pain (n=2,141) Model 4: Osteoporosis (n=4,818) 
 Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 1.53  1.06-2.22 0.023 1.51 1.09-2.09 0.014 
Age 
65-74 (Ref)   (Ref)   
75-84 1.08 0.72-1.62 0.719 1.11 0.84-1.48 0.457 
85-94 1.50 0.99-2.29 0.057 1.47 1.11-1.95 0.006 
≥95  2.29 1.24-4.22 0.008 2.50 1.72-3.66 <0.001 
Race 
White (Ref)   (Ref)   
Black 0.93 0.47-1.83 0.823 1.13 0.76-1.69 0.545 
Hispanic 1.70 0.74-3.90 0.209 1.37 0.81-2.32 0.238 
Asian 7.30 1.34-39.72 0.021 1.99 0.86-4.60 0.108 
Other 2.92 0.27-32.02 0.381 1.07 0.28-4.10 0.916 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
1.91 1.21-3.00 0.005 1.22 0.91-1.63 0.178 
Mild 
Impairment=2 
1.40 0.89-2.19 0.142 1.33 1.02-1.75 0.038 
Moderate 
Impairment=3 




2.37 1.04-5.40 0.040 1.96 1.23-3.12 0.005 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
1.56 1.13-2.15 0.006 0.99 0.82-1.21 0.954 
College 
Graduate  
1.57 0.86-2.88 0.142 1.17 0.82-1.69 0.387 
Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.80 0.48-1.34 0.401 0.65 0.44-0.96 0.032 
3.0-3.5 Hours 0.67 0.40-1.10 0.116 0.80 0.56-1.14 0.215 
3.5-4.0 Hours 0.51 0.30-0.88 0.015 0.62 0.42-0.91 0.015 
4.0-4.5 Hours 0.51 0.27-0.96 0.038 0.88 0.58-1.33 0.551 
>4.5 Hours 0.36 0.17-0.76 0.007 0.78 0.50-1.22 0.272 
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 Model 3: Back Pain (continued) Model 4: Osteoporosis (continued) 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 0.80 0.53-1.22 0.302 0.82 0.64-1.07 0.142 
30-50% 0.63 0.38-1.04 0.069 0.74 0.54-1.01 0.060 
>50% 0.88 0.43-1.79 0.731 1.25 0.82-1.91 0.299 
Facility For Profit 
No (Ref)      
Yes 0.71 0.50-1.01 0.057 0.99 0.80-1.23 0.919 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.64 0.89-3.03 0.112 0.86 0.57-1.29 0.463 
8-14 ADLs 1.10 0.59-2.07 0.759 1.06 0.72-1.56 0.766 
15-21 ADLs 2.03 1.13-3.66 0.018 1.20 0.83-1.75 0.329 
22-28 ADLs 1.85 0.94-3.66 0.077 1.15 0.75-1.76 0.520 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.82 0.59-1.16 0.266 0.83 0.67-1.03 0.089 
3-4 0.60 0.39-0.91 0.016 0.63 0.49-0.82 0.001 
5-6 0.35 0.20-0.63 <0.001 0.71 0.50-1.01 0.057 
7-8 0.72 0.29-1.80 0.483 0.60 0.25-1.44 0.253 
Family Support 
No (Ref)   (Ref)   
Yes 1.21 0.90-1.62 0.206 1.04 0.87-1.25 0.646 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  1.13 0.73-1.74 0.594 1.18 0.90-1.56 0.229 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive functioning; 
resident self-pay status; education; facility average staff hours per resident; facility percentage of 
residents who self-pay; facility for-profit status; resident number of activities of daily living 
(ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, resident 
family support; and facility compliance with federal law. 
 
All regressions used multi-level modeling at the state and facility levels. 
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Abstract 
 
Objective:  FDA has warned that transdermal fentanyl should be limited to individuals 
with prior opioid use and persistent pain.  Our objective was to quantify the prevalence of 
transdermal fentanyl prescribing in elderly nursing home residents without prior opioid 
use or persistent pain and the association of individual and facility traits with opioid-
naïve prescribing. 
 
Design:  Cross-sectional study. 
 
Setting:  Linked Minimum Data Set (MDS) assessments; Online Survey, Certification 
and Reporting (OSCAR) records; and Medicare Part D claims. 
 
Participants:  From a cross-section of all long-stay U.S. nursing home residents in 2008 
with an MDS assessment and Medicare Part D enrollment, we identified individuals (≥65 
years old) who initiated transdermal fentanyl, excluding those with Alzheimer’s, severe 
cognitive impairment, cancer or receipt of hospice care. 
 
Measurements:  We used Medicare Part D to select beneficiaries initiating transdermal 
fentanyl in 2008 and examined whether they were “opioid-naïve,” defined as no opioid 
prescriptions during the previous 60 days.  We obtained resident and facility 
characteristics from MDS and OSCAR records and defined persistent pain as moderate-
to-severe, daily pain on consecutive MDS assessments at least 90 days apart.  We 
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estimated associations of patient and facility attributes and opioid-naïve fentanyl 
initiation using multilevel mixed effects logistic regression analyses.   
 
Results:  Among 17,052 residents who initiated transdermal fentanyl, 6,190 (36.3%) were 
opioid-naïve and 15,659 (91.8%) did not have persistent pain.  In the regression analysis 
with adjustments, residents who were older (compared to those 65-74, ages 75-84 odds 
ratio (OR)=1.16, 95% CI=1.04-1.29; ages 85-94 OR=1.30, 95% CI 1.16-1.44; ages ≥95 
OR= 1.69, 95% CI = 1.46-1.95) or more cognitively impaired (compared to no cognitive 
impairment, borderline intact OR=1.06, 95% CI=0.93-1.20; mild impairment OR=1.31, 
95% CI=1.16-1.47; moderate impairment OR=1.60, 95% CI=1.44-1.78; moderate-to-
severe cognitive impairment, OR=1.99, 95% CI = 1.73-2.29) were more likely to initiate 
transdermal fentanyl without prior opioid use.  
 
Conclusion:  Most nursing home residents initiating transdermal fentanyl did not have 
persistent pain and many were opioid-naïve.  Changes in prescribing practices may be 
necessary to ensure FDA warnings are followed, particularly for vulnerable subgroups 
such as the cognitively impaired.  
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INTRODUCTION 
 
Nursing home care is critical for the health of millions in the United States.  
Nearly 3 million Americans aged 65 years and older resided in a nursing home at some 
point in 2009, and over 1 million of these residents were 85 years and older.1 More 
elderly will reside in nursing homes as the American population grows.  Most elderly 
nursing home residents experience significant diseases and debilitating conditions related 
to older age.  Nearly three-quarters of nursing home residents need assistance with at 
least one basic “activity of daily living” (ADL) and half need assistance with at least four 
ADLs.1 Forty percent of nursing home residents also have a moderate or severe cognitive 
deficit.1 Because of these qualities, nursing home residents are a vulnerable population 
who require special care.  
Pain is a common condition for many nursing home residents, including persistent 
pain (typically defined as occurring over a three-month period or longer).2 Prior studies 
have found that between 45 to 80 percent of residents experience some degree of pain 
that impairs functioning and quality of life3 and 5 to 49 percent of residents have 
persistent non-cancer pain, depending on the duration and intensity threshold.2,4,5 Pain in 
elderly nursing home residents can adversely affect their physical functioning, mental 
health, and social engagement, and thus severely limit their quality of life.6-8 Many 
nursing home residents are more vulnerable to pain’s damaging effects because of their 
greater frailty and diminished resilience.7  
Geriatric and nursing home guidelines recommend analgesics as an important 
option for treating resident pain, including acetaminophen, nonsteroidal anti-
inflammatory drugs (NSAIDs), and prescription opioids.9-11 Prescription opioids in 
particular have been used for decades to treat brief, acute pain, as well as cancer pain.12 
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These guidelines also recommend prescription opioids to treat persistent non-cancer pain 
under some conditions but note that additional studies are needed on their long-term 
safety and effectiveness.9-11 The elderly are particularly vulnerable to side effects from 
opioids.9-11  
Transdermal fentanyl is a long-acting opioid commonly prescribed for nursing 
home residents with pain.13 The U.S. Food and Drug Administration (FDA) initially 
approved transdermal fentanyl in 1990 for patients with moderate–to-severe, continuous 
pain who have been receiving opioid therapy (and are thus opioid-tolerant).14 FDA 
established the drug’s approved conditions of use, including warnings, that are specified 
in the drug’s labeling.15 Transdermal fentanyl is contraindicated in patients who do not 
have moderate-to-severe, continuous pain, and who are not opioid-tolerant from taking 
another opioid drug, such as a short-acting or other long-acting form.16 Patients who have 
only mild or intermittent pain, or who have not received any prior opioid drug (and are 
thus “opioid naïve”), deviate most significantly from the FDA-approved conditions.   
Inappropriate prescribing of transdermal fentanyl poses significant risks to 
nursing home residents.  Respiratory depression in opioid-naïve patients is an important 
concern.15 Because FDA received reports of death and life-threatening adverse events 
when the drug was used in patients who did not have moderate-to-severe, continuous pain 
or who were not opioid-tolerant, FDA communicated this risk in 2005 to the public and 
health care providers in a Public Health Advisory (PHA)17 and Information for Health 
Care Professionals (IHCP).18 FDA issued a second PHA19 and IHCP20 in December 2007 
when the agency continued to receive these serious adverse event reports. 
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Health care providers can rely, among other things, on the drug’s labeled 
conditions (including warnings and contraindications) and FDA’s safety updates (such as 
the Information for Healthcare Professionals) to determine whether a nursing home 
resident should be prescribed an opioid drug. The guidelines for pain management in the 
elderly and at nursing homes emphasize that prescription opioids must be selected 
appropriately for each patient according to FDA-approved labeled conditions.9,10 CMS 
guidelines emphasize that nursing homes should follow current practice standards, 
including the FDA-approved labeling conditions, in treating a resident’s pain with 
medication.21 In this way the practice and CMS guidelines incorporate the FDA’s 
condition that only patients with moderate-to-severe, continuous pain, and who are 
opioid-tolerant, initiate transdermal fentanyl.  
A critical question is whether these guidelines and FDA warnings are being 
followed for opioid prescribing in nursing homes.  The Institute of Medicine (IOM) has 
expressed significant concerns with inadequate care for nursing home residents, including 
for pain management and inappropriate drug prescribing.12 These care inadequacies may 
be more severe for more vulnerable subpopulations within nursing homes and at specific 
types of facilities.  Prior studies have identified disparities in pain management for 
nursing home residents who are older, non-white, and cognitively impaired.8,22-24 Certain 
facility characteristics, such as for-profit status, have also been associated with worse 
health outcomes for residents.25  
To determine whether transdermal fentanyl prescribing in this vulnerable elderly 
population has complied with FDA safety communications and drug labeling indications, 
we assessed data on nursing home residents, facilities, and medication prescribing in 
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2008 from the national Minimum Data Set (MDS), the Online Survey, Certification, and 
Reporting (OSCAR) database, and Medicare Part D.  Specifically, we evaluated the 
extent of transdermal fentanyl prescribing for elderly nursing home residents and 
determined whether residents receiving fentanyl transdermal prescriptions for the first 
time had moderate-to-severe, continuous pain and were not taking another opioid (opioid-
naïve).  We then assessed whether certain individual and facility-level factors were 




 Our source population was the approximately 1.4 million individuals who resided 
in a nursing home in the United States at any time between January 1, 2008, and 
December 31, 2008, and had at least one prescription drug documented in a Part D 
record.  Approximately 81% of nursing home residents were estimated to have enrolled 
in the Part D program in 2006 just prior to our study period.26 The Part D prescription 
record provides information about the drug, dose, dosage form strength, and days 
supply.27 We also relied on MDS measurements to create our study population.  All 
United States nursing homes are required by federal law (for Medicare and/or Medicaid 
certification) to use the MDS survey instrument to assess each nursing home resident 
periodically.28    
Inclusion Criteria.  Only those residents who received a transdermal fentanyl 
prescription in 2008 were eligible for our study, which narrowed the population to 
101,809 residents (7.3% of the source population) (Figure 3.1).  From this population, we 
only included residents with at least one MDS record before fentanyl initiation. We 
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defined fentanyl initiation as the date of a resident’s first transdermal fentanyl 
prescription during 2008.  We also defined the “duration end date” for each prescription 
by adding the number of days’ supply to the prescription date.  Only new fentanyl users 
were included in the study, defined as those residents who did not have an earlier 
transdermal fentanyl prescription with a duration end date within the two months prior to 
fentanyl initiation (e.g., the two-month window).  In addition, only those residents who 
had at least one Part D prescription during this two-month prior window and who were 
65 years or older were eligible for our study.  Finally, we only included those residents 
who had a long-term stay (defined as at least 90 continuous days) prior to their 
transdermal fentanyl initiation.  There were 32,244 eligible residents who met these 
criteria (Figure 3.1). 
Exclusion Criteria.  We excluded those individuals who had cancer or were 
terminally ill because of the distinct pain management issues faced by this patient 
population.  We also excluded those with Alzheimer’s disease or most severe cognitive 
impairment, defined as an MDS Cognitive Performance Scale (CPS) score of 5 or 6 
(Figure 1), because of the difficulty in assessing accurately their pain levels,23 which 
could affect analgesic prescribing. After these exclusions, 18,607 individuals remained in 
our study population.  We then excluded 994 individuals (5.3%) who resided in hospital-
based facilities, so that 18,800 individuals remained.  Finally, we dropped 561 subjects 
who were missing data for at least one covariate in our analysis (3.2% of the sample), so 
that our final study population consisted of 17,052 residents (Figure 3.1). 
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Measures 
We analyzed data from the MDS about each nursing home resident initiating 
transdermal fentanyl.  The MDS is a standardized survey instrument measuring each 
resident on fifteen domains, including any degree of pain, cognitive and physical 
functioning, psychosocial well-being, activities and diseases.29 The MDS assessor, a 
trained nursing home staff person, relies on personal observation, interviews with 
residents, resident medical records, discussions with resident family, and consultation 
with clinicians and other staff to complete the MDS questions and record all information 
on the MDS forms.29,30 The information gathered for the MDS is then used by the nursing 
home to develop individual care plans for each resident.28,30 The nursing home assesses 
each resident every three months for certain MDS measures (including cognitive and 
physical functioning, mood, and pain) and annually for all MDS measures and when any 
significant change in resident status occurs.29  
Our study relied on the MDS 2.0 version, which was used by nursing homes 
during our 2007-08 study period.  The MDS 2.0 measures in our study have been found 
generally reliable and valid for the domains when used by trained staff.31 For example, 
MDS 2.0 items have been incorporated into other valid and reliable instruments (e.g., 
MDS ADL Scale, MDS Cognitive Performance Scale) to measure resident 
characteristics, such as physical and cognitive functioning.31-33 We also relied on OSCAR 
data for measurement of facility factors, such as the facility’s staff-to-resident ratio, 
percentage of private pay residents, for-profit status, and compliance with federal law.  
The federal government compiles this nursing home facility information annually in 
OSCAR.34  
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Opioid-Naïve Prescribing.  We assessed whether each resident initiating 
transdermal fentanyl was opioid-naïve, defined as not having an opioid prescription with 
a duration end date within the two months prior to fentanyl initiation (e.g., the two-month 
window).  Our definition of an opioid prescription included codeine, fentanyl, 
hydrocodone, hydromorphone, levorphanol, meperedine, methadone, morphine, 
oxycodone, oxymorphone, and propoxyphene, as well as prescription drugs with these 
opioid active ingredients in combination with other analgesic ingredients, such as 
hydrocodone or oxycodone with acetaminophen (Figure 3.2).   
Persistent Pain.  We defined persistent pain as moderate-to-severe pain lasting 3 
months or longer to follow the drug indication and other study approaches.2,16 Each 
nursing home resident is assessed in the MDS at least every 3 months for the frequency 
and intensity of any pain over the previous 7 days.29 This measurement has been found 
valid for measuring pain frequency and intensity in a scored scale.35 We based our 
assessment of persistent pain on the most recent MDS pain measurements prior to 
transdermal fentanyl initiation.  For our study, a nursing home resident was considered in 
persistent pain if the individual had two consecutive MDS reports, at least 90 days apart 
but no more than 180 days apart, with moderate or severe pain daily during the prior 7-
day period.   
Covariates. We evaluated whether certain individual and facility factors were 
associated with opioid-naïve status.  For individual factors, we hypothesized that older 
age, poorer cognitive functioning, lower socioeconomic status (SES), and non-white 
race/ethnicity would be associated with greater opioid-naïve prescribing because these 
factors are related to worse care in nursing homes.  We measured cognitive functioning in 
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the MDS measurement (at persistent pain onset) based on the CPS score from 0 (intact) 
to 4 (moderate-to-severe impairment).  We measured SES based on highest completed 
education level and whether the resident paid for nursing home non-medical services out-
of-pocket (“self-pay”).  For facility factors, we hypothesized that smaller staff-to-resident 
ratio, fewer private pay residents, and for-profit status would be associated with greater 
opioid-naïve prescribing based on prior research on nursing home quality of care.25,36 We 
obtained these facility measurements from the most recent OSCAR survey before 
fentanyl initiation.   
We also identified potential confounders that could be associated with these 
individual and facility factors and opioid-naïve prescribing of transdermal fentanyl: 
gender, physical impairment, mood, family support, and facility compliance with federal 
law.  We measured physical impairment in the most recent MDS (at or before fentanyl 
initiation) by the degree of assistance needed for activities of daily living (ADLs) under 
the Morris Additive Scale from 0 (no help required) to 28 (most help needed); mood at 
the most recent MDS (at or before fentanyl initiation) by the MDS Mood Scale score 
from 0 (no mood symptoms) to 8 (most mood symptoms); family support based on 
whether a family member or significant other participated in the most recent MDS care 
plan meeting (at or before fentanyl initiation); compliance with federal law based on 
whether there were any significant outstanding legal violations of federal nursing home 
requirements, as recorded in the most recent OSCAR survey at or before fentanyl 
initiation; and whether the resident had persistent pain under our definition.   
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Statistical Analysis 
We first assessed the proportion of residents in our study population receiving a 
transdermal fentanyl prescription who were (1) not in persistent pain or (2) opioid-naïve 
at fentanyl initiation.  To test our hypothesis that certain individual and facility factors 
were associated with opioid-naïve prescribing, we fit a series of logistic regression 
models with opioid-naïve prescribing (versus not opioid-naïve prescribing) as the 
outcome.   
The first models were univariate logistic regressions with one of the following 
predictors per model: age (categorized as <65 years, ≥65 to 74 years, ≥75 to 84 years, 
≥85 years); race/ethnicity (White, Black, Hispanic, Asian, and other); cognitive 
functioning (categorized from 0-4 on the CPS Scale); self-pay status (yes versus no); 
education level (categorized as less than high school graduate, high school graduate, or 
college graduate/graduate school); facility staff hours per resident (categorized as <2.5 
hours, ≥2.5 to 3.0 hours, ≥3.0 to 3.5-hours, ≥3.5 to 4 hours, ≥4.0 to 4.5 hours, ≥4.5 
hours); facility proportion of self-pay residents (categorized as <10%, ≥ 10% to 30%, ≥ 
30% to 50%, ≥ 50%); and facility for-profit status (yes versus no).  We also conducted 
the univariate logistic regression for each confounder in our model: gender; degree of 
ADL assistance (categorized as 0, 1-7, 8-14, 15-21, 22-28 from the Morris Additive 
Scale), MDS Mood Scale (categorized as 0, 1-2, 3-4, 5-6, 7-8); family support (yes 
versus no); facility compliance with federal law (yes versus no); and persistent pain (yes 
versus no).   
The next model included all of these variables in a multilevel logistic regression.  
Because residents are clustered within nursing homes and nursing homes are clustered 
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within states, we included random effects (i.e., intercepts) in all models for these two 
levels to ensure more accurate standard errors.  Data were analyzed using SAS and Stata 
13 software. 
Sensitivity and Subgroup Analyses 
We conducted sensitivity analyses using a more stringent definition of opioid-
naïve status (i.e., no opioid prescribing within a 6-month window prior to transdermal 
fentanyl initiation) and only residents with the highest fentanyl prescribing (dose>=50 
mcg/hour).  We also restricted our study population to those residents whose last MDS 
assessment was within 10 days of fentanyl initiation, as well as those residents who did 
not have any temporary discharges (e.g., for hospitalizations) during the 2-month prior 
prescribing window.  Because different diseases and health conditions can cause pain, we 
also conducted subgroup analysis in those residents with arthritis and diabetes, as 
recorded in the MDS.  
RESULTS 
Persistent Pain 
Overall, only 8.2% of residents receiving transdermal fentanyl had persistent pain 
under our definition (i.e., at least 2 consecutive MDS assessments at least 90, but no more 
than 180, days apart with moderate or severe pain on a daily basis) (Table 3.1).  Also, 
only 21.5% of residents had severe pain (i.e. moderate or severe pain on a daily basis) 
and 36.8% of residents had no pain at their last pain assessment before transdermal 
fentanyl initiation (Figure 3.3). 
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Opioid-Naïve Status 
A total of 36.3% of residents receiving transdermal fentanyl were opioid-naïve at 
initiation (Table 3.1).  Of those residents with a prior opioid prescription, approximately 
11% had a prescription for another long-acting drug (oxycodone hydrochloride or 
morphine sulfate extended release).  Among all residents, a total of 57.1% were opioid-
naïve at fentanyl initiation and did not have persistent pain, while only 6.6% had received 
an opioid prior to fentanyl initiation and were in persistent pain (Table 3.1). 
Differences in Characteristics by Opioid-Naïve Status 
Residents who were or were not opioid-naïve differed by age, race, cognitive 
impairment, self-pay status, facility hours per resident, facility proportion of self-pay 
residents, facility for-profit status, physical impairment, family support, and persistent 
pain status (all p <=0.001) (Table 3.2).  There was no significant difference by gender 
(p=0.332), resident education level (p=0.152), facility average staff hours per resident 
(p=0.098), resident mood (p=0.362), or facility compliance with federal law (p=0.073) 
(Table 3.2).  Of those residents who were opioid-naïve, many also had prescriptions for 
antidepressants (54.4%), antipsychotics (21.8%), and mood stabilizing/anticonvulsant 
drugs (17.3%) (Table 3.3).  Participants who were opioid-naïve, though, had lower 
percentages for antidepressant, antipsychotic, and anti-anxiety prescriptions compared to 
those who were not opioid-naïve (Table 3.3).  Among opioid-naïve residents, 
approximately 20% were initiated at higher doses of transdermal fentanyl (50 mcg/hr or 
greater)  (Table 3.3). 
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Multivariate Associations  
Opioid-naïve prescribing of transdermal fentanyl was associated with many 
individual resident factors (Table 3.4).  In the multivariable logistic model, after 
accounting for mood, physical impairment, family support, and facility compliance with 
federal law, residents had a greater odds for opioid-naïve prescribing if they were older 
(compared to ages 65-74, ages 75-84 OR=1.16, 95% CI 1.04-1.29; ages 85-94 OR=1.30, 
95% CI 1.16-1.44; ages >95 OR=1.69, 95% CI 1.46-1.95); more cognitively impaired 
(compared to intact cognitive functioning, borderline intact OR=1.06, 95% CI 0.93-1.20; 
mild impairment OR=1.31, 95% CI 1.16-1.47; moderate impairment OR=1.60, 95% CI 
1.44-1.78; moderate-severe impairment OR=1.99, 95% CI 1.73-2.29); Asian (compared 
to White, OR=1.60, 95% CI 1.10-2.35); paid charges on their own (“self-pay” compared 
to non-self pay, OR=1.12, 95% CI 1.01-1.25); and increasing education (compared to 
education less than high school, high school graduate OR=1.09, 95% CI 1.01-1.17; 
college or graduate school OR=1.17, 95% CI 1.01-1.37).  These associations for age, 
cognitive impairment, Asian race, and education were statistically significant (p-
value<=0.05), except for borderline intact functioning (p-value=0.969).   
The facility factors were not statistically significantly associated with opioid-
naïve prescribing, except the facility’s average staff hours per resident in the 2.5-3.0 hour 
category and proportion of self-pay residents in the 10-30% and 30-50% categories had 
lower odds for opioid-naïve prescribing (compared to facilities with less than 2.5 average 
staff hours per resident, 2.5-3.0 hours OR=0.83, 95% CI 0.69-1.00; compared to facilities 
with less than 10% self-pay residents, ≥10% to 30% OR=0.85, 95% CI 0.77-0.95; ≥30 to 
50% OR=0.86, 95% CI 0.75-0.98). 
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We also found associations with opioid-naïve status for other variables included 
in our model as controls for our hypothesis.  Increasing number of ADLs requiring 
assistance was statistically significantly associated with increasing odds for opioid-naïve 
prescribing across the range of ADL assistance (for example, compared to 0 ADLs, 22-28 
ADLs OR=1.47, 95% CI 1.20-1.81), while increasing MDS mood scale scores were 
statistically significantly associated with decreasing odds for opioid-naïve prescribing 
except for the highest category (for example, compared to 0 mood score, 5-6 mood score 
OR=0.82, 95% CI 0.71-0.96).  Finally, persistent pain was statistically significantly 
associated with decreased odds for opioid-naïve prescribing (compared to no persistent 
pain, the persistent pain OR=0.44, 95% CI 0.38-0.51). 
Sensitivity and Subgroup Analyses 
  The results from the sensitivity and subgroup analyses were consistent with these 
findings.  For example, in the analysis including only residents with their last MDS 
assessment within 10 days prior to fentanyl initiation, we determined that 31.5% of these 
residents did not have any pain and 25.7% of the residents were opioid-naïve when they 
initiated prescription fentanyl.  For all sensitivity and subgroup analyses, we found 
similar associations as our main analysis between resident factors and opioid-naïve 
initiation.  Individual factors of increasing age, cognitive impairment, and number of 
ADLs requiring assistance were associated with increased odds for opioid-naïve fentanyl 
initiation, while increasing MDS mood scale scores and persistent pain were associated 
with decreased odds for opioid-naïve fentanyl initiation (Tables S3.A and S3.B).  Many 
of these associations were statistically significant (Tables S3.A and S3.B).    
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DISCUSSION 
In our analysis of individual-level, nationally representative data capturing 
nursing home resident care, we found that over 90% of residents prescribed transdermal 
fentanyl did not have persistent pain and over one-third were opioid-naïve.  These figures 
appear to indicate a significant failure to follow FDA warnings and practice guidelines 
for appropriate transdermal fentanyl initiation in nursing home residents.  We also found 
that more vulnerable residents within nursing homes, particularly the oldest-old and most 
cognitively impaired, were more likely to initiate transdermal fentanyl inappropriately 
because they were opioid-naïve.  These findings from a national nursing home population 
in 2008, after numerous FDA efforts to warn the public and health care practitioners 
about these transdermal fentanyl dangers, demonstrate the need for more effective risk 
communication and safer prescribing practices for long-acting opioids in nursing homes. 
Persistent Pain 
 We found that only 8.2% of residents in our study initiating transdermal fentanyl 
had persistent pain (i.e. moderate-to-severe daily pain on at least 2 consecutive MDS 
assessments at least 90, but no more than 180, days apart) (Table 3.1).  Although this 
figure is higher than some persistent pain estimates for the general nursing home 
population,5 this prevalence is extremely low for transdermal fentanyl initiators.  This 
low persistent pain prevalence raises important concerns that transdermal fentanyl 
prescribing is not following FDA-approved labeling, which emphasizes that the drug 
should only be initiated in patients with moderate-to-severe continuous pain (i.e., 
persistent pain under our definition).15 Our finding in the sensitivity analysis that at least 
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30% of residents did not have any pain within 10 days prior to initiating the transdermal 
fentanyl prescription reinforces this concern.   
Opioid-Naïve Status 
We also found that 36.3% of the residents in our study initiating transdermal 
fentanyl did not receive any opioid prescription in the prior two-month window (i.e., 
opioid-naïve) (Table 3.1).  This figure is similar to the results from another study, which 
found that 39.3% of 591 Medicaid residents in Rhode Island in 2004-2005 were opioid-
naïve upon the initiation of a long-acting opioid.  Our study results are concerning, 
because the FDA-approved labeling underscores that transdermal fentanyl should only be 
initiated in patients who are opioid-tolerant, so prescribing in opioid-naïve residents 
would clearly be inappropriate.15 Furthermore, 20% of the opioid-naïve initiators in our 
study received the transdermal fentanyl prescription at higher doses (≥50 mcg/hr), in 
contrast to precautions in the drug labeling and practice guidelines to initiate prescription 
opioids at the lowest doses and titrate upward if necessary (Table 3.3).9,10,15 
Factors Associated with Opioid-Naïve Transdermal Fentanyl Initiation 
Our study of nursing home residents identified important factors independently 
associated with opioid-naïve initiation of transdermal fentanyl, including increasing age, 
greater cognitive impairment, and being Asian (Table 3.4).  These effects remained even 
after adjustment for potential confounders: gender, number of ADL’s requiring help, 
MDS mood score, presence of family support, facility compliance with federal law, and 
persistent pain.  These effects increased steadily with increasing age and cognitive 
impairment, with the strongest effect for oldest age (>=95 years with an OR=1.69) and 
greatest cognitive impairment (moderate-severe cognitive impairment with an OR=1.99).  
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These associations for increasing age, greater cognitive impairment, and non-white race 
are consistent with our hypothesis that residents with these factors would be more likely 
to initiate transdermal fentanyl without having a prior opioid prescription.  The earlier 
study in Rhode Island nursing home residents also found a greater proportion of opioid-
naïve initiators were older or had cognitive impairment compared to non-naïve initiators, 
although these effects were not statistically significant in a multivariate analysis.13 Our 
study strengthens these findings and expands them to a national nursing home population.   
The results raise important concerns about disparities in appropriate treatment for 
more vulnerable subpopulations within nursing homes.  Prior studies, including our own, 
have found that approximately 15-25% of residents with non-cancer pain did not receive 
any analgesics.2,8,24 These studies have also indicated that residents who are older, 
cognitively impaired, or non-White are less likely to receive prescription analgesics for 
non-cancer pain.8,24 Thus, it is possible that prescription opioids are under-prescribed in 
some circumstances for residents with persistent pain but inappropriately prescribed for 
residents without such pain.  
Our finding that residents with higher SES (self-pay status and more education) 
had greater odds for opioid-naïve initiation is counter to our hypothesis that higher SES 
would correspond with better care and more appropriate fentanyl prescribing (i.e., lower 
odds for opioid-naïve prescribing).  Our findings may mean that residents with higher 
SES are more likely to receive transdermal fentanyl after experiencing any serious pain 
(whether persistent or acute) rather than first trying a short-acting opioid.  This finding 
must be explored further.   
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We also did not find that the facility characteristics were associated with opioid-
naïve initiation, in contrast to our hypothesis, except that the average hours per resident 
(in the 2.5-3.0 hours category) and the proportion of self-pay residents (in the 10-30% 
and 30-50% categories) were statistically significantly associated with lower odds for 
opioid-naïve prescribing.  This finding for the self-pay categories is consistent with a 
prior study’s conclusion that nursing home facilities with less than 10% private pay 
residents (and greater than 85% Medicaid residents) had poorer quality of care (measured 
by health deficiencies).37 It is important to note for staff hours, though, that a recent 
systematic review cautioned against overreliance on staff numbers for the quality of care 
in nursing homes because of the importance of other staffing factors, such as staff 
turnover rates.36  
Interestingly, although treated as a confounder in our model, an increase in a 
resident’s number of ADLs requiring assistance was associated with higher odds (nearly 
50% greater for the highest category) for opioid-naïve prescribing.  Because we also 
included persistent pain as a factor in our multivariate model, any association between 
this pain status, physical impairment, and opioid-naïve prescribing (i.e., in a confounding 
relationship) would be controlled.  In addition, an increase in a resident’s mood indicators 
was associated with lower odds for opioid-naïve prescribing.  This may indicate that 
residents with greater mood distress (e.g., verbal expression of distress, crying, 
tearfulness) are more likely to receive more appropriate pain medicine prescribing.  One 
study found that residents with greater mood distress (on the MDS mood scale) were 
more likely to receive prescription analgesics for pain.24   
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Implications 
It appears from our study findings that policy makers and practitioners may need 
to consider further steps to ensure the appropriate use of transdermal fentanyl in nursing 
home residents.  Our findings are more troubling given that FDA took additional actions 
to warn the public and practitioners on two occasions (2005 and 2007) about the dangers 
from initiating transdermal fentanyl in opioid-naïve patients and individuals without 
persistent pain, including serious injury or death.17-20 Since our study’s time period, FDA 
has implemented a Risk Evaluation and Mitigation Strategy (REMS) for long-acting 
opioids such as transdermal fentanyl that provides additional precautionary steps for their 
prescribing, such as healthcare provider training.38 The REMS plan, though, does not 
include specific steps or information beyond the product labeling to ensure appropriate 
prescribing in the elderly, including nursing home residents.  Concerns with opioid 
adverse events are generally even stronger in the elderly, particularly in vulnerable 
nursing home populations.9-11  
Nursing home practices and policies could also require specific additional steps to 
ensure transdermal fentanyl is not prescribed to residents who do not have persistent pain 
and are opioid-naïve.  In particular, our finding in the sensitivity analysis that over 30% 
of residents who initiated prescription fentanyl did not have any pain at their last 
assessment should be investigated further.  Many recent efforts have focused on 
improving the quality of nursing home pain care and prescribing by multimodal 
approaches incorporating more accurate pain assessment methods, improved 
communication between staff and clinicians, options for pharmacological and non-
pharmacological treatments, and education and training.39-41 Polypharmacy in nursing 
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home residents is particularly harmful and challenging to address.42 These efforts should 
also ensure that more vulnerable subpopulations within nursing homes (e.g., more 
cognitively impaired, older, and non-white residents) are not inappropriately prescribed 
transdermal fentanyl. 
Strengths and Limitations 
Our study has important strengths.  The source population included all nursing 
home residents in the United States in 2008 who received a transdermal fentanyl 
prescription, which strengthens the results’ generalizability.  In addition, we based our 
measures on comprehensive data for prescribing (Part D), resident traits (MDS), and 
facility characteristics (OSCAR).  We were also able to examine individual and facility 
level factors, including SES, and control for potential confounders, including the 
residents’ family support and facilities’ compliance with federal law.  Our conclusions 
are consistent with prior studies and expand on these earlier findings.  Our study results 
were also similar in our sensitivity analyses using a less strict definition of opioid-naïve 
status (larger prior 6-month window) and including only those residents initiating 
transdermal fentanyl at the highest doses (≥50 mg/hour).  Both of these conditions (e.g., 
no opioid in prior 6 months and prescribing at highest fentanyl doses) raise even greater 
concerns for resident safety. 
The study also has important limitations.  First, for residents who had a prior 
opioid prescription at transdermal fentanyl initiation (and thus were not opioid-naïve), we 
did not also assess whether these residents were opioid-tolerant.  The transdermal 
initiation for these residents would also be inappropriate under the FDA requirements if 
the prior opioid’s total daily dose equivalent was not at least 25 mcg/hour transdermal 
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fentanyl.15 However, the failure to prescribe any opioid prior to transdermal fentanyl 
initiation is the clearest and most significant deviation from these FDA requirements.  
From that perspective, our finding that more than one-third of nursing home residents 
were opioid-naïve at initiation is even more troubling.   
Second, there was a time lag between the last MDS measurement and fentanyl 
initiation date for each resident, which averaged 33 days overall and was greater than 60 
days for approximately 19% of the residents.  This gap could mean that some residents 
developed persistent pain after the last MDS assessment that justified the fentanyl 
initiation.  However, significant changes in resident pain status, such as the development 
of persistent pain requiring a long-acting opioid, would trigger an MDS assessment if 
considered a significant change in resident status.29 To address any misclassification for 
persistent pain status, we restricted the sample in our sensitivity analysis to those 
residents with an MDS assessment no more than 10 days prior to fentanyl initiation and 
found similar results as our main analysis.  
Third, our persistent pain definition may have misclassified some residents’ 
fentanyl initiation as non-adherent to the drug labeling condition for pain when in fact 
they had continuous, moderate-to-severe pain that met this condition.  In addition, if 
nursing home staff underestimated the intensity and/or duration for a resident’s pain in 
the MDS, then our study would have incorrectly classified their fentanyl initiation as non-
adherent to the persistent pain condition.  However, our finding that 92% of residents did 
not have persistent pain is so high that misclassification seems unlikely to account for a 
sufficiently large amount to alleviate our adherence concerns.  In addition, our sensitivity 
analysis showed that at least 30% of residents did not have any pain within 10 days prior 
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to initiating the transdermal fentanyl prescription.  Even with the potential for MDS 
measurement error, this finding is still concerning.   
Finally, the study’s cross-sectional nature precludes examining any causal 
associations between factors and inappropriate fentanyl prescribing.  However, we did 
obtain measurements for the individual factors prior to fentanyl prescribing, which helps 
address any concerns that the fentanyl prescribing could have affected these factors (such 
as the mood scale score). 
CONCLUSION 
We have examined the critical public health issue of transdermal fentanyl 
prescribing in a large, vulnerable population and assessed whether the prescribing follows 
FDA requirements.  Our findings, from a study population drawn from all nursing home 
residents in the United States, indicate that a large proportion of nursing home residents 
are receiving transdermal fentanyl inappropriately because they are not in persistent pain 
and are opioid-naïve.  In addition, certain resident factors (i.e., being older, more 
cognitively impaired, and Asian) are associated with more frequent opioid-naïve 
prescribing.  These results support the need for FDA, health care organizations, and 
nursing homes to continue their efforts to ensure appropriate transdermal fentanyl 
prescribing, with particular care for these more neglected subpopulations. 
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Figures and Tables 
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Figure 3.2.  Prescription Opioids.  
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Figure 3.3.  Number of Residents in Different Pain Categories at Last Assessment 
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Table 3.1.  Numbers of Residents with Persistent Pain and Opioid-Naïve Initiation 
of Transdermal Fentanyl (n=17,052)* 
 
  
Opioid-Naïve Initiation  









N (%)     9,736 (57.1)    5,923 (34.7)     15,659 (91.8) 
Yes 
N (%)     1,126 (6.6)**       267   (1.6)       1,393   (8.2) 
 Total Population  10,862 (63.7)    6,190 (36.3)     17,052 (100) 
* All percentages are based on total population of 17,052 residents in denominator. 
** Fentanyl prescribing complied with labeling conditions for persistent pain and no opioid-naïve 
initiation.   
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Table 3.2.  Fentanyl ER Prescribing: Characteristics of Nursing Home Residents 
Receiving New Fentanyl Extended Release Rx in 2008 by Opioid-Naïve Status 
(n=17,052)* 














Total Population 10,862 (63.7) 6,190 (36.3)  
Characteristics 
Gender 0.332 
Female 8,574 (78.9) 4,847 (78.3)  
Male 2,288 (21.1) 1,343 (21.7)  
Age <0.001 
65-74 1,981 (18.2) 836 (13.5)  
75-84 3,771 (34.7) 1,979 (32.0)  
85-94 4,246 (39.1) 2,644 (42.7)  
≥95  864 (8.0) 731 (11.8)  
Race <0.001 
White 9,616 (88.5) 5,406 (87.3)  
Black 850 (7.8) 546 (8.8)  
Hispanic 274 (2.5) 154 (2.5)  
Asian 70 (0.6) 70 (1.1)  
Other 52 (0.5) 14 (0.2)  
Cognitive Impairment by CPS Score <0.001 
Intact=0 2,207 (20.3) 867 (14.0)  
Borderline 
Intact=1 
1,714 (15.8) 723 (11.7)  
Mild 
Impairment=2 
2,186 (20.1) 1,167 (18.9)  
Moderate 
Impairment=3 
3,768 (34.7) 2,561 (41.4)  
Moderate-Severe 
Impairment=4 
987 (9.1) 872 (14.1)  
Resident Self-Pay <0.001 
No 9,525 (87.7) 5,301 (85.6)  
Yes 1,337 (12.3) 889 (14.4)  
Education Level 0.152 
< High 
School Graduate 
4,340 (40.0) 2,406 (38.9)  
High School 
Graduate 
5,923 (54.5) 3,406 (55.0)  
College Graduate 559 (5.5) 378 (6.1)  
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Facility Average Staff Hours Per Resident 0.098 
<2.5 Hours 508 (4.7) 305 (4.9)  
2.5-3.0 Hours 1,617 (14.9) 843 (13.6)  
3.0-3.5 Hours 3,174 (29.2) 1,903 (30.7)  
3.5-4.0 Hours 2,964 (27.3) 1,688 (27.3)  
4.0-4.5 Hours 1,594 (14.7) 912 (14.7)  
>4.5 Hours 1,005 (9.3) 539 (8.7)  
Facility’s Proportion of Residents Self-Pay 0.001 
<10% 1,649 (15.2) 1,030 (16.6)  
10-30% 6,408 (59.0) 3,502 (56.6)  
30-50% 2,299 (21.2) 1,314 (21.2)  
>50% 506 (4.7) 344 (5.6)  
Facility For Profit 0.040 
No 3,449 (31.8) 2,060 (33.3)  
Yes 7,413 (68.3) 4,130 (66.7)  
ADL Help: Morris Additive Scale <0.001 
0 ADLs  467 (4.3)  167 (2.7)  
1-7 ADLs 1,365 (12.6) 558 (9.0)  
8-14 ADLs 1,976 (18.2) 990 (16.0)  
15-21 ADLs 4,333 (39.9) 2,537 (41.0)  
22-28 ADLs 2,721 (25.1) 1,938 (31.3)  
MDS Mood Scale 0.362 
0 5,734 (52.8) 3,343 (54.0)  
1-2 2,712 (25.0) 1,543 (24.9)  
3-4 1,611 (14.8)  858 (13.9)  
5-6 690 (6.4) 376 (6.1)  
7-8 115 (1.1) 70 (1.1)  
Family Support 0.012 
No 5,549 (51.1) 3,039 (49.1)  
Yes 5,313 (48.9) 3,151 (50.9)  
Facility Compliant with Federal Law 0.073 
Yes 9,788 (90.1) 5,630 (91.0)  
No  1,074 (9.9) 560 (9.1)  
Persistent Pain <0.001 
No 9,736 (89.6) 5,923 (95.7)  
Yes 1,126 (10.4) 267 (4.3)  
Notes: Due to rounding, percentages do not all sum to 100.  NSAID=Non-Steroidal Anti-
Inflammatory Drug.  ADL=Activities of Daily Living.  CPS=Cognitive Performance Scale. 
 
* Excludes 561 (3.2%) observations with missing values. 
** All percentages correspond to column totals.      
*** p value corresponds to the Χ2 statistic. 
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Table 3.3.  Additional Treatments or Medications for Nursing Home Residents in 
2008 by Opioid-Naïve Status (n=17,052)*  














Total Population 10,862 (63.7) 6,190 (36.3)  
Treatments 
Muscle Relaxant <0.001 
No 9,969 (91.8) 5,949 (96.1)  
Yes 893 (8.2) 241 (3.9)  
Steroid <0.001 
No 9,539 (87.8) 5,679 (91.7)  
Yes 1,323 (12.2) 511 (8.3)  
Anti-Depressant <0.001 
No 3,547 (32.7) 2,804 (45.3)  
Yes 7,315 (67.3) 3,386 (54.7)  
Anti-Psychotic 0.657 
No 8,481 (78.1) 4,815 (77.8)  
Yes 2,381 (21.9) 1,375 (22.2)  
Mood Stabilizing/Anti-Convulsant <0.001 
No 8,198 (75.5) 5,118 (82.7)  
Yes 2,664 (24.5) 1,072 (17.3)  
Anti-Anxiety 0.001 
No 10,541 (97.0) 6,062 (97.9)  
Yes 321 (3.0) 128 (2.1)  
Physical Therapy  <0.001 
No 8,704 (80.1) 4,802 (77.6)  
Yes 2,158 (19.9) 1,388 (22.4)  
Fentanyl ER Strength <0.001 
12.5 mcg/hr 2,688 (24.7) 1,629 (26.3)  
25 mcg/hr 6,280 (57.8) 3,330 (53.8)  
50 mcg/hr 1,469 (13.5) 847 (13.7)  
75 mcg/hr 247 (2.3) 235 (3.8)  
100 mcg/hr 178 (1.6) 149 (2.4)  
Notes: Due to rounding, percentages do not all sum to 100.  NSAID=Non-Steroidal Anti-
Inflammatory Drug.  ADL=Activities of Daily Living.  CPS=Cognitive Performance Scale. 
 
* Excludes 561 (3.2%) observations with missing values. 
** All percentages correspond to row totals. 
*** p value corresponds to the Χ2 statistic.  
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Table 3.4.  Odds Ratios for Noncompliant Prescribing of Fentanyl ER (No Opioid in 
Two Months Prior to New Fentanyl ER Prescription). 
 
 Univariate Models* (n=17,052) Multivariate Model** (n=17,052) 
 Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 1.05  0.97-1.14 0.231 1.08 0.99-1.18 0.069 
Age  
65-74 (Ref)   (Ref)   
75-84 1.24 1.12-1.38 <0.001 1.16 1.04-1.29 0.007 
85-94 1.47 1.32-1.62 <0.001 1.30 1.16-1.44 <0.001 
≥95  1.99 1.73-2.28 <0.001 1.69 1.46-1.95 <0.001 
Race 
White (Ref)   (Ref)   
Black 1.17 1.03-1.32 0.014 1.09 0.96-1.24 0.173 
Hispanic 1.01 0.81-1.26 0.914 0.94 0.75-1.17 0.566 
Asian 1.85 1.28-2.68 0.001 1.60 1.10-2.35 0.015 
Other 0.52 0.28-0.97 0.039 0.50 0.27-0.94 0.033 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
1.09 0.95-1.24 0.218 1.06 0.93-1.20 0.378 
Mild 
Impairment=2 
1.38 1.23-1.56 <0.001 1.31 1.16-1.47 <0.001    
Moderate 
Impairment=3 




2.40 2.09-2.76 <0.001 1.99 1.73-2.29 <0.001 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
1.02 0.95-1.10 0.543 1.09 1.01-1.17 0.026 
College 
Graduate  
1.12 0.97-1.30 0.120 1.17 1.01-1.37 0.041 
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 Univariate Models (continued) Multivariate Model (continued) 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.84 0.70-1.01 0.059 0.83 0.69-1.00 0.048 
3.0-3.5 Hours 0.98 0.82-1.16 0.782 0.95 0.79-1.14 0.577 
3.5-4.0 Hours 0.91 0.76-1.09 0.287 0.87 0.73-1.05 0.146 
4.0-4.5 Hours 0.94 0.77-1.13 0.491 0.90 0.74-1.10 0.305 
>4.5 Hours 0.90 0.73-1.10 0.299 0.86 0.69-1.06 0.157 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 0.88 0.80-0.97 0.012 0.85 0.77-0.95 0.003 
30-50% 0.89 0.79-1.01 0.074 0.86 0.75-0.98 0.022 
>50% 1.04 0.86-1.24 0.708 0.95 0.78-1.16 0.644 
Facility For Profit 
No (Ref)      
Yes 1.00 0.93-1.09 0.924 1.03 0.95-1.12 0.483 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.13 0.92-1.40 0.247 1.06 0.85-1.31 0.606 
8-14 ADLs 1.42 1.16-1.74 0.001 1.24 1.01-1.53 0.039 
15-21 ADLs 1.68 1.38-2.04 <0.001 1.35 1.11-1.65 0.003 
22-28 ADLs 2.05 1.68-2.50 <0.001 1.47 1.20-1.81 <0.001 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.97 0.90-1.05 0.481 0.91 0.84-0.99 0.032 
3-4 0.93 0.84-1.03 0.163 0.87 0.78-0.96 0.007 
5-6 0.93 0.80-1.07 0.302 0.82 0.71-0.96 0.010 
7-8 1.05 0.76-1.45 0.774 0.85 0.62-1.19 0.348 
Family Support 
No (Ref)   (Ref)   
Yes 1.06 0.99-1.13 0.113 1.01 0.94-1.08 0.835 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  0.98 0.86-1.12 0.775 1.00 0.88-1.14 0.981 
Persistent Pain 
No (Ref)   (Ref)   
Yes 0.38 0.32-0.43 <0.001 0.44 0.38-0.51 <0.001 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Univariate Logistic Models.  This column presents the univariate logistic model results for each 
individual variable, unadjusted for the other variables. 
** Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive 
functioning; resident self-pay status; education; facility average staff hours per resident; facility 
percentage of residents who self-pay; facility for-profit status; resident number of activities of 
daily living (ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, 
resident family support; facility compliance with federal law; and resident persistent pain. 
 
All regressions used multi-level modeling at the state and facility levels. 
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Table S3.A.  Sensitivity Analyses: Four Multi-Level Models.* Odds Ratios for 
Noncompliant Prescribing of Fentanyl ER. 
 
 Model 1: Keep Only Highest 
Fentanyl Strengths of 50, 75 and 
100 mcg/hour (n=3,125) 
Model 2: “Opioid-Naïve” Means 
No Opioid in 6 Months Prior to 
Fentanyl Initiation  (n=16,260) 
 
Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 1.02  0.86-1.23 0.797 1.15 1.05-1.26 0.004 
Age  
65-74 (Ref)   (Ref)   
75-84 1.22 1.00-1.50 0.054 1.30 1.15-1.47 <0.001 
85-94 1.26 1.01-1.57 0.037 1.58 1.39-1.78 <0.001 
≥95  1.85 1.26-2.72 0.002 2.12 1.81-2.49 <0.001 
Race 
White (Ref)   (Ref)   
Black 1.10 0.84-1.44 0.486 1.14 0.98-1.31 0.080 
Hispanic 1.01 0.62-1.63 0.983 0.95 0.74-1.21 0.673 
Asian 0.64 0.22-1.84 0.406 1.93 1.30-2.85 0.001 
Other 0.85 0.30-2.45 0.767 0.66 0.33-1.30 0.228 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
1.00 0.77-1.29 0.982 1.04 0.90-1.21 0.573 
Mild 
Impairment=2 
1.20 0.94-1.52 0.143 1.28 1.12-1.46 <0.001 
Moderate 
Impairment=3 
1.30 1.04-1.63 0.021 1.79 1.59-2.02 <0.001 
Moderate-Severe 
Impairment=4 
1.31 0.95-1.79 0.098 2.33 2.00-2.71 <0.001 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
0.95 0.80-1.12 0.513 1.15 1.06-1.24 0.001 
College Graduate  0.53 0.36-0.77 0.001 1.30 1.10-1.53 0.002 
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 Model 1 (continued) Model 2 (continued) 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.93 0.64-1.36 0.723 0.79 0.64-0.97 0.023 
3.0-3.5 Hours 0.93 0.65-1.32 0.677 0.88 0.72-1.07 0.196 
3.5-4.0 Hours 1.08 0.75-1.55 0.687 0.84 0.69-1.02 0.079 
4.0-4.5 Hours 1.06 0.72-1.57 0.763 0.85 0.69-1.05 0.137 
>4.5 Hours 1.28 0.84-1.96 0.256 0.81 0.64-1.02 0.075 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 0.82 0.66-1.01 0.058 0.93 0.83-1.05 0.239 
30-50% 0.84 0.63-1.10 0.201 0.93 0.81-1.08 0.335 
>50% 0.95 0.61-1.49 0.828 1.05 0.85-1.29 0.679 
Facility For Profit 
No (Ref)   (Ref)   
Yes 1.04 0.86-1.26 0.708 1.00 0.91-1.09 0.953 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.36 0.82-2.26 0.233 1.08 0.85-1.37 0.541 
8-14 ADLs 1.60 0.98-2.60 0.059 1.06 0.84-1.34 0.609 
15-21 ADLs 1.73 1.08-2.77 0.022 1.21 0.97-1.51 0.096 
22-28 ADLs 2.08 1.27-3.37 0.003 1.24 0.99-1.56 0.064 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.87 0.72-1.05 0.140 0.89 0.81-0.97 0.008 
3-4 0.92 0.74-1.16 0.505 0.77 0.69-0.87 0.000 
5-6 0.79 0.55-1.12 0.184 0.80 0.68-0.93 0.005 
7-8 0.47 0.20-1.10 0.082 0.83 0.59-1.16 0.273 
Family Support 
No (Ref)   (Ref)   
Yes 1.17 1.00-1.37 0.045 1.01 0.94-1.09 0.809 
Facility Compliant with Federal Law 
Yes   (Ref)   (Ref)   
No  0.95 0.71-1.26 0.700 1.05 0.91-1.21 0.489 
Persistent Pain 
No (Ref)   (Ref)   
Yes 0.65 0.50-0.84 0.001 0.44 0.37-0.52 <0.001 
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 Model 3: Keep Only Residents 
with MDS Visit within 10 days 
prior to Fentanyl ER Rx 
(n=4,159) 
Model 4: Keep Only Residents 
With No Discharge During 
Study Period (n=12,982) 
 
Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 1.07 0.91-1.25 0.401 1.09 0.99-1.21 0.090 
Age  
65-74 (Ref)      (Ref)   
75-84 1.00 0.82-1.22 0.997 1.20 1.06-1.37 0.005 
85-94 1.19 0.97-1.45 0.089 1.29 1.14-1.47 <0.001 
≥95  1.46 1.11-1.93 0.007    1.76 1.48-2.08 <0.001 
Race 
White (Ref)   (Ref)   
Black 1.29 1.02-1.63 0.033    1.06 0.91-1.25 0.118 
Hispanic 1.09 0.73-1.64 0.665   0.97 0.74-1.27 0.657 
Asian 1.16 0.61-2.19 0.656 1.77 1.11-2.82 0.016 
Other 0.39 0.10-1.46 0.161 0.50 0.24-1.06 0.072 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)      (Ref)   
Borderline 
Intact=1 
1.08 0.85-1.38 0.515 1.06 0.92-1.23 0.378 
Mild 
Impairment=2 
1.22 0.97-1.54 0.082    1.29 1.12-1.47 <0.001 
Moderate 
Impairment=3 
1.62 1.31-1.99 <0.001 1.57 1.39-1.78 <0.001 
Moderate-Severe 
Impairment=4 
1.92 1.47-2.51 <0.001 2.06 1.75-2.43 <0.001 
Resident Self-Pay       
No (Ref)   (Ref)   
Yes 0.95 0.76-1.17 0.609 1.17 1.04-1.32 0.009 
Education Level       
<High School 
Graduate 
(Ref)   (Ref)   
High School 
Graduate 
1.08 0.94-1.25 0.265 1.14 1.05-1.24 0.002 
College Graduate  0.99 0.72-1.36 0.953 1.30 1.09-1.55 0.004 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.92 0.65-1.30 0.641 0.78 0.62-0.97 0.023 
3.0-3.5 Hours 0.95 0.68-1.32 0.748 0.93 0.76-1.15 0.514 
3.5-4.0 Hours 0.90 0.64-1.26 0.534 0.86 0.70-1.07 0.171 
4.0-4.5 Hours 0.99 0.69-1.42 0.963 0.85 0.68-1.07 0.174 
>4.5 Hours 0.88 0.59-1.30 0.518 0.85 0.66-1.08 0.187 
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 Model 3 (continued) Model 4 (continued) 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)      (Ref)   
10-30% 0.82 0.68-0.99 0.044 0.88 0.78-1.00 0.043 
30-50% 0.95 0.74-1.20 0.650 0.86 0.74-1.00 0.049 
>50% 0.84 0.58-1.23 0.377   1.02 0.81-1.23 0.888 
Facility For Profit       
No (Ref)   (Ref)   
Yes 1.08 0.92-1.27 0.324 0.99 0.90-1.10 0.892 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.31 0.80-2.14 0.277 0.99 0.78-1.26 0.952 
8-14 ADLs 1.35 0.85-2.16 0.207 1.16 0.93-1.46 0.191 
15-21 ADLs 1.50 0.95-2.36 0.084 1.25 1.01-1.56 0.043 
22-28 ADLs 1.53 0.96-2.43 0.075  1.37 1.09-1.72 0.006 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.89 0.75-1.05 0.178 0.93 0.84-1.02 0.127 
3-4 0.89 0.72-1.10 0.274 0.88 0.79-0.99 0.040 
5-6 0.73 0.54-0.99 0.043    0.82 0.69-0.98 0.026 
7-8 0.74 0.38-1.41 0.356      0.85 0.59-1.22 0.376 
Family Support 
No (Ref)   (Ref)   
Yes 1.16 1.01-1.32 0.032 1.02 0.94-1.11 0.603 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  1.06 0.84-1.35 0.602 0.97 0.84-1.13 0.721 
Persistent Pain 
No    (Ref)   
Yes 0.42 0.31-0.56 <0.001 0.44 0.37-0.52 <0.001 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive functioning; 
resident self-pay status; education; facility average staff hours per resident; facility percentage of 
residents who self-pay; facility for-profit status; resident number of activities of daily living 
(ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, resident 
family support; facility compliance with federal law; and resident persistent pain. 
 
All regressions used multi-level modeling at the state and facility levels. 
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Appendix S3.B.  Subgroup Analysis by Disease or Condition: Two Multi-Level 
Models.*  Odds Ratios for Noncompliant Prescribing of Fentanyl ER. 
 
 Model 1: Arthritis (n=7,310) Model 2: Diabetes (n=6,015) 
 
Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 1.06  0.92-1.23 0.437 1.01 0.88-1.16 0.889 
Age  
65-74 (Ref)   (Ref)   
75-84 1.11 0.93-1.33 0.236 1.19 1.02-1.39 0.024 
85-94 1.26 1.05-1.50 0.011 1.29 1.09-1.52 0.003 
≥95  1.67 1.33-2.09 <0.001 2.03 1.51-2.73 <0.001 
Race 
White (Ref)   (Ref)   
Black 0.98 0.80-1.22 0.877 1.05 0.88-1.27 0.573 
Hispanic 0.76 0.51-1.15 0.194 1.09 0.80-1.49 0.570 
Asian 1.64 0.85-3.16 0.139 1.71 0.97-3.01 0.062 
Other 0.49 0.17-1.40 0.183 0.37 0.13-1.03 0.058 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
1.09 0.90-1.32 0.382 0.90 0.73-1.10 0.313 
Mild 
Impairment=2 
1.45 1.21-1.73 <0.001 1.23 1.01-1.48 0.035 
Moderate 
Impairment=3 




2.00 1.59-2.50 <0.001 1.59 1.25-2.01 <0.001 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
1.06 0.94-1.18 0.338 1.11 0.99-1.26 0.080 
College 
Graduate  
1.17 0.91-1.50 0.233 1.15 0.88-1.52 0.307 
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 Model 1: Arthritis (continued) Model 2: Diabetes (continued) 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.88 0.66-1.17 0.381 0.88 0.64-1.20 0.406 
3.0-3.5 Hours 0.89 0.67-1.17 0.402 1.03 0.76-1.38 0.859 
3.5-4.0 Hours 0.83 0.62-1.09 0.184 0.98 0.72-1.33 0.895 
4.0-4.5 Hours 0.84 0.62-1.14 0.258 1.02 0.74-1.41 0.890 
>4.5 Hours 0.74 0.54-1.02 0.068 0.84 0.59-1.19 0.328 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 0.89 0.75-1.05 0.158 0.81 0.69-0.95 0.008 
30-50% 0.95 0.78-1.16 0.601 0.76 0.62-0.93 0.009 
>50% 0.95 0.71-1.28 0.760 0.93 0.66-1.32 0.685 
Facility For Profit 
No (Ref)      
Yes 1.06 0.94-1.21 0.352 1.00 0.87-1.15 0.985 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 0.91 0.65-1.29 0.597 1.32 0.86-2.03 0.197 
8-14 ADLs 1.22 0.88-1.69 0.240 1.50 1.00-2.26 0.052 
15-21 ADLs 1.41 1.03-1.94 0.032 1.82 1.23-2.71 0.003 
22-28 ADLs 1.51 1.09-2.10 0.013 1.97 1.31-2.95 0.001  
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.97 0.86-1.10 0.653 1.00 0.87-1.16 0.952 
3-4 0.82 0.70-0.96 0.012 0.90 0.75-1.08 0.254 
5-6 0.85 0.69-1.05 0.140 1.01 0.79-1.29 0.959 
7-8 0.84 0.53-1.35 0.478 0.94 0.53-1.67 0.842 
Family Support 
No (Ref)   (Ref)   
Yes 1.03 0.93-1.15 0.550 1.07 0.95-1.20 0.254 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  0.94 0.77-1.13 0.500 1.12 0.91-1.37 0.273 
Persistent Pain 
No (Ref)   (Ref)   
Yes 0.44 0.35-0.55 <0.001 0.53 0.42-0.67 <0.001 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive functioning; 
resident self-pay status; education; facility average staff hours per resident; facility percentage of 
residents who self-pay; facility for-profit status; resident number of activities of daily living 
(ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, resident 
family support; facility compliance with federal law; and resident persistent pain. 
 
All regressions used multi-level modeling at the state and facility levels. 
  






CHAPTER 4: INAPPROPRIATE CO-PRESCRIBING WITH  
LONG-ACTING OXYCODONE AMONG NURSING HOME 
RESIDENTS IN THE UNITED STATES  
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Abstract 
 
Objective:  Due to its risks, FDA approved extended-release oxycodone hydrochloride 
(oxycodone ER) only for use in individuals with moderate-to-severe, continuous pain.  
FDA also cautioned against individuals taking other central nervous system (CNS) 
depressants simultaneously with oxycodone ER.  Our objective was to quantify the 
prevalence of oxycodone ER prescribing in elderly nursing home residents without 
moderate-to-severe, continuous pain and with any CNS depressant co-prescribing, as well 
as the association of individual and facility traits with this co-prescribing. 
 
Design:  Cross-sectional study. 
 
Setting:  Linked Minimum Data Set (MDS) assessments; Online Survey, Certification 
and Reporting (OSCAR) records; and Medicare Part D claims. 
 
Participants:  From a cross-section of all long-stay U.S. nursing home residents in 2008 
with an MDS assessment and Medicare Part D enrollment, we identified individuals (≥65 
years old) who initiated oxycodone ER, excluding those with Alzheimer’s, severe 
cognitive impairment, cancer or receipt of hospice care. 
 
Measurements:  We used Medicare Part D to select beneficiaries initiating oxycodone ER 
between December 1, 2007, and November 30, 2008, and examined whether they had 
persistent pain or were co-prescribed any CNS depressant within the 30 days (the 
“window”) after the first oxycodone ER prescription.  A CNS drug was co-prescribed if 
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any day within the prescription’s duration (prescription date to the end of days supply) 
overlapped with the 30-day window. A CNS depressant included a sedative, hypnotic, 
atypical antipsychotic, antiemetic, or muscle relaxant.  We obtained resident and facility 
characteristics from MDS and OSCAR records and defined persistent pain as moderate-
to-severe, daily pain on consecutive MDS assessments at least 90 days, but no more than 
180 days, apart.  We estimated associations of patient and facility attributes and CNS 
depressant co-prescribing at oxycodone ER initiation using multilevel mixed effects 
logistic regression analyses.   
 
Results:  Among 4,317 residents who initiated oxycodone ER, 1,147 (26.6%) were co-
prescribed a CNS depressant and 3,801 (88.1%) did not have persistent pain.  Nearly 4% 
of residents were co-prescribed 2 or more CNS depressants.  In the regression analysis 
with adjustments, residents who were older (compared to ages 65-75, ages 75-84 odds 
ratio (OR)=0.77, 95% CI=0.64-0.92; ages 85-94 OR=0.52, 95% CI 0.43-0.64; ages ≥95 
OR= 0.38, 95% CI = 0.24-0.60); Black (compared to White, OR=0.60, 95% CI=0.44-
0.81) or more cognitively impaired (compared to no cognitive impairment, mild 
impairment OR=0.71, 95% CI=0.57-0.88; moderate impairment OR=0.52, 95% CI=0.42-
0.65; moderate-severe cognitive impairment, OR=0.32, 95% CI = 0.21-0.49) were less 
likely to have CNS depressant co-prescribing. 
  
Conclusion:  Most nursing home residents initiating oxycodone ER did not have 
persistent pain and many were co-prescribed a CNS depressant.  Changes in prescribing 
practices may be necessary to ensure FDA warnings are followed. 
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INTRODUCTION 
 
More than 1.4 million Americans reside in nursing homes, where they receive 
critical medical and daily care.1 This population will increase as the elderly population 
grows in the United States.2 Elderly nursing home residents suffer from numerous 
diseases, poorer health, and greater frailty than the general population, which can lead to 
significant cognitive and physical decline.2 Many residents also experience debilitating 
pain from these health conditions.3 Nursing homes face many challenges in effectively 
identifying and treating residents’ adverse health conditions, including their pain.2  
Nursing homes frequently rely on pharmaceutical therapies for disease treatment 
and pain management.  This approach can be effective for many conditions and types of 
pain if nursing home practitioners carefully select, administer and monitor the 
prescription drug use.4-6 However, inappropriate drug prescribing can threaten patient 
safety because of potential adverse effects.  One study estimated that over 50 percent of 
elderly nursing home residents receive at least one potentially inappropriate prescription 
each year.7 The elderly are more susceptible to drug adverse events because of their 
pharmacokinetic and pharmacodynamic differences from the general population and 
diminished resilience.4-6 
Nursing home residents are particularly vulnerable to the harms from 
inappropriate prescribing because they use more medications and have more co-morbid 
conditions.8-10 The prescribing of multiple drugs together can also cause interactive 
effects in a patient.11 This co-prescribing of numerous drugs to an individual 
(“polypharmacy”) has been identified as a serious risk factor for adverse events in 
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nursing homes.8,12 One study in the elderly found that 26% of patients with osteoarthritis 
were inappropriately prescribed an opioid because of potential drug-drug interactions.11  
The U.S. Food and Drug Administration (FDA) plays an important role in 
ensuring appropriate pharmaceutical use by evaluating each prescription drug’s safety 
and efficacy before approval.  The indications for each drug’s use, approved by FDA, are 
included in the drug labeling.13 The labeling also includes any warnings and cautions 
about possible side effects, including safety risks to specific types of patients and 
potential dangerous interactions with other drugs.13 The Centers for Medicare and 
Medicaid Services (CMS), which establishes federal standards for all nursing homes 
receiving Medicare and/or Medicaid funds, including proper medication use, 
recommends nursing homes follow FDA labeling conditions for drug prescribing.14 
FDA’s role in ensuring prescription drug safety has been particularly visible in the 
agency’s regulation of opioids.  Opioids are prescribed frequently in nursing homes to 
treat residents’ pain but also present important safety risks.3,15 FDA approved extended 
release (ER) formulations for opioids that provide a longer drug release in the patient’s 
body.16 Oxycodone hydrochloride (“oxycodone”) ER, available since the 1990’s, is a 
widely used opioid in nursing homes.3,17 Oxycodone ER, like other opioids, affects the 
body’s central nervous system (CNS).18,19 Although effective in treating more serious 
pain over a longer duration, the drug can increase a patient’s risk for severe respiratory 
depression upon first being administered.18,19 The FDA-approved labeling warns of this 
risk and emphasizes that the drug is only for patients with moderate-to-severe, continuous 
pain.18  
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The drug labeling also cautions against use of oxycodone ER in combination with 
other CNS depressants, specifically phenothiazines (typical psychotics), sedatives, 
hypnotics, and antiemetics, as well as muscle relaxants.18 The use of these CNS 
depressants in combination with oxycodone ER presents serious risks for respiratory 
depression in patients, which can be fatal, as well as profound sedation or coma.18,19 The 
labeling also warns that the elderly are even more susceptible to these side effects.18 
  The risks from concomitant drug use with opioids are not limited to CNS 
depressants.  The co-prescribing of other CNS drugs, such as atypical antipsychotics and 
antidepressants, with opioids increases the risks for psychoactive adverse events, 
including delusions and sedation.20 The CMS nursing home guidelines recommend more 
broadly against the co-administration of CNS drugs (not just CNS depressants) because 
of this potential for adverse drug interactions.14,21   
To determine whether oxycodone ER prescribing in this vulnerable elderly 
population has complied with the indications approved by FDA, we assessed data on 
nursing home residents, facilities, and medication prescribing in 2008 from the national 
Minimum Data Set (MDS), the Online Survey, Certification, and Reporting (OSCAR) 
database, and Medicare Part D.  Specifically, we evaluated the extent of this oxycodone 
ER prescribing for elderly nursing home residents and determined whether residents 
receiving these opioid prescriptions for the first time had moderate-to-severe, continuous 
pain (referred to as “persistent pain”) and were co-prescribed any CNS depressant listed 
in the FDA warning.  We then assessed whether certain individual and facility-level 
factors were associated with co-prescribing of a CNS depressant.  Finally, based on the 
broader CMS recommendation against co-prescribing of CNS drugs, including opioids, 
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we assessed oxycodone ER co-prescribing with more comprehensive CNS drug 





 Our study’s source population was the approximately 1.4 million individuals who 
resided in a nursing home in the United States at any time between December 1, 2007, 
and November 30, 2008, and had at least one prescription drug documented in a Part D 
record.  Approximately 81% of nursing home residents were estimated to have enrolled 
in the Part D program in 2006 just prior to our study period.22 The Part D prescription 
record provides information about the drug, dose, dosage form strength, and days 
supply.23 We also relied on MDS measurements to create our study population.  All 
United States nursing homes are required by federal law (for Medicare and/or Medicaid 
certification) to use the MDS survey instrument to assess each nursing home resident 
periodically.2  
Inclusion Criteria.  Only those residents who received an oxycodone ER 
prescription between December 1, 2007, and November 30, 2008, were eligible for the 
study population, with 29,489 residents (2.0% of the source population) (Figure 4.1).  We 
then only included residents with at least one MDS record before initiating the 
oxycodone ER drug.  We defined this initiation as the date of a resident’s first 
prescription for oxycodone ER during the December 1, 2007 to November 30, 2008 time 
period.  We also defined the “duration end date” for each prescription by adding the 
number of days’ supply to the prescription date.  Only new oxycodone ER users were 
included in the study population, defined as those residents who did not have an earlier 
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oxycodone ER prescription (or prescription duration end date) within two months prior to 
initiation.  In addition, only those residents who had at least one Part D prescription 
during this 2-month prior window, as well as during the one-month period after initiation, 
and who were 65 years or older were eligible for our study.  Finally, we only included 
those residents who had a long-term stay (defined as at least 90 continuous days) prior to 
their study drug initiation.  There were 6,348 eligible residents who met these criteria 
(Figure 4.1). 
Exclusion Criteria.  We excluded those individuals who had cancer or were 
terminally ill because of the distinct pain management issues faced by this patient 
population.  We also excluded those with Alzheimer’s disease or most severe cognitive 
impairment, defined as an MDS Cognitive Performance Scale (CPS) score of 5 or 6 
(Figure 4.1), because of the difficulty in assessing accurately their pain levels,24 which 
could affect analgesic prescribing. After these exclusions, 4,606 individuals with 
oxycodone ER remained in our study population.  After excluding those who resided in 
hospital-based facilities, we dropped 112 (2.5%) residents who were missing data for at 
least one covariate in our analysis.  Our final study population consisted of 4,317 
residents with oxycodone ER (Figure 4.1). 
Measures 
We analyzed data from the MDS about each nursing home resident initiating 
oxycodone ER.  The MDS is a standardized survey instrument measuring each resident 
on fifteen domains, including any degree of pain, cognitive and physical functioning, 
psychosocial well-being, activities and diseases.25 The MDS assessor, a trained nursing 
home staff person, relies on personal observation, interviews with residents, resident 
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medical records, discussions with resident family, and consultation with clinicians and 
other staff to complete the MDS questions and record all information on the MDS 
forms.25,26 The information gathered for the MDS is then used by the nursing home to 
develop individual care plans for each resident.2,26 The nursing home assesses each 
resident every three months for certain MDS measures (including cognitive and physical 
functioning, mood, and pain) and annually for all MDS measures and when any 
significant change in resident status occurs.25  
Our study relied on the MDS 2.0 version, which was used during our 2007-08 
study period.  The MDS 2.0 measures in our study have been found generally reliable and 
valid for the domains when used by trained staff.27 For example, MDS 2.0 items have 
been incorporated into other valid and reliable instruments (e.g., MDS ADL Scale, MDS 
Cognitive Performance Scale) to measure resident characteristics, such as physical and 
cognitive functioning.27-29 We also relied on OSCAR data for measurement of facility 
factors, such as the facility’s staff-to-resident ratio, percentage of private pay residents, 
for-profit status, and compliance with federal law.  The federal government compiles 
annually in OSCAR this information about each nursing home facility.30  
Co-Prescribing of Central Nervous System (CNS) Depressants and Agents.  We 
assessed whether each resident initiating oxycodone ER was co-prescribed a CNS 
depressant, defined as having at least one CNS depressant prescription (or prescription 
duration end date) within a 30-day period after study drug initiation (e.g., the one-month 
window).  This approach is consistent with the method used in other studies.11 Our 
definition of a CNS depressant followed the FDA warning and included any sedative, 
hypnotic, atypical antipsychotic, muscle relaxant, or antiemetic drug (Figure 4.2a).  We 
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also assessed alternatively whether each resident was co-prescribed a CNS agent, defined 
more broadly as any antidepressant, antipsychotic (typical and atypical), anti-anxiety, 
mood stabilizer, or muscle relaxant drug (Figure 4.2b).  
Persistent Pain.  We defined persistent pain as moderate-to-severe pain lasting 3 
months or longer, which follows the drug indication and other study approaches.3,31 Each 
nursing home resident is assessed in the MDS at least every 3 months for the frequency 
and intensity of any pain over the previous 7 days.25 This measurement has been found 
valid for measuring pain frequency and intensity in a scored scale.32 We based our 
assessment of persistent pain on the most recent MDS pain measurements prior to study 
drug initiation.  For our study, a nursing home resident was considered in persistent pain 
if the individual had two consecutive MDS reports, at least 90 days apart but no more 
than 180 days apart, with moderate or severe pain daily during the prior 7-day period.   
Covariates. We evaluated whether certain individual and facility factors were 
associated with CNS depressant co-prescribing.  For individual factors, we hypothesized 
that older age, poorer cognitive functioning, lower socioeconomic status (SES), and non-
white race/ethnicity would be associated with greater CNS depressant co-prescribing 
because these factors are related to worse care in nursing homes.15,24,33 We measured 
cognitive functioning in the MDS measurement (at persistent pain onset) based on the 
CPS score from 0 (intact) to 4 (moderate-to-severe impairment).  We measured SES 
based on highest completed education level and whether the resident paid for nursing 
home non-medical services out-of-pocket (“self-pay”).  For facility factors, we 
hypothesized that smaller staff-to-resident ratio, fewer private pay residents, and for-
profit status would be associated with greater CNS depressant co-prescribing based on 
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prior research on nursing home quality of care.34,35 We obtained these facility 
measurements from the most recent OSCAR survey before oxycodone ER initiation.   
We also identified potential confounders that could be associated with these 
individual and facility factors and CNS co-prescribing with the study drug: gender, 
physical impairment, mood, family support, facility compliance with federal law, and 
mental health condition.  We measured physical impairment in the most recent MDS (at 
or before study drug initiation) by the degree of assistance needed for activities of daily 
living (ADLs) under the Morris Additive Scale from 0 (no help required) to 28 (most 
help needed); mood at the most recent MDS (at or before fentanyl initiation) by the MDS 
Mood Scale score from 0 (no mood symptoms) to 8 (most mood symptoms); family 
support based on whether a family member or significant other participated in the most 
recent MDS care plan meeting (at or before study drug initiation); compliance with 
federal law based on whether there were any significant outstanding legal violations of 
federal nursing home requirements, as recorded in the most recent OSCAR survey at or 
before study drug initiation; and mental health condition based on whether the MDS 
recorded at least one of the following diagnoses: depression, anxiety disorder, bi-polar 
disorder, or schizophrenia.   
Statistical Analysis 
We first assessed the proportion of residents in our study populations receiving an 
oxycodone ER prescription, who were (1) not in persistent pain or (2) co-prescribed a 
CNS depressant.  We also assessed the proportion of residents who were co-prescribed a 
CNS agent.  To test our hypothesis that certain individual and facility factors were 
associated with CNS depressant co-prescribing, we fit a series of logistic regression 
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models with CNS depressant co-prescribing (versus no CNS depressant co-prescribing) 
as the outcome.   
The first models were univariate logistic regressions with one of the following 
predictors per model: age (categorized as 65-74 years, 75 to 84 years, 85 to 94 years, ≥95 
years); race/ethnicity (White, Black, Hispanic, and other); cognitive functioning 
(categorized from 0-4 on the CPS Scale); self-pay status (yes versus no); education level 
(categorized as less than high school graduate, high school graduate, or college 
graduate/graduate school); facility staff hours per resident (categorized as <2.5 hours, 
≥2.5 to 3.0 hours, ≥3.0 to 3.5-hours, ≥3.5 to 4 hours, ≥4.0 to 4.5 hours, ≥4.5 hours); 
facility proportion of self-pay residents (categorized as <10%, ≥ 10% to 30%, ≥ 30% to 
50%, ≥ 50%); and facility for-profit status (yes versus no).  We also conducted the 
univariate logistic regression for each confounder in our model: gender; degree of ADL 
assistance (categorized as 0, 1-7, 8-14, 15-21, 22-28 from the Morris Additive Scale), 
MDS Mood Scale (categorized as 0, 1-2, 3-4, 5-6, 7-8); family support (yes versus no); 
facility compliance with federal law (yes versus no); the existence of at least one mental 
health condition (yes versus no); and persistent pain (yes versus no).   
The next model included all of these variables in a multivariable logistic 
regression.  Because residents are clustered within nursing homes and nursing homes are 
clustered within states, we included random effects (i.e., intercepts) in all models for 
these two levels to ensure more accurate standard errors.  In addition, we conducted 
sensitivity analyses using a more stringent definition of CNS depressant co-prescribing 
(i.e., at least 2 CNS depressants) and restricted our study population to those residents 
whose last MDS assessment was within 30 days of oxycodone ER initiation.  For 
	   121 
comparison, we also conducted additional multivariable logistic regression analyses with 
CNS agent co-prescribing as an alternative outcome (i.e., co-prescribing with at least 2 
CNS agents in the first model and at least 3 CNS agents in the second model).  Data were 
analyzed using SAS and Stata 13 software.  
RESULTS 
Persistent Pain 
 Only 12.0% of residents receiving oxycodone ER had persistent pain under our 
definition (i.e., at least 2 consecutive MDS assessments at least 90, but no more than 180, 
days apart with moderate or severe pain on a daily basis) (Table 4.1).  In addition, only 
29.3% of residents with oxycodone ER had severe pain (i.e. moderate or severe pain on a 
daily basis) and only 28.5% of residents had no pain at their last pain assessment before 
oxycodone ER initiation (Figure 4.3). 
Co-Prescribing Status 
A total of 27% of residents initiating oxycodone ER were co-prescribed a drug in 
at least one CNS depressant category (Table 4.1).  Among all residents initiating 
oxycodone ER, approximately 8% had persistent pain and were not co-prescribed any 
CNS depressants (Table 4.1).  In addition, approximately 4% of residents initiating 
oxycodone ER were co-prescribed drugs in at least two CNS depressant categories, 
although few residents were co-prescribed drugs in more than two CNS depressant 
categories (Table 4.2).  Only 6% of residents initiated oxycodone ER at higher doses 
(>20 mg), although this figure was slightly higher (8%) for those with CNS depressant 
co-prescribing (Table 4.3). 
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The most commonly co-prescribed CNS depressants were hypnotics (11%); 
muscle relaxants (9%); and antiemetics (8%) (Table 4.4).  Sedatives were only prescribed 
for 3% of residents, with no barbiturates and very few benzodiazepines (≤1%) (Table 
4.4).  Typical psychotics were rarely prescribed (≤1%) (Table 4.4).  Most CNS 
depressants were co-prescribed in only one category, but the most frequent co-prescribing 
combinations were the hypnotic-antiemetic, hypnotic-muscle relaxant, and antiemetic-
muscle relaxant categories (Table 4.5). 
In our alternate analysis, 38% of residents initiating oxycodone ER were co-
prescribed drugs in at least two CNS agent categories; 10% in at least three CNS agent 
categories; and 1% in at least four CNS agent categories (Table 4.6).  Only 6% of 
residents with CNS agent co-prescribing received oxycodone ER prescriptions at higher 
doses (>20 mg) (Table 4.7).  The most commonly prescribed CNS agents were 
antidepressants (72%); mood stabilizers (29%) and antipsychotics (20%) (Table 4.8).  
Atypical psychotic drugs were over 98% of the co-prescribed drugs in the antipsychotic 
category.  Only 3% of oxycodone ER initiators were prescribed any anti-anxiety drug, 
primarily buspirone (Table 4.8).  The most frequently prescribed two-category 
combinations were antidepressants-mood stabilizers (14%) and antidepressants-
antipsychotics (9%) (Table 4.9).  The most frequently prescribed three-category 
combination was antidepressants-antipsychotics-mood stabilizers (5%) (Table 4.9).  We 
also found that nearly 80% of antipsychotic prescribing was for off-label uses (no 
diagnosed bipolar disorder or schizophrenia) (Table 4.10). 
The residents in our study population received prescriptions for 12 different drugs 
on average (based on the median value) within the 30-day window.  Our analysis found 
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that 80% of oxycodone ER initiators were prescribed 9 or more total drugs, a common 
threshold for identifying polypharmacy (Table 4.11).  Approximately 3% of residents had 
prescriptions for 29 or more drugs during the one-month window after oxycodone ER 
initiation (Table 4.11). 
Differences in Characteristics By Co-Prescribing Status 
Oxycodone ER initiators who were or were not co-prescribed a CNS depressant 
differed by age, cognitive impairment, resident self-pay status, facility proportion of 
residents with self-pay status, facility for-profit status, family support, persistent pain 
status, and mental health condition (all p ≤0.001) (Table 4.12).  There was no significant 
difference in CNS depressant co-prescribing status by gender (p=0.496), race (p=0.051), 
education level (p=0.467), facility average staff hours per resident (p=0.490), MDS mood 
scale (p=0.592), or facility compliance with federal law (p=0.566). (Table 4.12). 
Multivariate Associations   
CNS depressant co-prescribing with oxycodone ER was associated with many 
individual resident factors (Table 4.13).  In the multivariable logistic model, after 
accounting for mood, physical impairment, family support, facility compliance with 
federal law, persistent pain status, and mental health condition, residents had a lower 
odds for CNS depressant co-prescribing if they were older (compared to ages 65-74, ages 
75-84 OR=0.77, 95% CI 0.64-0.92; ages 85-94 OR=0.52, 95% CI 0.43-0.64; ages >95 
OR=0.38, 95% CI 0.24-0.60); Black (compared to Whites, OR=0.60, 95% CI 0.44-0.81); 
and more cognitively impaired (compared to intact cognitive functioning, borderline 
intact OR=0.89, 95% CI 0.73-1.10; mild impairment OR=0.71, 95% CI 0.57-0.88; 
moderate impairment OR=0.52, 95% CI 0.42-0.65; moderate-severe impairment 
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OR=0.32, 95% CI 0.21-0.49).  These associations for age, Black race, and cognitive 
impairment were statistically significant (p≤0.001), except for borderline intact 
functioning (p-value=0.289).  The facility factors in our hypothesis were not statistically 
significantly associated with CNS depressant co-prescribing for either morphine or 
oxycodone ER initiators.   
Sensitivity Analyses 
  The results from our two sensitivity analyses were consistent with these findings, 
because the factors of older age, increasing cognitive impairment and Black race had 
lower odds for CNS depressant co-prescribing in both models (Appendix S4.A).  These 
effect estimates were more pronounced in the model assessing odds for CNS depressant 
co-prescribing in at least two categories (for example, age ≥95 OR=0.08, 95% CI 0.01-
0.59 and moderate-severe cognitive impairment OR=0.19, 95% CI 0.04-0.83) (Appendix 
S4.A).  In this same sensitivity model, male gender also had lower odds for co-
prescribing (OR=0.48, 95% CI 0.30-0.77). 
Alternate Analyses 
 In our alternate analyses (i.e., using broader CNS agent categories), the factors of 
male gender, older age, and resident self-pay status were statistically significantly 
associated with lower odds for CNS agent co-prescribing in 2 categories (for example, 
male OR=0.82, 95% CI 0.70-0.96; age ≥95 OR= 0.22, 95% CI 0.15-0.33; self-pay status 
OR=0.80, 95% CI 0.65-0.99), while increasing cognitive impairment was statistically 
significantly associated with higher odds for CNS agent co-prescribing in 2 categories 
(for example, moderate-severe impairment OR=1.70, 95% CI 1.22-2.35) (Appendix 
S4.B).  Residents with increasing MDS Mood scale score also had higher odds for co-
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prescribing in 2 CNS agent categories (for example, MDS mood score 7-8 OR=2.60, 
95% CI 1.25-5.43) (Appendix S4.B).  This association was even stronger for the outcome 
with co-prescribing in 3 CNS agent categories (MDS mood score 7-8 OR=3.70, 95% CI 
1.63-8.39). 
DISCUSSION 
In our analysis of individual-level, nationally representative data capturing 
nursing home resident care, we found that nearly 90% of residents prescribed transdermal 
fentanyl did not have persistent pain and over one-quarter were co-prescribed a CNS 
depressant.  These figures appear to indicate a significant failure to follow FDA warnings 
for appropriate oxycodone ER use in nursing home residents.  Even if CNS depressant 
co-prescribing was medically justified for some residents, our finding that nearly 40% of 
oxycodone ER users were co-prescribed 2 or more other CNS agents raises important 
safety concerns from potential drug interactions.  These findings from a national nursing 
home population in 2008, after FDA and CMS efforts to warn the public and health care 
practitioners about co-prescribing dangers, demonstrate the need for more effective risk 
communication and safer prescribing practices for long-acting opioids in nursing homes. 
Persistent Pain 
Overall, we found that only 12.0% of residents receiving oxycodone ER had 
persistent pain under our definition (Table 4.1).  In addition, only 29.3% of residents had 
severe pain (i.e. moderate or severe pain on a daily basis) at their last pain assessment 
before oxycodone ER initiation (Figure 4.3).  Most surprisingly, 28.5% had no pain at 
their last assessment before initiation (Figure 4.3).  Even for those residents with an MDS 
assessment 5 days or less before drug initiation, over 20% had no pain.  These findings 
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indicate that oxycodone ER prescribing for many residents did not follow the FDA’s 
approved labeling condition that the drug only be used for moderate-to-severe, 
continuous pain.  
Co-Prescribing of CNS Depressants 
We also found that 27% of oxycodone ER initiators were co-prescribed at least 
one CNS depressant, and 4% were co-prescribed at least two CNS depressants (Table 
4.2).  These study results raise questions about the propriety of this co-prescribing, 
especially for those residents receiving multiple CNS depressants, because the FDA-
approved labeling cautions against the co-prescribing of CNS depressants, particularly in 
the elderly.18 Hypnotics, antiemetics, and muscle relaxants were the most frequently co-
prescribed with oxycodone ER (Table 4.4).  FDA has approved hypnotics for sleep,36 
antiemetics for severe nausea and vomiting, as well as schizophrenia,37 and muscle 
relaxants for acute musculoskeletal conditions.38 These drugs on their own can pose 
safety risks to elderly patients, including from sedation, respiratory depression, and other 
adverse effects.36-38 A recent study found that non-benzodiazepine hypnotics may also 
increase the risk for hip fractures (from falls) in nursing home residents.39   
Treatment decisions for nursing home residents are based, in part, on medical 
judgment and the availability of treatment options.5 Importantly, there are usually 
alternative therapies for the conditions treated by these CNS depressant drugs, such as 
insomnia40 and schizophrenia.41 In addition, if a CNS depressant is medically necessary, 
there are therapies for persistent pain (other than oxycodone ER) that would not interact 
with the CNS depressant.4,42,43 Thus, it seems unlikely that the co-prescribing of 
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oxycodone ER and another CNS depressant was necessary for over one-quarter of 
residents, but this question should be investigated further.    
Some nursing home prescribing practices appear to follow FDA’s cautions about 
co-prescribing.  Sedatives were one of the least prescribed drug categories, except for 
buspirone, and there were almost no prescriptions for first generation antipsychotics or 
benzodiazepines (Table 4.4).  The FDA labeling, though, is not the critical catalyst for 
this practice.  Instead, by the time of our study period, CMS had ceased payment 
authorizations for benzodiazepines under the Part D program.39 In addition, typical 
antipsychotic use was already infrequently prescribed (<2%) in nursing home residents, 
regardless of opioid prescribing.44 Finally, for 92% of residents co-prescribed a CNS 
depressant, the oxycodone ER drug was prescribed in the lowest dose range (≤20 mg) 
(Table 4.3), which at least followed FDA precautions that oxycodone ER drugs should be 
initiated at lower doses in patients who also receive a CNS depressant.18  
Co-Prescribing of CNS Agents 
Our alternate analysis reinforces the concerns with CNS drug co-prescribing, 
because we found that nearly 40% of oxycodone ER initiators were co-prescribed at least 
2 CNS agents and 10% were co-prescribed at least 3 CNS agents (Table 4.6).  This high 
prevalence of CNS agent co-prescribing with oxycodone ER raises important concerns 
for potential adverse events.  Studies have found that opioid co-prescribing with CNS 
agents, such as antipsychotics and antidepressants, increase the risk for serious 
respiratory depression and opioid overdose.19,20 One study identified this co-prescribing 
risk even with relatively low daily opioid doses, which suggests that CNS agent co-
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prescribing at the lowest oxycodone ER doses in 94% of residents (Table 4.7) may not be 
sufficient to ensure safety.19    
Studies have also found that nursing home residents prescribed opioids, 
antipsychotics, anti-convulsants (sometimes used as mood stabilizers) or antidepressants 
have an increased risk for adverse events, including neuropsychiatric effects, and 
falls.8,9,45,46 We found that 5% of residents were co-prescribed drugs in all three CNS 
categories with oxycodone ER (Table 4.9).  These risks from individual CNS agents are 
stronger when used in combination (polypharmacy).20 In addition, our finding that 80% 
of nursing home residents initiating oxycodone ER were co-prescribed at least 9 drugs 
raises even broader polypharmacy concerns (Table 4.11).  This polypharmacy prevalence 
for oxycodone ER initiators is twice the estimate for all nursing home residents based on 
the 2004 National Nursing Home Survey (NNHS).12 The 3% of residents receiving 
prescriptions for at least 29 different drugs during the 30-day window raises alarming 
polypharmacy concerns, even if some of these drugs were not overlapping (e.g., 
discontinued some drugs before initiating other drugs in the window). 
Our finding that 20% of residents were prescribed an antipsychotic, nearly all 
atypical, is consistent with other recent estimates that 25% of nursing home residents 
receive antipsychotic drugs.44 Atypical antipsychotics are frequently used (estimated 
between 40-86%) for off-label indications, i.e., not the FDA-approved indications for the 
treatment of schizophrenia and bi-polar disorder.47,48 In fact, we found that nearly 80% of 
the residents initiating oxycodone ER and prescribed antipsychotics had not been 
diagnosed with schizophrenia or bipolar disorder, suggesting much of this prescribing 
was for off-label uses (Table 4.10).  A common off-label use for atypical antipsychotics 
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is the treatment of dementia behavioral symptoms, but FDA has warned of an increased 
mortality risk from the drugs in these patients.44    
Factors Associated with CNS Depressant Co-Prescribing 
In the multivariate regression analysis, we found that increasing age and cognitive 
impairment was statistically significantly associated with lower odds for co-prescribing in 
one CNS depressant category (Table 4.13).  This finding contradicted our hypothesis of 
an opposite effect and suggests that nursing homes are more compliant with the FDA 
warning against CNS depressant co-prescribing for older and more cognitively impaired 
residents.  Some studies have indicated that advanced age is not a risk factor for 
inappropriate drug prescribing,7 and that polypharmacy risks (for greater number of 
medications) are lower for older and more cognitively impaired nursing home residents.49 
Our analysis also found that Black residents had statistically significant lower odds for 
CNS depressant co-prescribing, which also contradicts our hypothesis of worse nursing 
home care for minority residents.  This finding, though, is consistent with one study 
identifying lower odds of medication polypharmacy for Black nursing home residents.12   
Sensitivity Analysis 
In our sensitivity analysis, assessing the odds for co-prescribing in two or more 
CSN depressant categories, we found statistically significant associations for increasing 
age, moderate-severe cognitive impairment, and Black race with decreased odds for co-
prescribing that were even stronger than the main model results (Table S4.A).  In 
addition, male residents had half the odds for co-prescribing as women, which is 
consistent with studies finding that female nursing home residents have higher odds for 
polypharmacy.  These findings suggest that residents who are younger (65-74 years), 
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more cognitively intact, and White are even more likely to have co-prescribing with two 
or more depressants, but this association must be investigated further.  
Alternate Analysis: Factors Associated with CNS Agent Co-Prescribing  
Our alternate analysis with the broader CNS agent categories found similar results 
that increasing age had statistically significantly lower odds for CNS agent co-prescribing 
(Table S4.B).  However, the analysis also found that increasing cognitive impairment had 
higher odds for this co-prescribing, which is consistent with our hypothesis.  This result is 
the opposite from the main model assessing CNS depressant co-prescribing and means 
that residents initiating oxycodone ER with greater cognitive impairment are more likely 
to receive antidepressants, atypical antipsychotics, and/or mood stabilizers, but less likely 
to receive CNS depressants.  
Although treated as a confounder in our model, we also found that increasing 
MDS mood scale scores were associated with higher odds for co-prescribing with 3 or 
more CNS agents (Table S4.B).  Most strikingly, the highest MDS mood scale score, 
corresponding with the greatest degree of mood disturbances and agitation, had nearly 4 
times the odds for CNS agent co-prescribing.  This association is independent of the 
resident’s diagnosis for those mental health conditions included in the model.  This 
finding raises important concerns that mood disturbance behaviors (independent of a 
mental health diagnosis) may be a factor in the co-prescribing of 3 or more CNS agents 
with oxycodone ER initiation, particularly for those residents who did not have any pain 
at their last assessment.  One study using the 2004 NNHS survey found that depressed 
mood indicators and behavioral symptoms were positively associated with antipsychotic 
drug prescribing in nursing home residents.44 Many recent public health initiatives have 
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focused on the inappropriate use of pharmaceuticals to sedate nursing home residents.2,48 
Our study’s finding about mood disturbance and CNS agent co-prescribing should be 
investigated further. 
Implications 
Our research findings demonstrate the need for policy makers and practitioners to 
consider further steps to ensure the appropriate use of oxycodone ER in nursing home 
residents.  The finding that 28.5% of residents initiating oxycodone ER did not have any 
recorded pain raises important questions about FDA’s regulation of extended-release 
opioids, particularly whether the approved labeling’s cautionary statements are sufficient 
to ensure oxycodone ER’s safe use in nursing homes.  Furthermore, the co-prescribing of 
at least 2 different types of CNS agents in 40% of residents, and at least three different 
types of CNS agents in 10% of residents, illuminates the extent of co-prescribing risks in 
nursing homes that are beyond the FDA’s approved labeling warning, which only focuses 
on CNS depressants.   
In addition to strengthening and expanding a drug’s labeling statements about 
risks, FDA can incorporate other policy approaches.  Since our study’s time period, FDA 
has implemented a Risk Evaluation and Mitigation Strategy (REMS) for long-acting 
opioids such as oxycodone ER that provides additional precautionary steps for their 
prescribing, such as healthcare provider training.50 The REMS plan, though, does not 
include steps or information beyond the product labeling to ensure appropriate 
prescribing in the elderly, including nursing home residents.  FDA could consider 
including more specific guidance for proper use in the elderly, such as in the nursing 
home setting, to assist practitioners.    
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Other stakeholders have an important role in the appropriate use of oxycodone ER 
in nursing homes.  CMS has federal oversight over nursing home practices.  The agency 
could consider strengthening its guidance about CNS drug co-prescribing and examining 
this co-prescribing in nursing homes more carefully as part of its inspection program.14  
Nursing homes could also incorporate steps in their practices and procedures to ensure 
extended-release opioids, such as oxycodone ER, are not prescribed to residents without 
persistent pain or inappropriately co-prescribed with CNS drugs.  Nursing homes might 
focus first on ensuring that residents without any recorded pain are not prescribed an 
extended-release opioid.    
Many recent efforts have attempted to improve the quality of nursing home pain 
care and prescribing by multimodal approaches incorporating more accurate pain 
assessment methods, improved communication between staff and clinicians, options for 
pharmacological and non-pharmacological treatments, and education and training.51-53 
Inappropriate prescribing in nursing home residents is particularly harmful and 
challenging to address,54 but one recent study found an educational intervention for 
nursing home staff was effective in reducing inappropriate use.55  Our study has 
identified specific problems with oxycodone ER prescribing that might be more 
manageable for nursing homes to target through educational efforts.    
Strengths and Limitations 
Our study has important strengths.  The source population included all nursing 
home residents in the United States who received an oxycodone ER prescription in 2008, 
which strengthens the results’ generalizability.  In addition, we based our measures on 
comprehensive data for prescribing (Part D), resident traits (MDS), and facility 
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characteristics (OSCAR).  We were also able to examine individual and facility level 
factors, including SES, and control for potential confounders, including the residents’ 
family support and facilities’ compliance with federal law.  Our findings about the 
prevalence of CNS drug co-prescribing are consistent with prior studies in nursing homes 
and expand on these earlier findings to residents initiating oxycodone ER.  In addition, 
our study analyzes not only CNS depressant use, but also CNS agents more generally, 
which provides a more complete assessment of nursing home co-prescribing practices 
with this extended-release opioid.  
The study also has important limitations.  First, we could not determine the 
medical reasons for the CNS depressant co-prescribing in residents.  There may have 
been legitimate medical need for this prescribing in many residents, particularly for those 
residents only prescribed one CNS depressant.  We also could not assess if the nursing 
home closely monitored residents during their CNS depressant co-prescribing, which 
might help justify the medical decision to initiate the oxycodone ER.  Our alternate 
analysis helps address these limitations, though, because the co-prescribing of CNS drugs 
in the broader CNS categories, particularly 40% with two categories and 10% with three 
categories, raises significant safety concerns. 
Second, there was a time lag between the last MDS measurement and oxycodone 
ER initiation date for each resident, which averaged 34 days overall and was greater than 
60 days for approximately 20% of the residents.  This gap could mean that some residents 
developed persistent pain after the last MDS assessment that justified the oxycodone ER 
initiation.  However, important changes in resident pain, such as the development of 
persistent pain requiring a long-acting opioid, would trigger an MDS assessment if 
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considered a significant change in resident status.25 To address any misclassification for 
persistent pain status, we restricted the sample in our sensitivity analysis to those 
residents with an MDS assessment no more than 30 days prior to oxycodone ER initiation 
and found similar results as our main analysis.  
Third, our persistent pain definition may have misclassified some residents’ 
oxycodone ER initiation as non-adherent to the labeling condition for pain when they 
actually had continuous, moderate-to-severe pain satisfying this condition.  In addition, if 
nursing home staff underestimated the intensity and/or duration for a resident’s pain in 
the MDS measurement, then our study would have classified incorrectly their fentanyl 
initiation as non-adherent to the persistent pain condition.  However, our finding that 
88% of residents did not have persistent pain is so great that misclassification seems 
unlikely to account for a sufficiently large extent to alleviate our adherence concerns.  In 
addition, our sensitivity analysis showed that at least 20% of residents did not have any 
pain within 5 days prior to initiating the transdermal fentanyl prescription.  This finding 
is still troubling even with the potential for MDS measurement error.    
Finally, the study’s cross-sectional nature precludes examining any causal 
associations between factors and inappropriate oxycodone prescribing.  However, we did 
obtain measurements for the individual factors prior to the oxycodone prescribing, which 
can alleviate concerns that the opioid prescribing would have affected these resident 
factors in ways (such as the mood scale score) that might have influenced co-prescribing 
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CONCLUSION 
We have examined the important public health issue of long-acting opioid 
prescribing in a large, institutional setting and assessed whether the prescribing follows 
federal requirements and guidelines.  Our findings, from a study population drawn from 
all nursing home residents in the United States, indicate that a large proportion of 
residents have received oxycodone ER inappropriately because they were not in 
persistent pain and were co-prescribed multiple CNS agents.  In addition, certain resident 
factors, particularly being younger and more cognitively impaired, were associated with 
more frequent co-prescribing of CNS agents (e.g., antidepressant, antipsychotic, and 
mood stabilizer drugs).  These results support the need for FDA, CMS, and nursing 
homes to take additional steps to better ensure appropriate extended-release opioid 
prescribing for residents.  These public health efforts will be critical to help protect these 
vulnerable individuals from the unnecessary risks posed by dangerous prescribing 
practices in nursing homes.  
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Figures and Tables 
 
Figure 4.1.  Oxycodone Hydrochloride ER.  Source and Study Populations from 
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Figure 4.2a.  Central Nervous System (CNS) Depressants.  
 
   
Sedatives   
   
Benzodiazepines Buspirone Barbiturates 
alprazolam buspirone amobarbital 
chlordiazepoxide  pentobarbital 
clonazepam  phenobarbital 
clorazepate  secobarbital 
diazepam   
lorazepam   
oxazepam   
   
Hypnotics   
   
Benzodiazepines Non-Benzodiazepines  
flurazepam eszoplicone  
temazepam zaleplon  
triazolam zolpidem  
 zopiclone  
   
Antipsychotics (Atypical)  Muscle Relaxants 
   
chlorpromazine  baclofen 
fluphenazine  carisoprodol 
perphenazine  chlorzoxazone 
thioridazine  cyclobenzaprine 
trifluoperazine  dantrolene 
  metaxalone 
Antiemetics  orphenadrine 
  tizanidine 
prochlorperazine   
promethazine   
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Figure 4.2b.  Central Nervous System (CNS) Agents. 
 
    
Antidepressants    
    
amitriptyline escitalopram paroxetine  
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Antipsychotics    
    
Typical Atypical Atypical (cont.) Atypical (cont.) 
chlorpromazine  aripiprazole loxapine pimozide 
fluphenazine clozapine lurasidone quetiapine 
perphenazine fluoxetine-olanzapine molindone risperidone 
thioridazine haloperidol olanzapine thiothixene 
trifluoperazine iloperidone paliperidone ziprasidone 
    
Anti-Anxiety Drugs   
    
Benzodiazepines Buspirone   
alprazolam  buspirone   
chlordiazepoxide    
clonazepam    
clorazepate    
diazepam    
lorazepam    
oxazepam    
    
Mood Stabilizers Muscle Relaxants   
    
carbamazepine baclofen   
divalproex sodium carisoprodol   
gabapentin chlorzoxazone   
lamotrigine cyclobenzaprine   
lithium  dantrolene   
oxcarbazepine  metaxalone   
topiramate orphenadrine   
 tizanidine   
    
  
	   144 
Figure 4.3.  Number of Residents in Different Pain Categories at Last Assessment 
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Table 4.1.  Numbers of Residents Initiating Oxycodone Hydrochloride ER Persistent 
Pain and Co-Prescribed at Least 1 CNS Depressant (n=4,317)* 
 
  CNS Depressant Co-Prescribed  








N (%) 2,836 (65.7)      965 (22.4 ) 3,801 (88.1) 
Yes 
N (%)       334 (7.7)**      182   (4.2)           516 (12.0) 
 Total Population 3,170 (73.4) 1,147 (26.6)      4,317 (100)*** 
*All percentages are based on total population of 4,317 residents in denominator. 
**Oxycodone Hydrochloride ER prescribing adhered to labeling condition for persistent pain and 
warnings against concomitant CNS depressant medication.  




Table 4.2.  CNS Depressants: Total Number of Categories with Drugs Co-
Prescribed for Residents Initiating Oxycodone Hydrochloride ER (n=4,317). 
 
Number of Categories Prescribed Number of Residents (Percentage) 
0                            3,170 (73.4) 
1   978 (22.7) 
2                               155   (3.6) 
3                                 13   (0.3) 




Table 4.3.  Dosage Strength of Oxycodone Hydrochloride ER by Co-Prescribing 
Status. 
 








Lower (≤20 mg)  
N (%) 1,054 (91.9) 3,005 (94.8) 4,059 (94.0) 
Higher(>20 mg) 
N (%)          93  (8.1)       165   (5.2)    258   (6.0) 
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Table 4.4.  CNS Depressants Co-Prescribed for Residents Initiating Oxycodone 
Hydrochloride ER: By Category (n=4,317). 
 





 482 (11.2) 
     7   (0.2) 
Muscle Relaxant 372 (8.6) 






 103 (2.4) 
   21 (0.5) 
     0 (0.0) 
First Generation Antipsychotic   26 (0.6) 




Table 4.5.  CNS Depressant Category Combinations: Drugs Co-Prescribed for 
Residents Initiating Oxycodone Hydrochloride ER (n=4,317). 
 
CNS Depressant Combinations Number of Residents (Percentage)* 
No CNS Depressants 3,170 (73.4) 
1 CNS Depressant Only    978 (22.7) 
 Hypnotic 365 (8.5) 
 Muscle Relaxant 279 (6.5) 
 Antiemetic 231 (5.4) 
 Sedative   83 (1.9) 
 First Generation Antipsychotic   20 (0.5) 
 2 CNS Depressants    155 (3.6) 
 Hypnotic 
 Muscle Relaxant 
 
  49 (1.1) 
 Hypnotic 
 Antiemetic 
      
  48 (1.1) 
 Antiemetic 
 Muscle Relaxant 
 
  24 (0.6) 
3 CNS Depressants      13 (0.3) 
4 CNS Depressants        1 (0.02) 
* Only included combinations >0.5% of population. 
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Table 4.6.  CNS Agents: Total Number of Categories with Drugs Co-Prescribed for 
Residents Initiating Oxycodone Hydrochloride ER (n=4,317). 
 
Number of Categories Prescribed Number of Residents (Percentage) 
0                               716  (16.6) 
1                            1,961  (45.4) 
2                            1,209  (28.0) 
3                               382    (8.9) 
4                                 48    (1.1) 




Table 4.7.  Dosage Strength of Oxycodone Hydrochloride ER by Co-Prescribing 
Status. 
 
  CNS Agent Co-Prescribing  









Lower (≤20 mg) 
N (%)     1,549 (94.5)   2,510 (93.8)  4,059 (94.0) 
Higher(>20 mg) 
N (%)          91   (5.5)      167   (6.2)     258   (6.0) 




Table 4.8. CNS Agents Co-Prescribed for Residents Initiating Oxycodone 
Hydrochloride ER: By Category (n=4,317). 
 
CNS Agent Category Number of Residents (Percentage)* 
Antidepressant 3,107 (72.0) 
Mood Stabilizer 1,271 (29.4) 
Antipsychotic 
 Second Generation 
 First Generation 
   850 (19.7) 
834 (19.3) 
  26   (0.6) 




   122 (2.8) 
103 (2.4) 
  21 (0.5) 
* Category sums exceed 3,601 total because of overlapping prescriptions for individuals. 
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Table 4.9.  CNS Agent Category Combinations: Drugs Co-Prescribed for Residents 
Initiating Oxycodone Hydrochloride ER (n=4,317). 
 
CNS Agent Combinations Number of Residents (Percentage)* 
No CNS Agents    716 (16.6) 
1 CNS Agent Only 1,961 (45.4) 
 Antidepressant 1,560 (36.1) 
 Mood Stabilizer    228 (5.3) 
 Antipsychotic    106 (2.5) 
 Muscle Relaxant      54 (1.3) 
 Anti-Anxiety      13 (0.3) 
 2 CNS Agents 1,209 (28.0) 
 Antidepressant 
 Mood Stabilizer 
 
   593 (13.8) 
 Antidepressant 
 Antipsychotic 
      
   365 (8.5) 
 Antidepressant 
 Muscle Relaxant 
 
   124 (2.9) 
 Antipsychotic 
 Mood Stabilizer 
 
     55 (1.3) 
 Antidepressant  
 Anti-Anxiety 
 
     43 (1.0) 
3 CNS Agents  382 (8.9) 
 Antidepressant 
 Antipsychotic 
 Mood Stabilizer 
 
 
   215 (5.0) 
 Antidepressant 
 Mood Stabilizer 
 Muscle Relaxant 
 
 
    83 (1.9) 
 Antidepressant 
 Antipsychotic 
 Muscle Relaxant 
 
 
     35 (0.8) 
4 CNS Agents    48 (1.1) 
 Antidepressant 
 Antipsychotic 
 Mood Stabilizer 




     28   (0.7) 
5 CNS Agents    1 (0.02) 
* Only included combinations >0.5% of population. 
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Table 4.10.  Prescribing of Antipsychotics for Off-Label Uses During 30-Day 
Window After Oxycodone Hydrochloride ER Initiation (n=4,377). 
 
  




N (%) Total 
Bipolar Disorder or 
Schizophrenia Diagnosis 
Yes 180 (21.2) 76 (2.2) 256 
No 670 (78.8) 3,391 (97.8) 4,051 




Table 4.11.  Total Number of Drugs Prescribed During 30-Day Window After 
Oxycodone Hydrochloride ER Initiation (n=4,317).  
 
Categories Number of Residents (Percentage) 
1-4 Drugs                                149   (3.5) 
5-8 Drugs                                725 (16.8) 
9-12 Drugs                             1,392 (32.2) 
13-16 Drugs                             1,067 (24.7) 
17-20 Drugs                                556 (12.9) 
21-24 Drugs                                208   (4.8) 
25-28 Drugs                                  74   (1.7) 
≥29 Drugs                                146   (3.4) 
Total                             4,317 
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Table 4.12.  Characteristics of Nursing Home Residents by CNS Depressant Co-
Prescribing within 30 Days After Oxycodone Hydrochloride ER Initiation 
(n=4,317).* 















Total Population 3,170 (73.4) 1,147 (26.6)  
Characteristics 
Gender 0.496 
Female 2,434 (76.8) 892 (77.8)  
Male 736 (23.2) 255 (22.2)  
Age <0.001 
65-74 671 (21.2) 380 (33.1)  
75-84 1,159 (36.6) 450 (39.2)  
85-94 1,161 (36.6) 290 (25.3)  
≥95  179 (5.7) 27 (2.4)  
Race 0.051 
White 2,789 (88.0) 1,037 (90.4)  
Black 264 (8.3) 69 (6.0)  
Hispanic 80 (2.5) 32 (2.8)  
Other 37 (1.2) 9 (0.8)  
Cognitive Impairment by CPS Score <0.001 
Intact=0 772 (24.4) 396 (34.5)  
Borderline 
Intact=1 
542 (17.1) 244 (21.3)  
Mild 
Impairment=2 
675 (21.3) 226 (19.7)  
Moderate 
Impairment=3 
989 (31.2) 251 (21.9)  
Moderate-Severe 
Impairment=4 
192 (6.1) 30 (2.6)  
Resident Self-Pay 0.002 
No 2,717 (85.7) 1,025 (89.4)  
Yes  453 (14.3) 122 (10.6)  
Education Level 0.467 
< High School 
Graduate 
1,086 (34.3) 376 (32.8)  
High School 
Graduate 
1,848 (58.3)  675 (58.9)  
College Graduate 236 (7.4) 96 (8.4)  
Facility Average Staff Hours Per Resident 0.490 
<2.5 Hours 118 (3.7) 46 (4.0)  
2.5-3.0 Hours 365 (11.5) 141 (12.3)  
3.0-3.5 Hours 963 (30.4)  371 (32.4)  
3.5-4.0 Hours 948 (29.9)  309 (26.9)  
4.0-4.5 Hours  472 (14.9) 166 (14.5)  
>4.5 Hours 304 (9.6) 114 (9.9)  
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Facility’s Proportion of Residents Self-Pay <0.001 
<10% 387 (12.2) 154 (13.4)  
10-30% 1,833 (57.8)  736 (64.2)  
30-50% 778 (24.5) 215 (18.7)  
>50% 172 (5.4) 42 (3.7)  
Facility For Profit <0.001 
No 1,094 (34.5) 336 (29.3)  
Yes 2,076 (65.5)  811 (70.7)  
ADL Help: Morris Additive Scale 0.199 
0 ADLs  149 (4.7) 71 (6.2)  
1-7 ADLs  438 (13.8) 174 (15.2)  
8-14 ADLs  654 (20.6) 223 (19.4)  
15-21 ADLs 1,362 (43.0) 472 (41.2)  
22-28 ADLs 567 (17.9) 207 (18.1)  
MDS Mood Scale 0.592 
0 1,811 (57.1) 654 (57.0)  
1-2 696 (22.0) 240 (20.9)  
3-4  474 (15.0) 170 (14.8)  
5-6 165 (5.2) 74 (6.5)  
7-8  24 (0.8) 9 (0.8)  
Family Support 0.004 
No 1,744 (55.0)  687 (59.9)  
Yes 1,426 (45.0)  460 (40.1)  
Facility Compliant with Federal Law 0.566 
Yes 2,876 (90.7) 1,034 (90.2)  
No  294 (9.3) 113 (9.9)  
Persistent Pain <0.001 
No 2,836 (89.5) 965 (84.1)  
Yes 334 (10.5) 182 (15.9)  
Mental Health Condition****  
No 941 (29.7) 274 (23.9) <0.001 
Yes 2,229 (70.3) 873 (76.1)  
Notes: Due to rounding, percentages do not all sum to 100.  ADL=Activities of Daily Living.  
CPS=Cognitive Performance Scale. 
 
* Excludes 112 (2.6%) observations with missing values. 
** All percentages correspond to row totals.      
*** p value corresponds to the Χ2 statistic. 
**** Mental Health Condition.  Resident has at least one of the following diagnosed conditions: 
depression, anxiety disorder, bipolar disorder, or schizophrenia.  
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Table 4.13.  Odds Ratios for Co-Prescribing of At Least 1 Central Nervous System 
(CNS) Depressant with Oxycodone Hydrochloride ER Initiation.* 
 
 Univariate Models** (n=4,317) Multivariate Model*** 
(n=4,317) 
 Odds 
Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 0.94  0.80-1.12 0.504 0.86 0.72-1.02 0.085 
Age  
65-74 (Ref)   (Ref)   
75-84 0.70 0.58-0.83 <0.001 0.77 0.64-0.92 0.005 
85-94 0.45 0.37-0.55 <0.001 0.52 0.43-0.64 <0.001 
≥95 0.28 0.18-0.44 <0.001 0.38 0.24-0.60 <0.001 
Race 
White (Ref)   (Ref)   
Black 0.64 0.48-0.86 0.003 0.60 0.44-0.81 0.001 
Hispanic 1.02 0.66-1.60 0.915 0.97 0.61-1.53 0.896 
Asian 0.57 0.26-1.23 0.151 0.65 0.29-1.43 0.282 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
0.88 0.71-1.08 0.395 0.89 0.73-1.10 0.289 
Mild 
Impairment=2 
0.65 0.53-0.80 <0.001 0.71 0.57-0.88 0.002 
Moderate 
Impairment=3 
0.48 0.40-0.59 <0.001 0.52 0.42-0.65 <0.001 
Moderate-Severe 
Impairment=4 
0.30 0.20-0.46 <0.001 0.32 0.21-0.49 <0.001 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
1.06 0.91-1.24 0.433 0.98 0.83-1.15 0.803 
College Graduate  1.20 0.91-1.58 0.207 1.14 0.85-1.52 0.374 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 1.02 0.67-1.54 0.943 1.03 0.67-1.58 0.898 
3.0-3.5 Hours 1.15 0.78-1.71 0.473 1.18 0.79-1.76 0.417 
3.5-4.0 Hours 1.01 0.68-1.50 0.974 1.05 0.70-1.58 0.824 
4.0-4.5 Hours 1.01 0.66-1.54 0.960 1.15 0.75-1.78 0.519 
>4.5 Hours 1.03 0.66-1.59 0.910 1.18 0.75-1.86 0.471 
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 Univariate Models (continued) Multivariate Model (continued) 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 1.07 0.86-1.33 0.540 1.07 0.85-1.35 0.553 
30-50% 0.78 0.60-1.02 0.069 0.85 0.64-1.12 0.253 
>50% 0.65 0.43-0.98 0.039 0.74 0.48-1.14 0.173 
Facility For Profit 
No (Ref)      
Yes 1.11 0.94-1.31 0.210 0.98 0.82-1.16 0.784 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 0.78 0.55-1.11 0.172 0.91 0.63-1.30 0.592 
8-14 ADLs 0.66 0.47-0.92 0.016 0.85 0.60-1.21 0.373 
15-21 ADLs 0.72 0.52-0.98 0.040 0.93 0.67-1.29 0.664 
22-28 ADLs 0.73 0.52-1.03 0.073 1.08 0.76-1.55 0.664 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.98 0.82-1.18 0.860 1.01 0.84-1.22 0.934 
3-4 1.04 0.84-1.28 0.715 1.05 0.85-1.30 0.664 
5-6 1.37 1.01-1.86 0.045 1.58 1.15-2.18 0.005 
7-8 1.17 0.52-2.63 0.707 1.50 0.65-3.45 0.337 
Family Support 
No (Ref)   (Ref)   
Yes 0.84 0.73-0.97 0.018 0.92 0.79-1.06 0.255 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  1.00 0.77-1.30 0.990 0.96 0.74-1.26 0.790 
Persistent Pain 
No (Ref)   (Ref)   
Yes 1.51 1.22-1.85 <0.001 1.28 1.03-1.58 0.025 
Mental Health Condition**** 
No (Ref)   (Ref)   
Yes 1.33 1.13-1.56 0.001 1.18 1.00-1.40 0.057 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Central nervous system depressants are any sedative, typical antipsychotic, hypnotic, 
antiemetic, as well as muscle relaxant drugs. 
** Univariate Logistic Models.  This column presents the univariate logistic model results for 
each individual variable, unadjusted for the other variables. 
*** Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive 
functioning; resident self-pay status; education; facility average staff hours per resident; facility 
percentage of residents who self-pay; facility for-profit status; resident number of activities of 
daily living (ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, 
resident family support; facility compliance with federal law; resident persistent pain; and at least 
one mental health diagnosis. 
**** Mental Health Condition.  Resident has at least one of the following diagnosed conditions: 
depression, anxiety disorder, bipolar disorder, or schizophrenia.  
 
All regressions used multi-level modeling at the state and facility levels.  
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Appendix S4.A.  Sensitivity Analyses.  Odds Ratios for Co-Prescribing Central 
Nervous System (CNS) Depressant with Oxycodone Hydrochloride ER Initiation.* 
 
 Model 1: Keep Only Residents 
with MDS Visit within 30 days 
prior to Oxycodone ER Initiation 
(n=2,215) 
Model 2: Alternative Outcome 
CNS Depressant Co-




Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender       
Female (Ref)   (Ref)   
Male 0.85  0.67-1.08 0.195 0.48 0.30-0.77 0.002 
Age  
65-74 (Ref)   (Ref)   
75-84 0.81 0.64-1.04 0.096 0.52 0.35-0.78 0.001 
85-94 0.49 0.37-0.65 <0.001 0.27 0.16-0.46 <0.001 
≥95  0.39 0.21-0.72 0.003 0.08 0.01-0.59 0.014 
Race 
White (Ref)   (Ref)   
Black 0.55 0.37-0.83 0.004 0.27 0.10-0.72 0.008 
Hispanic 0.80 0.43-1.50 0.483 0.83 0.27-2.54 0.746 
Other 0.70 0.27-1.86 0.479 1.25 0.25-6.23 0.786 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
0.91 0.69-1.21 0.533 0.93 0.59-1.47 0.764 
Mild 
Impairment=2 
0.75 0.56-0.99 0.042 0.66 0.40-1.09 0.106 
Moderate 
Impairment=3 
0.48 0.36-0.64 <0.001 0.50 0.30-0.84 0.009 
Moderate-Severe 
Impairment=4 
0.22 0.11-0.42 <0.001 0.19 0.04-0.83 0.027 
Resident Self-Pay 
No (Ref)   (Ref)   




(Ref)   (Ref)   
High School 
Graduate 
1.05 0.85-1.31 0.638 1.18 0.80-1.74 0.391 
College Graduate  1.20 0.80-1.81 0.377 0.96 0.47-1.97 0.914 
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 Model 1 (continued) Model 2 (continued) 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 1.30 0.69-2.42 0.682 0.77 0.30-1.99 0.595 
3.0-3.5 Hours 1.23 0.68-2.23 0.999 0.87 0.36-2.07 0.745 
3.5-4.0 Hours 1.30 0.71-2.37 0.556 0.92 0.38-2.22 0.849 
4.0-4.5 Hours 1.28 0.68-2.41 0.687 0.95 0.37-2.48 0.921 
>4.5 Hours 1.60 0.84-3.07 0.350 1.05 0.39-2.83 0.923 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 1.10 0.81-1.49 0.551 1.13 0.67-1.91 0.638 
30-50% 0.92 0.63-1.35 0.668 0.66 0.33-1.30 0.226 
>50% 1.13 0.65-1.97 0.655 0.71 0.24-2.15 0.548 
Facility For Profit 
No (Ref)   (Ref)   
Yes 0.99 0.78-1.27 0.966 1.15 0.74-1.77 0.540 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 0.70 0.43-1.16 0.168 0.73 0.36-1.47 0.379 
8-14 ADLs 0.63 0.39-1.01 0.054 0.50 0.24-1.02 0.057 
15-21 ADLs 0.75 0.48-1.18 0.211 0.55 0.28-1.05 0.071 
22-28 ADLs 0.92 0.57-1.50 0.746 0.87 0.42-1.77 0.692 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.94 0.72-1.22 0.633 0.49 0.29-0.81 0.005 
3-4 0.99 0.73-1.33 0.924 0.79 0.47-1.30 0.353 
5-6 1.26 0.81-1.95 0.303 1.50 0.76-2.95 0.242 
7-8 1.05 0.32-3.44 0.942 0.93 0.11-8.15 0.946 
Family Support 
No (Ref)   (Ref)   
Yes 0.91 0.74-1.12 0.376 1.21 0.85-1.72 0.289 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  1.07 0.75-1.52 0.712 0.74 0.39-1.41 0.367 
Persistent Pain 
No (Ref)   (Ref)   
Yes 1.37 1.03-1.82 0.029 1.88 1.23-2.86 0.003 
Mental Health Condition*** 
No (Ref)   (Ref)   
Yes 1.15 0.91-1.44 0.250 1.12 0.74-1.69 0.585 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
 
* Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive functioning; 
resident self-pay status; education; facility average staff hours per resident; facility percentage of 
residents who self-pay; facility for-profit status; resident number of activities of daily living 
(ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, resident 
family support; facility compliance with federal law; resident persistent pain, and at least one 
mental health diagnosis. 
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** Central nervous system depressants are any sedative, typical antipsychotic, hypnotic, 
antiemetic, as well as muscle relaxant drugs. 
*** Mental Health Condition.  Resident has at least one of the following diagnosed conditions: 
depression, anxiety disorder, bipolar disorder, or schizophrenia.  
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Appendix S4.B.  Alternate Analyses.*  Odds Ratios for Central Nervous System 
(CNS) Agent Co-Prescribing with Oxycodone Hydrochloride ER Initiation.**  
 
 Model 1: Odds Ratio for 
 ≥ 2 CNS Agents Co-Prescribed 
(n=4,317) 
Model 2: Odds Ratio for 




Ratio 95% CI p-Value 
Odds 
Ratio 95% CI p-Value 
Characteristics 
Gender 
Female (Ref)   (Ref)   
Male 0.82  0.70-0.96 0.015 0.89 0.69-1.14 0.357 
Age  
65-74 (Ref)   (Ref)   
75-84 0.69 0.58-0.81 <0.001 0.53 0.42-0.68 <0.001 
85-94 0.39 0.33-0.47 <0.001 0.33 0.25-0.45 <0.001 
≥95  0.22 0.15-0.33 <0.001 0.12 0.04-0.32 <0.001 
Race 
White (Ref)   (Ref)   
Black 0.82 0.63-1.06 0.128 0.69 0.45-1.06 0.092 
Hispanic 0.89 0.59-1.35 0.590 0.59 0.28-1.24 0.162 
Other 1.31 0.69-2.49 0.415 0.81 0.28-2.37 0.697 
Cognitive Impairment by CPS Score 
Intact=0 (Ref)   (Ref)   
Borderline 
Intact=1 
1.19 0.97-1.45 0.092 1.25 0.91-1.72 0.173 
Mild 
Impairment=2 
1.20 0.99-1.46 0.068 1.28 0.93-1.76 0.126 
Moderate 
Impairment=3 
1.43 1.19-1.73 <0.001 1.56 1.15-2.11 0.004 
Moderate-Severe 
Impairment=4 
1.70 1.22-2.35 0.002 1.66 1.00-2.73 0.049 
Resident Self-Pay 
No (Ref)   (Ref)   
Yes 0.80 0.65-0.99 0.042 0.74 0.51-1.09 0.126 
	   	  
	   158 




(Ref)   (Ref)   
High School 
Graduate 
1.04 0.90-1.20 0.598 1.10 0.87-1.38 0.425 
College Graduate 1.20 0.92-1.56 0.183 1.22 0.81-1.84 0.330 
Facility Average Staff Hours Per Resident 
<2.5 Hours (Ref)   (Ref)   
2.5-3.0 Hours 0.87 0.59-1.28 0.476 0.51 0.31-0.84 0.008 
3.0-3.5 Hours 0.82 0.57-1.17 0.270 0.45 0.29-0.71 0.001 
3.5-4.0 Hours 0.81 0.56-1.16 0.240 0.41 0.26-0.64 <0.001 
4.0-4.5 Hours 0.91 0.62-1.33 0.621 0.42 0.25-0.70 0.001 
>4.5 Hours 0.98 0.66-1.46 0.915 0.49 0.29-0.84 0.009 
Facility’s Proportion of Residents Self-Pay 
<10% (Ref)   (Ref)   
10-30% 1.07 0.87-1.31 0.533 0.96 0.71-1.30 0.807 
30-50% 0.88 0.69-1.12 0.304 0.75 0.52-1.09 0.134 
>50% 0.93 0.64-1.36 0.709 0.67 0.34-1.32 0.249 
Facility For Profit 
No (Ref)   (Ref)   
Yes 1.16 0.99-1.36 0.061 1.10 0.86-1.41 0.438 
ADL Help: Morris Additive Scale 
0 ADLs  (Ref)   (Ref)   
1-7 ADLs 1.04 0.74-1.46 0.820 0.98 0.57-1.66 0.931 
8-14 ADLs 0.91 0.65-1.26 0.560 0.79 0.47-1.34 0.379 
15-21 ADLs 0.95 0.70-1.29 0.734 1.01 0.62-1.64 0.974 
22-28 ADLs 0.80 0.57-1.12 0.195 1.08 0.64-1.82 0.783 
MDS Mood Scale 
0 (Ref)   (Ref)   
1-2 0.99 0.84-1.18 0.948 1.09 0.83-1.42 0.540 
3-4 1.29 1.07-1.56 0.009 1.28 0.96-1.72 0.089 
5-6 1.81 1.35-2.43 <0.001 2.01 1.36-2.97 <0.001 
7-8 2.60 1.25-5.43 0.011 3.70 1.63-8.39 0.002 
Family Support 
No (Ref)   (Ref)   
Yes 0.89 0.78-1.02 0.083 0.88 0.71-1.09 0.251 
Facility Compliant with Federal Law 
Yes  (Ref)   (Ref)   
No  0.97 0.77-1.23 0.813 0.98 0.69-1.38 0.892 
Persistent Pain 
No (Ref)   (Ref)   
Yes 1.25 1.02-1.52 0.030 1.32 0.99-1.76 0.061 
Mental Health Condition*** 
No (Ref)   (Ref)   
Yes 2.68 2.28-3.15 <0.001 2.56 1.88-3.49 <0.001 
Notes: CI=confidence interval; Ref=reference; ADL=Activities of Daily Living; CPS=Cognitive 
Performance Scale.  Boldface type indicates p <0.05. 
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* Multivariate Logistic Regression Model.  Adjusted for gender; age; race; cognitive functioning; 
resident self-pay status; education; facility average staff hours per resident; facility percentage of 
residents who self-pay; facility for-profit status; resident number of activities of daily living 
(ADLs) on Morris Additive scale requiring help; resident score on MDS mood scale, resident 
family support; facility compliance with federal law; resident persistent pain, and at least one 
mental health diagnosis. 
** Central nervous system agents are any antidepressant, antipsychotic, anti-anxiety, mood 
stabilizer, or muscle relaxant drugs. 
*** Mental Health Condition.  Resident has at least one of the following diagnosed conditions: 
depression, anxiety disorder, bipolar disorder, or schizophrenia.  
 
All regressions used multi-level modeling at the state and facility levels.  






CHAPTER 5: SUMMARY AND CONCLUSIONS 
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Key findings 
The dissertation findings’ overarching theme is that prescription analgesics are not used 
frequently enough in a substantial proportion of elderly nursing home residents, while 
long-acting opioids are inappropriately initiated and used in a large number of other 
residents.  The first aim identified the nursing home’s failure to use analgesics when 
these therapies appeared medically necessary for residents with the most serious, lasting 
pain (i.e., persistent pain).  The second and third aims identified the inappropriate 
prescribing of long-acting opioids in nursing homes, based on whether the resident had 
persistent pain, a prior opioid (for transdermal fentanyl initiation), or CNS drug co-
prescribing (for oxycodone ER initiation and use).  
  
Summary of Chapter 2 findings 
In Chapter 2 we identified the prevalence of no analgesic prescribing for nursing 
home residents with persistent pain.  We found that 16.7% of residents in our study did 
not receive any prescription analgesics (i.e., opioid, NSAID, and/or acetaminophen).  
This prevalence figure for no analgesic prescribing is troubling, because these residents 
had the most intense pain over a long time period (i.e., daily moderate-to-severe pain for 
at least three months).  We also found that few residents with persistent pain received 
physical therapy (less than 10% after excluding those without MDS measurements), 
suggesting these residents did not receive alternative pain treatments. 
 In Chapter 2 we also identified individual characteristics independently associated 
with no analgesic prescribing, including increasing age, greater cognitive impairment, 
being Black or Asian, paying for nursing home expenses without assistance (“self-pay”), 
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and being a high school or college graduate.  This effect increased steadily with 
increasing age and cognitive impairment.  The oldest-old (≥95 years) or those with 
moderate-severe cognitive impairment had the greatest odds for no prescribing 
(approximately double, compared to those 65-74 or cognitively intact, respectively).  
These associations for increasing age, greater cognitive impairment, and non-white race 
support our hypothesis that residents with these characteristics would be less likely to 
receive analgesic prescriptions for persistent pain.  These conclusions raise important 
concerns about pain treatment disparities for more vulnerable nursing home 
subpopulations. 
Our finding that residents with greater socioeconomic status (i.e. resident self-pay 
and college/graduate school education) also have greater odds for not receiving 
prescription analgesics is the opposite conclusion from our hypothesis.  This finding may 
indicate that Medicaid and other government programs to assist residents with nursing 
home charges also help ensure better prescribing practices, even though Medicare Part D 
covers residents on Medicaid.  This finding that higher SES status may be associated with 
worse prescribing practices must be explored further.  
For facility characteristics, consistent with our hypothesis, we found the 
increasing proportion of self-pay residents (in the 10-30% and 30-50% categories) and 
staff hours per resident (peaking at the 3.5-4.0 hour category) were statistically 
significantly associated with lesser odds for no analgesic prescribing (i.e., equivalent to a 
greater odds for prescribing.  Despite our hypothesis, we did not find any statistically 
significant association between for-profit status and analgesic prescribing.  
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Finally, although treated as a confounder in our model, we found that an increase 
in a resident’s number of mood indicators was statistically significantly associated with 
lower odds (nearly half for the category with most mood indicators) for no analgesic 
prescribing (i.e., equivalent to greater odds for analgesic prescribing).  This may indicate 
that residents with greater mood distress (e.g., verbal expression of distress, crying, 
tearfulness, repetitive health complaints) are more likely to receive staff attention for pain 
medicine prescribing, compared to those residents with less visible distress.   
 
Summary of Chapter 3 findings 
In Chapter 3 we identified the high prevalence of nursing home non-adherence to 
FDA warnings for transdermal fentanyl use.  We found that only 8.2% of residents 
initiating transdermal fentanyl had persistent pain (i.e. daily moderate-to-severe pain for 
at least 3 months).  This low prevalence for persistent pain raises important concerns that 
transdermal fentanyl prescribing is not following FDA-approved labeling, which 
emphasizes that the drug should only be initiated in patients with moderate-to-severe 
continuous pain (i.e., persistent pain under our definition).1 Our finding in the sensitivity 
analysis that at least 30% of residents did not have any pain within 10 days prior to 
initiating the transdermal fentanyl reinforces this concern.   
Our study also found that 36.3% of residents initiating transdermal fentanyl did 
not receive any opioid prescription in the two-month period prior to initiation, which 
means they were opioid-naïve.  Our study results are concerning, because the FDA has 
warned repeatedly that transdermal fentanyl should only be initiated in patients who are 
opioid-tolerant, so prescribing in opioid-naïve residents would clearly be inappropriate.1 
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Furthermore, 20% of the opioid-naïve initiators received transdermal fentanyl at higher 
doses (≥50 mcg/hr), in contrast to precautions in the drug labeling and practice guidelines 
that opioids should be initiated at lower doses and then titrated upward if necessary.1-3 
In Chapter 3 we also identified important factors independently associated with 
opioid-naïve initiation of transdermal fentanyl in nursing homes, including increasing 
age, greater cognitive impairment, and being Asian.  These effects increased steadily with 
increasing age and cognitive impairment, with the strongest effect for oldest age and 
greatest cognitive impairment.  These associations for increasing age, greater cognitive 
impairment, and non-white race support our hypothesis that residents with these factors 
would be more likely to initiate transdermal fentanyl without having a prior opioid 
prescription.  These results raise important concerns about disparities in appropriate 
treatment for more vulnerable subpopulations within nursing homes.  Based on the 
findings described in Chapters 2 and 3, it is possible that prescription opioids are under-
prescribed in some circumstances for residents with persistent pain but inappropriately 
prescribed for residents without such pain.  
Our finding that residents with higher SES (self-pay status and more education) 
had greater odds for opioid-naïve initiation is counter to our hypothesis that higher SES 
would correspond with better care and more appropriate fentanyl prescribing (i.e., lower 
odds for opioid-naïve prescribing).  This conclusion is similar to our unexpected finding 
in Chapter 2 that higher SES is associated with worse care (i.e., no analgesic prescribing 
for pain).  This counterintuitive finding, and any possible reasons, must be explored 
further.   
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Finally, we did not find that facility characteristics were associated with opioid-
naïve initiation, except greater average hours per resident (in the 2.5-3.0 hours category) 
and proportion of self-pay residents (in the 10-30% and 30-50% categories) were 
statistically significantly associated with lower odds for opioid-naïve prescribing, which 
was consistent with our hypothesis for better care (i.e., lower odds for opioid-naïve 
prescribing) in these facilities.  
 
Summary of Chapter 4 findings 
In Chapter 4 we identified the high prevalence of nursing home non-adherence to 
FDA warnings for oxycodone ER use, which was similar to our finding in Chapter 3 for 
transdermal fentanyl.  We found that only 12.0% of residents initiating oxycodone ER 
had persistent pain under our definition.  Most troubling, 28.5% had no pain at their last 
assessment before initiation.  Even for those residents with an MDS assessment 5 days or 
less before drug initiation, over 20% had no pain.  These findings indicate that oxycodone 
ER prescribing for many residents did not follow the FDA’s approved labeling condition 
that the drug only be used for moderate-to-severe, continuous pain.  
We also found that 27% of oxycodone ER initiators were co-prescribed at least 
one CNS depressant, and 4% were co-prescribed at least two CNS depressants.  These 
study results raise questions about the propriety of this prescribing, because the FDA-
approved labeling cautions against the co-prescribing of CNS depressants, particularly in 
the elderly.4 Hypnotics, antiemetics, and muscle relaxants were the most frequently co-
prescribed with oxycodone ER, which on their own can pose safety risks to elderly 
patients, including from sedation, respiratory depression, and other adverse effects.5-7,8   
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In particular, we found that sedatives were one of the least prescribed drug 
categories, except for buspirone, and there were almost no prescriptions for first 
generation antipsychotics or benzodiazepines.  These low prescribing levels for 
benzodiazepines are probably caused by CMS policies excluding benzodiazepines from 
the Part D program,8 rather than FDA regulatory steps.  For 92% of residents co-
prescribed a CNS depressant, the oxycodone ER drug was prescribed in the lowest dose 
range (≤20 mg), which at least followed FDA precautions that oxycodone ER drugs 
should be initiated at lower doses in patients who also receive a CNS depressant.4  
Our alternate analysis reinforces the concerns with CNS drug co-prescribing, 
because we found that nearly 40% of oxycodone ER initiators were co-prescribed at least 
2 CNS agents and 10% were co-prescribed at least 3 CNS agents.  This high prevalence 
of CNS agent co-prescribing with oxycodone ER raises important concerns for potential 
adverse events, even at lower oxycodone ER doses.9,10 Drug combinations with opioids, 
antipsychotics, anti-convulsants, and antidepressants (all co-prescribed in 5% of 
residents) are particularly dangerous.11-14 Our finding that 80% of nursing home residents 
initiating oxycodone ER were co-prescribed at least 9 drugs, and 3.4% of residents were 
co-prescribed at least 29 drugs, illuminates a very troubling polypharmacy practice for 
nursing home residents initiating oxycodone ER.  
In Chapter 4 we also identified important factors that were independently 
associated with lower odds for CNS depressant co-prescribing, including increasing age, 
cognitive impairment, and Black race.  This finding contradicted our hypothesis of an 
opposite effect and suggests that nursing homes may be following more closely the FDA 
warning against CNS depressant co-prescribing for older, more cognitively impaired, and 
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Black residents.  Our alternate analysis with broader CNS agent categories also found 
that increasing age had statistically significantly lower odds for CNS agent co-
prescribing.  In addition, the analysis found that increasing cognitive impairment had 
higher odds for this co-prescribing, which is opposite the main model finding but 
consistent with our hypothesis.  These results may mean that residents initiating 
oxycodone ER with greater cognitive impairment are more likely to receive 
antidepressants, atypical antipsychotics, and/or mood stabilizers, but less likely to receive 
CNS depressants.  
Finally, we found that increasing MDS mood scale scores (treated as a 
confounder) were associated with higher odds for co-prescribing with 3 or more CNS 
agents.  Most alarming, the highest MDS mood scale score, corresponding with the 
greatest degree of mood disturbances and agitation, had nearly 4 times the odds for CNS 
agent co-prescribing.  This association is independent of the resident’s diagnosis for 
certain psychiatric conditions which were included in the model.  This finding raises 
important concerns that mood disturbance behaviors (independent of a psychiatric 
diagnosis) may be a factor in the co-prescribing of 3 or more CNS agents with oxycodone 
ER initiation.  Our study’s finding about mood disturbance and CNS agent co-prescribing 
should be investigated further. 
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Implications and future steps 
The dissertation attempts to provide a foundation for future research assessing 
nursing home pain management and analgesic prescribing, as well as policies and 
guidelines in these areas. 
 
Research implications 
Based on the dissertation findings, there are four general areas for further 
research.  First, additional studies should examine some of the assumptions that underlie 
our findings, particularly the persistent pain definition, appropriateness of analgesics for 
persistent pain, and these drugs’ safety and effectiveness in nursing home residents.  
Second, further research should examine the heterogeneity in outcomes between 
residents, facilities, and states, as well as focus on specific subpopulations, rather than 
relying on average effect estimates to characterize the nursing home population.  Third, 
studies must examine the associations that we identified for inadequate pain management 
and prescribing practices, including in more recent nursing home populations, and 
determine if our dissertation findings are replicable.  Fourth, further research must be 
conducted in nursing homes to elucidate the causes for the prescribing patterns and 
associations that we found, particularly to understand more clearly the underlying 
mechanisms for inadequate care and health disparities that we identified. 
The dissertation’s persistent pain definition is the crux for all three aims, but the 
validity and reliability of this definition for measuring persistent pain must be explored 
further.  Although the MDS 2.0 has been found valid in measuring the pain intensity and 
duration over the past week,15 a critical question is the extent of each resident’s pain 
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experience between measurements, which can be up to 90 days between quarterly reports.  
So a limitation in our definition involves the potential gaps in pain measurement between 
quarterly MDS assessments.  Residents could have many variations in pain intensity and 
duration during these gaps, including no pain, that could require different care 
approaches.  Studies that measure resident pain directly in nursing homes on a more 
frequent basis between MDS assessments, using comprehensive and valid methods,16 
could compare these results to persistent pain measurement using our definition.  Studies 
in more recent nursing home populations could also use the revised MDS 3.0 version, 
which would be more relevant for current practice.17   
Even if other studies confirm that our reliance on the MDS accurately and reliably 
measures the most severe, ongoing pain in residents, the question remains whether each 
of these residents should receive prescription analgesic therapy.  Additional study will be 
necessary to determine those factors in residents with persistent pain that support 
prescription analgesic use.  This research could allow for a more nuanced approach in 
assessing inadequate analgesic prescribing and identifying those residents who are being 
neglected.  We examined physical therapy and other drugs with possible uses for pain 
(such as gabapentin for neuropathic pain), but there are many other approaches that 
nursing homes could use that are not captured in our data, including OTC drugs and 
social support.18 Researchers must examine more closely the various treatments for 
residents with persistent pain in nursing homes, including those not captured in the MDS, 
to develop a clearer picture for which residents with persistent pain should receive 
prescription analgesics.   
	   170 
Underlying the concerns we have raised with inadequate nursing home 
prescribing, particularly for our first aim, lies the fundamental question of each drug’s 
comparative safety and efficacy.  Further research will be necessary to compare 
prescription opioids against each other, as well as prescription opioids to prescription 
NSAIDs and no prescription analgesics.19,20 These studies could use essential outcomes, 
such as cognitive and physical functioning and pain levels for everyday activities, to 
assess the drugs’ effects on residents’ quality of life.19 Studies that measured these 
outcomes more directly and compared different alternative therapies not measured in the 
MDS, such as OTC drugs, would be quite useful.21 Randomized clinical trials for these 
assessments, where ethically feasible, will be critical.22 
Additional research must also explore heterogeneity between nursing home 
residents in their pain experience and factors for care.  For example, pain has many 
different possible causes that can shape the effect on each individual and require different 
therapeutic approaches.23 Residents can differ substantially in their pain experiences, as 
well as factors for their care.24,25 The estimates from our models are for population 
average effects, which may not apply to certain subpopulations, such as for persistent 
pain prevalence and inadequate prescribing.  We examined some subgroups in our 
research, where possible, and found results similar to the general population (e.g., for 
residents with diabetes), but additional studies should examine more closely residents 
with specific types of health conditions and pain experiences.  Population-average effects 
can hide important variation within nursing homes for resident care.25 It would be helpful 
to understand the extent that individual nursing homes are providing disparate care to 
residents within their own facilities. 
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It will also be important to explore variations in our measurements between 
facilities and regions.  For example, studies have shown that clinical practice can vary, 
depending on the facility and region, in pain management practices, including opioid 
prescribing.26,27 These cultural norms can influence strongly the care decisions that are 
made in institutional settings for treating pain.21,28 It will be important to assess the 
variations by region and nursing homes in our outcomes – the prevalence of persistent 
pain, analgesic prescribing, and non-adherent opioid prescribing. The analysis could also 
examine the variation between nursing homes and states in resident composition and 
health indicators, particularly those characteristics included in our models. This 
assessment could help identify cultural or regional influences on our findings and shape 
more refined policy approaches.  
Our health disparity findings will also require further research for confirmation.  
It would be helpful to use models with different measures for our facility characteristics 
and potential confounders.  The role of facility quality is critical for our research, 
including its association with our individual and facility characteristics (such as 
percentage of self-pay residents) and outcomes (i.e., prescribing for persistent pain and 
adherence to long-acting opioid guidelines and drug labeling).25,29 This classic 
confounding threat must be controlled with more refined measures.  Our use of a binary 
variable to capture a facility’s compliance with federal law may have been too blunt, so 
alternative approaches to measure this concept must be explored.  Likewise, a resident’s 
family support can influence care outcomes in our models and could be associated with 
our examined individual and facility factors.30,31 However, the binary variable for care 
meeting participation may lack sufficient refinement to discriminate the degrees of 
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support.  In addition, our models only included variables for mood and ADL assistance as 
possible additional confounders.  Additional research could help refine these models and 
ensure variables are capturing underlying characteristics that might otherwise bias the 
results.  
In addition to confirming our findings for inadequate pain treatment (Chapter 2), 
inappropriate opioid prescribing (Chapter 3 and 4), and health disparities related to these 
outcomes (Chapters 2-4), further research must also explore the underlying mechanisms 
for these nursing home practices.  For example, we must understand further how older 
age, greater cognitive impairment, and minority race can be associated with underuse of 
prescription analgesics for persistent pain (Chapter 2) but also overuse for these 
subpopulations without serious pain (Chapter 3).  The mechanisms for such disparities 
are complex and can be grounded in implicit stereotyping and bias on the part of 
healthcare providers.32,33 Qualitative research in nursing homes to explore these 
mechanisms further will also be crucial.34   
 We must also understand further the influence of government programs, 
particularly Medicare and Medicaid, on care and prescribing decisions for nursing home 
residents.  For example, the CMS policy to exclude benzodiazepines from Part D 
coverage essentially halted this drug prescribing in nursing homes, at least for those 
residents in the Part D program (estimated at more than 80% upon program initiation).8,35 
This financial condition potentially had greater impact on prescribing than any FDA 
warning or CMS nursing home inspection.  Medicaid coverage for nursing home care 
might also impact pain management decisions.36 It would be helpful for research to 
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incorporate these policies more explicitly in analyses for nursing home pain management 
and analgesic prescribing. 
 
Policy implications 
The dissertation research could also help inform policies and practices to ensure 
better pain management and analgesic prescribing in nursing homes.  These policies and 
practices could incorporate in particular our findings in Chapters 3 and 4 for long-acting 
opioid misuse. 
As the federal agency charged with ensuring that prescription drugs are safe and 
effective for their approved uses, FDA must consider steps to protect nursing home 
residents from dangerous prescribing for long-acting opioids, particularly in residents 
who do not have any pain, are opioid-naïve (for transdermal fentanyl), or are co-
prescribed CNS depressants (for oxycodone ER).  Before the time period for our study 
(2007-2008), FDA took regulatory steps to ensure the safer use of long-acting opioids, 
such as communications to health care professionals and the public, as well as stronger 
warnings in drug labeling.37-43 The high prevalence of non-adherence in nursing homes, 
though, is extremely concerning, particularly for those residents without any measured 
pain  (i.e., over 30% for transdermal fentanyl and 20% for oxycodone ER in our 
sensitivity analyses) and who were opioid-naïve (over one-third of transdermal fentanyl 
initiators).   
FDA must take additional action, tailored for the nursing home setting, to address 
non-adherence to critical conditions for safe opioid use.  FDA has recently requested that 
research be conducted using post-marketing data sources for prescription drug use in 
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patients to enhance the agency’s understanding of actual prescribing practices and 
dangers.44 Our dissertation research contributes to this effort.  FDA can move forward 
now based on our research, because these non-adherence findings are not limited by the 
measurement and methodological challenges we faced in our other models to identify and 
quantify persistent pain and health care disparities.  FDA has regulatory authority directly 
over the drug manufacturers to require certain steps, particularly through REMS, while 
FDA can use risk communications and guidance to influence nursing home practices.45   
First, FDA can update the REMS plan for long-acting opioids to include steps for 
health care practitioners in nursing homes.  The current REMS plan requires that drug 
manufacturers make training available to health care providers about safe use for long-
acting opioids.46 FDA has developed a blueprint for this training, which covers opioid 
abuse and misuse risks for the general population.47 The REMS plan, though, could add 
specific education for nursing home practitioners about the particular dangers to residents 
from inappropriate long-acting opioid prescribing.  In addition to the widespread use in 
residents without pain, this training could address the problem of opioid-naïve 
transdermal fentanyl initiation and CNS drug co-prescribing with oxycodone ER.  The 
REMS plan could also require certifications,48 based on completed training and written 
agreements, for health care practitioners in nursing homes to receive the drugs from 
manufacturers.  Finally, FDA could require drug manufacturers to assess the REMS plan 
effectiveness in nursing homes and submit periodic reports to FDA.48 It is critical that 
FDA make these assessments publically available.48   
Second, FDA could direct specific communications and guidance to nursing 
homes to address the risks we have identified in this dissertation.  Research has indicated 
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that these risk communications are more effective in changing prescriber behavior when 
they are more specific, repeated frequently, and acceptable alternatives are available.49 
Although FDA does not exercise regulatory authority over nursing home practices, the 
agency has issued guidance in the past to assist nursing homes with the safe use of FDA-
regulated products, such as medical oxygen.50 Similarly, FDA could issue guidance to 
nursing homes based on our research about the dangers of prescribing long-acting opioids 
to residents who do not have persistent pain, who are opioid-naïve (particularly for 
transdermal fentanyl), or who are co-prescribed CNS depressants (particularly for 
oxycodone ER). 
CMS is another important federal agency that can implement policies to address 
these research findings.  CMS has regulatory authority over nearly all nursing homes 
through its Medicare and Medicaid programs.  CMS has general regulations prohibiting 
nursing homes from using “unnecessary drugs” in residents, but these regulations do not 
provide specific examples or details.51 The agency has issued recommendations in 
guidance for appropriate pain management and analgesic use, including that health care 
practitioners in nursing homes follow FDA-approved labeling conditions for drug 
prescribing.52 States are responsible for conducting nursing home inspections and use 
these recommendations as a guide for inspectional observations.52 These 
recommendations, though, do not specifically address the problems identified in this 
dissertation, including long-acting opioid prescribing in residents without pain, 
transdermal fentanyl initiation in opioid-naïve individuals, and CNS drug co-prescribing 
with oxycodone ER.   
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CMS could issue more detailed recommendations against these practices, along 
with alternative therapies, that could be tracked in individual inspections.  This more 
specific approach might help to change nursing home practices.  In addition, our finding 
in Chapter 4 that residents initiating oxycodone ER with severe mood disturbances are 
four times more likely to experience CNS agent co-prescribing may indicate that nursing 
homes are overmedicating residents with these drugs to quell their mood disturbances, 
despite earlier CMS guidance against this practice.52 So CMS should investigate this 
possibility further. 
The Drug Enforcement Agency (DEA) is another federal agency that might 
contribute to these policy efforts in nursing homes.  DEA has regulatory authority over 
the sale and prescribing of controlled substances, including opioid drugs.  Our finding 
that at least 30-40 percent of transdermal fentanyl and oxycodone ER initiators do not 
have any pain at their last MDS assessment raises important concerns that the drugs are 
not actually being administered to these residents.  Instead, drug diversion by staff 
remains a very real concern and must be considered further.53 DEA has been working 
with CMS to combat opioid diversion in the Medicaid program.54 These agencies could 
investigate more closely the possibility of long-acting opioid diversion in the nursing 
home context. 
Geriatric health organizations are another relevant stakeholder to improve nursing 
home pain management and analgesic prescribing practices.  As described in Chapter 1, 
the American Geriatric Society (AGS) has issued practice guidelines for the use of 
analgesics, including opioids, in elderly adults with persistent pain.2 These 
recommendations follow the WHO stepped approach for cancer in treating persistent pain 
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with analgesics.  However, the guidelines are very general and fail to address specifically 
the inadequate pain management and inappropriate prescribing that we identified in our 
study.  At the very least, these guidelines could incorporate recommendations for long-
acting opioids, such as clearer precautions against opioid-naïve use, CNS depressant co-
prescribing, and prescribing in residents without pain.  The American Medical Directors 
Association (AMDA) has also issued guidelines for pain management in nursing homes, 
but this guidance is less specific than the AGS guidelines.3 As the primary organization 
for nursing homes, it is critical that AMDA provide specific recommendations and advice 
to nursing homes about these problems with long-acting opioid misuse. 
Finally, nursing homes themselves are at the heart of any practice reforms.  An 
important focus in recent years has been on resident-directed care (also known as “culture 
change”), which attempts to empower nursing home residents with more involvement in 
decisions about their care.25 The newer MDS 3.0 assessment tool includes items about a 
resident’s quality of life.  Despite these efforts’ good intentions, nursing homes today 
face an overwhelming number of responsibilities beyond the core care functions for 
residents, which are even more burdensome in light of significant resource and staff 
restraints.  There are numerous overlapping regulatory and reform initiatives for nursing 
homes to track and assess quality indicators.25 Some have argued that too much focus is 
placed on indicator tracking and process, rather than essential quality improvements for 
nursing home residents.25 And it remains unclear if these efforts have improved quality 
outcomes.25  
Given these constraints, we recommend that nursing homes focus first on the 
problems we identified for long-acting opioid use.  Nursing homes can take steps to 
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ensure that residents without recorded pain in the MDS are not initiated on a long-acting 
opioid.  Nursing homes could also use available approaches to limit polypharmacy in 
residents,55 particularly those taking long-acting opioids and CNS agents, and implement 
checks on transdermal fentanyl prescribing in opioid-naïve residents.  These would be 
specific and manageable actions that could yield tangible and more immediate 
improvements in resident outcomes.   
For longer term approaches to the deeper care issues for pain management and 
analgesic prescribing, it will be necessary for all stakeholders - researchers, government 
agencies, practice organizations, nursing homes, practitioners, and residents and their 
families - to work together in developing, assessing, and acting on the evidence for 
lasting improvements in nursing home care.  
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